Genetically modified microorganisms and their uses
Genetically modified microorganisms expressing Amuc_1100, IL-10, and IL-22 polypeptides address the limitations of current autoimmune disease treatments by modulating multiple signaling pathways, offering improved symptom relief and reduced side effects.
Patent Information
- Application Number
- JP2024531338
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-26
- Filing Date
- 2022-11-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for autoimmune diseases, such as inflammatory bowel disease, graft-versus-host disease, systemic lupus erythematosus, arthritis, and asthma, primarily rely on nonsteroidal anti-inflammatory drugs and immunosuppressants, which only alleviate symptoms and have significant side effects, while targeting single signaling pathways provides limited therapeutic efficacy.
Genetically modified microorganisms expressing exogenous genes encoding Amuc_1100, IL-10, and IL-22 polypeptides, which are secreted extracellularly to modulate multiple signaling pathways, administered to treat autoimmune diseases.
The combination of Amuc_1100, IL-10, and IL-22 polypeptides in genetically modified microorganisms effectively modulates immune responses, providing therapeutic benefits for autoimmune diseases by improving symptom relief and reducing side effects.
Smart Images

Figure 2024544610000033 
Figure 2024544610000034 
Figure 2024544610000035
Abstract
Description
[Technical field]
[0001] (cross reference) This application claims priority to Chinese patent application No. 2021114207638, filed on November 26, 2021. The entire text of the above Chinese patent application is incorporated herein by reference.
[0002] The present invention is in the field of biopharmaceuticals, in particular genetically modified microorganisms and uses thereof. [Background technology]
[0003] Inflammation is a normal response of the body that clears pathogenic or damaged cells from the body and aids in tissue repair. Disorders of the immune system often lead to abnormal inflammation. Inflammatory diseases involving the immune system commonly underlie a variety of human diseases.
[0004] Autoimmune diseases are conditions in which an abnormal immune response occurs against healthy body sites. At least 80 different autoimmune diseases affect 24 million people in the United States alone. Current treatments include nonsteroidal anti-inflammatory drugs (NSAIDs) and immunosuppressants. However, these treatments only alleviate symptoms, but do not provide a complete cure. In addition, these treatments often cause serious side effects.
[0005] Autoimmune diseases are complex diseases caused by multiple pathogenic signaling pathways. Currently, approved drugs against a single signaling pathway have limited therapeutic efficacy, suggesting that regulating multiple signaling pathways should provide better therapeutic efficacy. However, research on regulating multiple signaling pathways is very limited. First, it is unclear which multiple signaling pathways would be effective to regulate. Second, it is unclear which pharmacological methodology can more effectively regulate multiple signaling pathways. Due to the lack of effective treatments, the industry has made great efforts to discover and develop new methods to treat autoimmune diseases, but no significant progress has been obtained yet.
[0006] Thus, there is an urgent need in the field to develop more efficient methods for treating inflammatory or autoimmune diseases. Summary of the Invention
[0007] In one aspect, the present disclosure provides a genetically modified microorganism comprising at least two exogenous genes, each encoding a polypeptide selected from the group consisting of: a) an Amuc_1100 polypeptide, b) an IL-10 polypeptide, and c) an IL-22 polypeptide.
[0008] In some embodiments, the genetically modified microorganism comprises exogenous genes encoding a) an Amuc_1100 polypeptide and an IL-10 polypeptide, b) an IL-10 polypeptide and an IL-22 polypeptide, or c) an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0009] In another aspect, the disclosure provides a combination of genetically modified microorganisms, the combination of genetically modified microorganisms comprising at least two different genetically modified microorganisms, each genetically modified microorganism expressing at least one different exogenous gene, each of the exogenous genes encoding a polypeptide selected from the group consisting of: a) an Amuc_1100 polypeptide, b) an IL-10 polypeptide, and c) an IL-22 polypeptide.
[0010] In some embodiments, the polypeptide encoded by the exogenous gene can be expressed by the microorganism and / or can be secreted extracellularly / outside the microbial organism after expression.
[0011] In some embodiments, the microorganism is capable of expressing and / or secreting the polypeptide encoded by the exogenous gene in the intestinal tract of a human or animal.
[0012] In some embodiments, the secretion is via a native or non-native secretory system of the microorganism.
[0013] In some embodiments, the Amuc_1100 polypeptide, IL-10 polypeptide and / or IL-22 polypeptide is a polypeptide that has had its own signal peptide removed.
[0014] In some embodiments, the Amuc_1100 polypeptide, IL-10 polypeptide and / or IL-22 polypeptide from which its own signal peptide has been removed is linked to a signal peptide, for example, the Amuc_1100 polypeptide, IL-10 polypeptide and / or IL-22 polypeptide is linked to a first signal peptide, a second signal peptide or a third signal peptide, respectively. The first signal peptide, the second signal peptide and the third signal peptide are capable of secreting the polypeptide to the outside of the microbial organism.
[0015] In another aspect, the present disclosure provides a nucleotide sequence comprising at least one recombinant expression cassette, comprising i) at least one or at least two exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide and / or an IL-22 polypeptide, respectively, and ii) one or more regulatory elements operably linked to said at least one or at least two exogenous genes.
[0016] In some embodiments, the nucleotide sequence comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively, an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively, or an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively.
[0017] In some embodiments, the nucleotide sequence comprises an exogenous gene encoding each of an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide.
[0018] In another aspect, the present disclosure provides a composition comprising (a) a genetically modified microorganism described herein as an active ingredient, and (b) a physiologically or pharmacologically acceptable vector.
[0019] In some embodiments, the composition is a pharmaceutical composition.
[0020] In some embodiments, the composition is an oral formulation.
[0021] In another aspect, the present disclosure provides the use of a genetically modified microorganism or composition described herein in the manufacture of a medicament for treating or preventing an inflammatory disease or an autoimmune disease.
[0022] In some embodiments, the autoimmune disease is selected from the group consisting of inflammatory bowel disease, graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), arthritis, asthma, and combinations thereof.
[0023] In another aspect, the disclosure provides a use of a genetically modified microorganism or composition described herein in the manufacture of a medicament for improving the therapeutic effect of a therapeutic agent for an inflammatory or autoimmune disease.
[0024] In another aspect, the present disclosure provides a method for producing a genetically modified microorganism of the present disclosure, comprising the step of introducing into a microorganism a nucleotide sequence described in the present disclosure such that an exogenous gene in said nucleotide sequence is capable of being expressed in the microorganism.
[0025] In another aspect, the present disclosure provides a method for treating or preventing an inflammatory or autoimmune disease in an individual in need thereof, comprising administering to the individual an effective amount of a genetically modified microorganism described herein, or a composition described herein.
[0026] In another aspect, the present disclosure provides a method of improving the therapeutic efficacy of a drug, including a drug for treating an inflammatory or autoimmune disease, in an individual undergoing treatment with the drug, comprising administering to the individual an effective amount of a genetically modified microorganism described herein, or a composition described herein.
[0027] In another aspect, the disclosure provides use of a genetically modified microorganism in the preparation of a medicament for treating an inflammatory or autoimmune disease selected from the group consisting of inflammatory bowel disease (IBD), graft versus host disease (GvHD), systemic lupus erythematosus (SLE), arthritis, and asthma, wherein said genetically modified microorganism comprises at least one, at least two, or at least three exogenous genes encoding a polypeptide selected from the group consisting of a) an Amuc_1100 polypeptide, b) an IL-10 polypeptide, and c) an IL-22 polypeptide, respectively. [Brief description of the drawings]
[0028] [Figure 1] FIG. 1 shows a schematic diagram of the insertion of an exogenous gene expression cassette into the EcN genome. [Diagram 2] FIG. 2 is a comparison of the yield of IL-10 expressed by strain CBT4078 under aerobic and anaerobic conditions. [Diagram 3]FIG. 3 shows the results of comparing the expression levels of Amuc_1100(Y259A) with different copy numbers (Figure A) and the results of comparing the stability improvement of Amuc_1100 by remodeling the cell outer membrane (Figure B). Here, columns A and B of Figure A represent strain CBT4101 having only a single copy of Amuc_1100(Y259A) under the control of promoter BBA_J23101, column C represents strain CBT4107 having only a single copy of Amuc_1100(Y259A) under the control of promoter BBA_J23110, column D represents strain CBT4102 having two copies of Amuc_1100(Y259A) under the control of promoter BBA_J23110, and column E represents strain CBT4103 having two copies of Amuc_1100(Y259A) under the control of promoter BBA_J23110. Column A represents strain CBT4103 with 3 copies of Amuc_1100(Y259A) under the control of promoter BBA_J23101, column B represents strain CBT4108 with a single copy of Amuc_1100(Y259A) under the control of promoter BBA_J23101 and 2 copies of Amuc_1100(Y259A) under the control of promoter BBA_J23110, and column G represents strain CBT4109 with 3 copies of Amuc_1100(Y259A) under the control of promoter BBA_J23110. [Figure 4] FIG. 4A shows the chromosomal profile of EcN expressing a combination of IL-10, IL-22 and Amuc_1100. FIG. 4B shows the growth status of strains expressing alone, two-gene combination and three-gene combination. FIG. 4C shows the biological activity of secreted IL-10. FIG. 4D shows the biological activity of secreted IL-22. FIG. 4E shows the biological activity of secreted Amuc_1100. In the figure, "Standard (40 μg / mL)" represents the Amuc_1100 standard with a concentration of 40 μg / mL, "EcN" represents Amuc_1100 secreted from strain EcN, and "CBT4080 (28.8 μg / mL)" represents Amuc_1100 of strain CBT4080 with a concentration of 28.8 μg / mL. [Diagram 5] FIG. 5 shows the expression level of IL-10 in the culture supernatant after adding sodium salicylate at different concentrations and continuing culture for 1 to 4 hours. [Figure 6]Figure 6A shows the results of comparing colon length at endpoints using different strains in a T cell transfer-induced mouse colitis model, and Figure 6B shows the results of HE staining of colon histopathological slices using different strains in a T cell transfer-induced mouse colitis model. [Figure 7] Figure 7A shows the weight change in a DSS-induced mouse colitis model. Figure 7B shows the DAI score in a DSS-induced mouse colitis model. Figure 7C shows the colon length at the endpoint in a DSS-induced mouse colitis model. [Figure 8] FIG. 8 shows the survival rates of mice in each experimental group in the GvHD animal model. [Figure 9] Figure 9A shows the renal tubule injury score of mice of each experimental group in SLE animal model. Figure 9B shows the concentration of anti-double-stranded DNA antibody IgG in the serum of mice of each experimental group in SLE animal model. Figure 9C shows the urinary albumin concentration of mice of each experimental group in SLE animal model. Figure 9D shows the glomerular injury shown by the PAS staining result of kidney histopathological slice of mice of each experimental group in SLE animal model. [Figure 10] Figure 10A shows the footpad thickness of mice in each experimental group in the CIA animal model, and Figure 10B shows the disease score of mice in each experimental group in the CIA animal model. [Figure 11] FIG. 11A shows the results of the total number of cells in the bronchoalveolar lavage fluid (BALF) of mice of each experimental group in an asthma animal model. FIG. 11B shows the results of the number of eosinophils in the bronchoalveolar lavage fluid (BALF) of mice of each experimental group in an asthma animal model. FIG. 11C shows the results of the number of macrophages in the bronchoalveolar lavage fluid (BALF) of mice of each experimental group in an asthma animal model. FIG. 11D shows the results of the number of neutrophils in the bronchoalveolar lavage fluid (BALF) of mice of each experimental group in an asthma animal model. FIG. 11E shows the results of the number of lymphocytes in the bronchoalveolar lavage fluid (BALF) of mice of each experimental group in an asthma animal model. [Figure 12] FIG. 12 shows the nucleotide sequence of the pCBT001 plasmid expressing the Cas9 protein (SEQ ID NO: 136). [Figure 13] FIG. 13 shows the nucleotide sequence of the pCBT003 plasmid (SEQ ID NO:137). [Figure 14] FIG. 14 shows the nucleotide sequence of the pMUT2-kana plasmid (SEQ ID NO:138). [Figure 15] FIG. 15 shows the nucleotide sequence of the pCBT012 plasmid (SEQ ID NO:215). [Figure 16] FIG. 16 shows the nucleotide sequence of the pCBT013 plasmid (SEQ ID NO:216). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The following description of the present disclosure is merely used to describe various embodiments of the present disclosure. Therefore, the specific modifications discussed should not be interpreted as limiting the scope of the present disclosure. It is clear to those skilled in the art that various equivalents can be obtained and changes and modifications can be made without departing from the scope of the present disclosure, and it will be understood that such equivalent examples are included in the present specification. All references cited in this specification, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.
[0030] I. Definition As used herein, the words "a" and "said" refer to one or more (i.e., to at least one) of the grammatical object of the article. For example, "a protein" refers to one or more proteins.
[0031] The term "about" can mean a value or composition that is within an acceptable error range of a particular value or composition as determined by one of ordinary skill in the art, and will depend in part on how the value or composition is measured or measured.
[0032] As used herein, the term "amino acid" refers to an organic compound containing an amine (-NH2) and a carboxy (-COOH) functional group, and a side chain specific to each amino acid. In this disclosure, the names of amino acids are given in standard one-letter or three-letter codes as shown in Table 1. [Table 1]
[0033] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to polymers of amino acid sequences in which one or more amino acid residues are artificial chemical mimetics of a corresponding naturally occurring amino acid sequence, as well as to polymers of naturally occurring amino acid sequences and to polymers of non-naturally occurring amino acid sequences.
[0034] "Conservative substitution" in the context of an amino acid sequence refers to the replacement of an amino acid residue with a different amino acid residue that contains a side chain with similar physicochemical properties. For example, conservative substitutions can be made between amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu, and Ile), between amino acid residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn, and Gln), between amino acid residues with acidic side chains (e.g., Asp, Glu), between amino acid residues with basic side chains (e.g., His, Lys, and Arg), or between amino acid residues with aromatic side chains (e.g., Trp, Tyr, and Phe). As is known in the art, conservative substitutions usually do not cause significant changes in the conformational structure of a protein and can retain the biological activity of the protein.
[0035] The term "mutant" as used herein refers to a polypeptide or polynucleotide having at least 70% sequence identity with the parent sequence. A mutant may differ from the parent sequence by one or more amino acid residues or one or more nucleotides. For example, a mutant may have a substitution (including but not limited to a conservative substitution), addition, deletion, insertion or truncation of one or more amino acid residues or one or more nucleotides of the parent sequence, or any combination thereof. For example, in certain embodiments, a mutant Amuc_1100 has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with its naturally occurring counterpart.
[0036] As used herein, the term "fragment" refers to a subsequence of a parent polypeptide or polynucleotide of any length. A fragment can still retain at least some of the function of the parent sequence.
[0037] The term "fusion" when used in reference to an amino acid sequence (e.g., a peptide, polypeptide, or protein) refers to the joining of two or more amino acid sequences into a single non-naturally occurring amino acid sequence, for example by chemical conjugation or recombination. A fused amino acid sequence may be produced by genetic recombination of two encoding polynucleotide sequences, or may be expressed by a method in which a construct containing a recombinant polynucleotide is introduced into a microorganism.
[0038] The term "derivative" as used herein with respect to a polypeptide or polynucleotide refers to a chemically modified polypeptide or polynucleotide in which one or more clearly defined numbers of substituents are covalently attached to one or more specific amino acid residues of a polypeptide or to one or more specific nucleotides of a polynucleotide. Exemplary chemical modifications to a polypeptide may be, for example, alkylation, acylation, esterification, amidation, phosphorylation, glycosylation, labeling, methylation, or attachment to one or more moieties of one or more amino acids. Exemplary chemical modifications to a polynucleotide may be (a) terminal modifications, such as 5'-end modifications or 3'-end modifications, (b) nucleobase (or "base") modifications, including base replacement or removal, (c) sugar modifications, including modifications at the 2', 3', and / or 4' positions, and (d) backbone modifications, including modification or replacement of phosphodiester bonds.
[0039] In accordance with the teachings of the present specification, these fragments, variants, derivatives, mutants and analogs are within the scope well known to those skilled in the art, whereby the conservatively substituted analogs are preferably generated by amino acid substitutions based on Table 2. [Table 2]
[0040] As used herein, the term "homology" refers to a nucleic acid sequence (or its complementary strand) or an amino acid sequence that has at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with another sequence when optimally aligned.
[0041] The term "% sequence identity" with respect to an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid sequence (or nucleic acid) residues in a candidate sequence that are identical to the amino acid sequence (or nucleic acid) residues of a reference sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum number of identical amino acids (or nucleic acids). In other words, the percentage (%) of sequence identity of an amino acid sequence (or nucleic acid sequence) can be calculated by dividing the number of amino acid residues (or bases) that are identical to the reference sequence to which it is compared by the total number of amino acid residues (or bases) in the candidate sequence or the reference sequence (whichever is shorter). Conservative substitutions of amino acid residues may or may not be considered identical residues. Alignments for determining percentage amino acid (or nucleic acid) sequence identity can be performed using, for example, BLASTN, BLASTp (available at the US National Center for Biotechnology Information (NCBI) website; Altschul SF et al., Journal of Molecular Biology, 215:403-410 (1990); Stephen F. et al., Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 (available at the European Bioinformatics Institute website; Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin et al., J. Am. Soc. 1999, 21:111-112 (1999)), or BLASTP (available at the US National Center for Biotechnology Information (NCBI) website; Altschul SF et al., Journal of Molecular Biology, 215:403-410 (1990); Stephen F. et al., Nucleic Acids Res., 25:3389-3402 (1997)). This can be achieved using publicly available tools such as MA et al., Bioinformatics (Oxford, England), 23(21):2947-8 (2007)) and ALIGN or Megalign (DNASTAR) software. The skilled person may use the default parameters provided by said tools or customize the alignment parameters, if necessary, for example by selecting an appropriate algorithm.
[0042] As used herein, the terms "nucleotide sequence," "nucleic acid," or "polynucleotide" encompass oligonucleotides (i.e., short polynucleotides) and may refer to synthetic and / or non-naturally occurring nucleic acid molecules (e.g., containing nucleotide analogs or modified backbone residues or linkages) and may refer to deoxyribonucleotide or ribonucleotide oligonucleotides in single- or double-stranded form. Additionally, the terms encompass nucleic acids containing analogs of natural nucleotides. The terms also encompass nucleic acid-like structures having synthetic backbones. Unless otherwise indicated, a particular polynucleotide sequence encompasses conservative and modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, complementary sequences, and sequences explicitly indicated. Specifically, degenerate codon substitution is achieved by producing sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0043] As used herein, the term "encoded" refers to a sequence that can be transcribed into mRNA and / or translated into a peptide or protein. The term "coding sequence" or "gene" refers to a polynucleotide sequence that codes for a peptide or protein. These two terms can be used interchangeably in this disclosure. In some embodiments, a coding sequence is a complementary DNA (cDNA) sequence that is reverse transcribed from a messenger RNA (mRNA). In some embodiments, a coding sequence is an mRNA.
[0044] The term "operably linked" means that two or more biological sequences of interest are juxtaposed in a relationship that allows them to function in a desired manner with or without a spacer or linker. When used with polypeptides, the term means that the polypeptide sequences are linked in a manner that allows the linked product to have a desired biological function. For example, the variable region of an antibody can be operably linked to a constant region to provide a stable product with antigen-binding activity. The term can also be used with polynucleotides. For example, when a polynucleotide encoding a polypeptide is operably linked to a regulatory sequence (e.g., a promoter, enhancer, silencer sequence, etc.), the term means that the polynucleotide sequences are linked in a manner that allows the expression of the polypeptide by the polynucleotide to be regulated.
[0045] The term "vector" as used herein refers to a carrier into which a genetic element can be operably inserted to express said genetic element, thereby producing a protein, RNA or DNA encoded by said genetic element, or to replicate said genetic element. Vectors are used to transform, transduce or transfect host cells (e.g., microorganisms) to express the genetic elements they carry in the host cell. Different vectors are suitable for different host cells. Examples of vectors include plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs), bacteriophages such as lambda phage or M13 phage, and animal viruses. A vector may contain multiple expression control elements, including promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. A vector may also contain an origin of replication. A vector may also contain materials to aid in entry into a cell, including, but not limited to, viral particles, liposomes, or protein coatings. The vector may be an expression vector or a cloning vector.
[0046] II. Genetically Modified Microorganisms In one aspect, the present application provides a genetically modified microorganism comprising at least one exogenous gene selected from the group consisting of a gene encoding and expressing an Amuc_1100 polypeptide, a gene encoding and expressing an IL-10 polypeptide, a gene encoding and expressing an IL-22 polypeptide, and any combination thereof.
[0047] In another aspect, the present application provides a genetically modified microorganism comprising at least two exogenous genes, each encoding a polypeptide selected from the group consisting of: (i) an Amuc_1100 polypeptide, (ii) an IL-10 polypeptide, and (iii) an IL-22 polypeptide.
[0048] In one embodiment, the genetically modified microorganism comprises a) an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively; b) an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively; or c) an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively.
[0049] In one embodiment, the genetically modified microorganism comprises exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0050] In certain embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, or an IL-22 polypeptide.
[0051] As used herein, an "exogenous gene" is a gene that has been introduced into the microorganism by genetic modification. An exogenous gene may include a heterologous gene that is not naturally expressed in the microorganism, or an endogenous gene that is also naturally expressed in the microorganism that has been introduced by genetic modification (e.g., to increase expression).
[0052] In the present application, the polypeptide expressed by an exogenous gene in the microorganism is called an exogenous polypeptide. In some embodiments, the exogenous polypeptide is selected from an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide. In some embodiments, the exogenous polypeptide is a heterologous polypeptide that is not naturally expressed in the microorganism, such as a human IL-10 polypeptide, a human IL-22 polypeptide, etc. If the microorganism used does not endogenously express Amuc_1100, Amuc_1100 may be a heterologous polypeptide.
[0053] Microorganisms useful in the present invention include bacteria, archaea, fungi (eg, yeasts, filamentous fungi) and algae.
[0054] In some embodiments, the microorganisms provided herein include probiotic or non-pathogenic microorganisms.
[0055] As used herein, a "non-pathogenic microorganism" refers to a microorganism that is unable to cause disease or adverse reactions in a host. In some embodiments, a non-pathogenic microorganism does not contain lipopolysaccharide (LPS). In some embodiments, a non-pathogenic microorganism is a commensal bacterium. In some embodiments, a non-pathogenic microorganism is an attenuated pathogenic bacterium.
[0056] In some embodiments, the microorganism used in the present invention is a probiotic microbial organism. As used herein, "probiotic microbial organism" refers to an organism that, when administered in an effective amount, provides beneficial effects on the health or well-being of an individual, such as health benefits related to improving the balance of the human or animal microflora and / or restoring normal microflora. By definition, all probiotic microbial organisms have a demonstrated non-pathogenic characteristic. In general, probiotics help the intestinal microflora maintain (or rediscover) its balance, integrity, and diversity. The effect of probiotics may be strain-dependent.
[0057] In some embodiments, the probiotic microbial organism includes a preparation of probiotic microbial cells (eg, live microbial cells).
[0058] In some embodiments, the probiotic microbial organism is a probiotic bacteria or a probiotic yeast.
[0059] In some embodiments, the probiotic bacteria is selected from the group consisting of Bacteroides, Bifidobacterium (e.g., Bifidobacterium bifidum), Clostridium, Escherichia, Lactobacillus (e.g., Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus plantarum), and Lactococcus. In some embodiments, the probiotic bacteria belongs to the genus Escherichia. In some embodiments, the probiotic bacteria belongs to the Nissle 1917 (EcN) strain of Escherichia coli. In some embodiments, the probiotic yeast is selected from the group consisting of Saccharomyces cerevisiae, Candida utilis, Kluyveromyces lactis, and Saccharomyces carlsbergensis. In some embodiments, the probiotic microbial organism is the Nissle 1917 (EcN) strain of Escherichia coli.
[0060] As a model strain for studying microbial genetics, physiology, and metabolism, Escherichia coli has become one of the important chassis or host bacteria due to its advantages such as diverse gene modification tools and well-defined genetic backgrounds.
[0061] In some embodiments, the probiotic bacteria are bacteria normally present in the human intestinal tract.
[0062] In some embodiments, the probiotic yeast is selected from the group consisting of Saccharomyces cerevisiae, Candida utilis, Kluyveromyces lactis, and Saccharomyces carlsbergensis.
[0063] The term "genetic modification" in this application refers to modification or alteration in DNA and / or RNA or introduction of exogenous DNA or RNA into a cell (e.g., a microbial organism) by artificial intervention. Generally, the modification or alteration can be introduced through recombinant nucleic acid expression vectors, mutation, or gene editing.
[0064] The term "genetically modified microorganism" as used herein refers to a microorganism into which an exogenous gene or an exogenous expression cassette (including a vector containing an expression cassette) has been introduced. "Genetically modified microorganism" is also used interchangeably with "genetically engineered microorganism", "genetically engineered microorganism", "genetically modified microorganism" or "genetically modified microorganism". In the present application, the exogenous expression cassette comprises a polynucleotide encoding a polypeptide or protein of interest and allows its expression. Introduction of the expression cassette into the microorganism can be achieved by calcium phosphate transfection, DEAE-dextran mediated transfection or electroporation (Davis, L., Dibner, M., Battey, I., "Basic Methods in Molecular Biology" (1986)), or by gene editing technology (e.g., CRISPR technology).
[0065] A genetically modified microorganism also includes any progeny of the microorganisms provided herein or their derivatives, it being understood that all progeny may differ from the parent cell since mutations may occur during replication.
[0066] The present application also provides a nucleotide sequence comprising at least one recombinant expression cassette, comprising i) at least one or at least two exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide and / or an IL-22 polypeptide, respectively, and ii) one or more regulatory elements operably linked to said at least one or at least two exogenous genes.
[0067] In some embodiments, the present disclosure further provides combinations of genetically modified microorganisms, including combinations of genetically modified microorganisms that include at least one (e.g., including at least one, at least two, or at least three) exogenous genes described in this disclosure.
[0068] In some embodiments, the combination of genetically modified microorganisms includes two different genetically modified microorganisms each expressing one of the different exogenous genes, the polypeptides encoded by the exogenous genes being a) an Amuc_1100 polypeptide and an IL-10 polypeptide, b) an IL-10 polypeptide and an IL-22 polypeptide, or c) an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively.
[0069] In some embodiments, the combination of genetically modified microorganisms includes three different genetically modified microorganisms each expressing one of the different exogenous genes. Alternatively, the combination of genetically modified microorganisms includes two different genetically modified microorganisms each expressing one exogenous gene and two other exogenous genes, where the polypeptides encoded by the exogenous genes are Amuc_1100 polypeptide, IL-10 polypeptide, and IL-22 polypeptide, respectively.
[0070] A.Amuc_1100 Amuc_1100 is known as an outer membrane protein present in the bacterial species Akkermansia muciniphila ("A. muciniphila"). Amuc_1100, along with two other members Amuc_1099 and Amuc_1101, is located within a gene cluster involved in the formation of type IV pilus-like structures (Ottman et al., PLoS One, 2017). An exemplary amino acid sequence of Amuc_1100 is published in GenBank: ACD04926.1. In this disclosure, the terms "Amuc_1100" and "AMUC_1100" are used interchangeably.
[0071] The term "Amuc_1100" as used herein broadly encompasses Amuc_1100 polypeptides, as well as Amuc_1100 polynucleotides, e.g., DNA or RNA sequences of a polypeptide encoding Amuc_1100. The term "Amuc_1100" as used herein further encompasses wild-type Amuc_1100 and functional equivalents that are functionally equivalent to the wild-type Amuc_1100 polypeptide.
[0072] In this application, when the term "wild-type" is used to describe a polypeptide or polynucleotide, it means that the sequence of said polypeptide or polynucleotide is identical to a sequence found in nature. A wild-type polypeptide or polynucleotide may be a native or naturally occurring polypeptide or polynucleotide sequence, or may include fragments thereof that are not themselves found in nature.
[0073] In this application, the term "functional equivalent" when used to describe a polypeptide or polynucleotide refers to any variant that has differences in amino acid sequence or polynucleotide sequence or chemical structure compared to a reference sequence, yet retains at least partially one or more biological functions of the reference sequence.
[0074] In this application, the term "variant", when used to describe a polypeptide or polynucleotide, encompasses all kinds of different forms of said polypeptide or polynucleotide, including, but not limited to, fragments, mutants, fusions, derivatives, mimetics, or any combination thereof, of a naturally occurring polypeptide or polynucleotide.
[0075] In the present application, the term "wild-type Amuc_1100" means that the sequence of the Amuc_1100 polypeptide or polynucleotide is identical to the sequence found in nature. Wild-type Amuc_1100 may be the native or naturally occurring Amuc_1100 sequence, as well as fragments thereof that are not themselves found in nature. Wild-type Amuc_1100 may also include naturally occurring mutants, such as mutants or isoforms found in various bacterial strains or different native sequences. The wild-type full-length Amuc_1100 polypeptide has a length of 317 amino acid residues. Exemplary amino acid sequences of wild-type Amuc_1100 include, but are not limited to, Amuc_1100(1-317) of the amino acid sequence shown in SEQ ID NO: 1, Amuc_1100(31-317) shown at positions 31-317 of the amino acid sequence shown in SEQ ID NO: 1, and Amuc_1100(81-317) shown at positions 81-317 of the amino acid sequence shown in SEQ ID NO: 1.
[0076] Amino acid sequence of Amuc_1100(1-317) (SEQ ID NO:1): MSNWITDNKPAAMVAGVGLLLFLGLSATGYIVNSKRSELDKKISIAAKEIKSANAAEITPSRSSNEELEKELNRYAKAVGSLETAYKPFLASSALVPTTPTAFQNELKTFRDSLISSCKKKNILITDTSSWLGFQVYSTQAPSVQAASTLGFELKAIN SLVNKLAECGLSKFIKVYRPQLPIETPANNPEESDEADQAPWTPMPLEIAFQGDRESVLKAMNAITGMQDYLFTVNSIRIRNERMMPPPIANPAAAKPAAAQPATGAASLTPADEAAAPAAPAIQQVIKPYMGKEQVFVQVSLNLVHFNQPKAQEPSED
[0077] In some embodiments, the Amuc_1100 polypeptide includes a functional equivalent of a wild-type Amuc_1100 polypeptide.
[0078] In the present application, a functional equivalent of wild-type Amuc_1100 refers to any Amuc_1100 variant that, despite having differences in amino acid sequence or polynucleotide sequence or chemical structure, at least partially retains one or more biological functions of wild-type Amuc_1100, including, but not limited to, a) regulating and / or promoting intestinal immune system function in a mammal, b) maintaining, restoring and / or increasing the physical integrity of the intestinal mucosal barrier in a mammal, c) activating TLR2, d) enhancing immune response to cancer immunotherapy (e.g., immune checkpoint modulators) in a mammal, and e) reducing, delaying and / or preventing drug resistance to one or more immune checkpoint modulators in a mammal.
[0079] In certain embodiments, the functional equivalent of Amuc_1100 retains substantial biological activity of the parent molecule. In some embodiments, the functional equivalent of Amuc_1100 described herein still retains substantially similar function as wild-type Amuc_1100. For example, the functional equivalent of Amuc_1100 may retain at least partial (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) activity of wild-type Amuc_1100, such as regulating gut immunity and / or activating TLR2.
[0080] Functional equivalents of Amuc_1100 polypeptides may include mutants, fragments, fusions, derivatives, or any combination thereof of wild-type Amuc_1100. Functional equivalents of Amuc_1100 may include engineered variants of wild-type Amuc_1100, such as artificial polypeptide sequences obtained by recombinant methods or chemical synthesis. Functional equivalents of Amuc_1100 may include unnatural amino acid residues without affecting activity. Suitable unnatural amino acids include, for example, β-fluoroalanine, 1-methylhistidine, γ-methylene glutamic acid, α-methylleucine, 4,5-dehydrolysine, hydroxyproline, 3-fluorophenylalanine, 3-aminotyrosine, 4-methyltryptophan, and the like.
[0081] In the present application, Amuc_1100 variants may encompass any kind of different forms of Amuc_1100, including, but not limited to, fragments, mutants, fusions, derivatives, mimetics or any combination thereof of wild-type Amuc_1100.
[0082] Without wishing to be bound by any theory, certain wild-type Amuc_1100 fragments (eg, Amuc_1100(31-317)) can bind to and activate TLR2 with higher affinity than their full-length counterparts.
[0083] In some embodiments, the Amuc_1100 fragment has the amino acid sequence shown in SEQ ID NO:2. AINSLVNKLAECGLSKFIKVYRPQL (SEQ ID NO: 2)
[0084] In some embodiments, the Amuc_1100 fragment has the amino acid sequence set forth in SEQ ID NO:3. SLETAYKPFLASSALVPTTPTAFQNELKTFRDSLISSCKKKNILTDTSSWLGFQVYSTQAPSVQAASTLGFELKAINSLVNKLAECGLSKFIKVYRPQLPIETPANNPEESDEADQAPWTPMPLEIAFQGDRESVLKAMNAITGMQDYLFTVNSIRIRNERMMPPPIANPAAAKPAAAQPATGAASLTPADEAAAPAAPAIQQVIKPYMGKEQVFVQVSLNLVHFNQPKAQEPSED (SEQ ID NO: 3)
[0085] In some embodiments, the Amuc_1100 polypeptide comprises a sequence as set forth in SEQ ID NO:5 or comprises an amino acid sequence having at least 80% sequence identity with the sequence as set forth in SEQ ID NO:5 and still retains gut immunity regulating and / or toll-like receptor 2 (TLR2) activating activity. In some embodiments, the Amuc_1100 polypeptide comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the sequence as set forth in SEQ ID NO:5 and still retains gut immunity regulating and / or toll-like receptor 2 (TLR2) activating activity. In some embodiments, the nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO:5 is set forth in SEQ ID NO:4.
[0086] In some embodiments, the Amuc_1100 polypeptide has a Y259A or Y259S mutation at position 259 (wherein the numbering of position 259 is based on the sequence set forth in SEQ ID NO:5). In some embodiments, the Amuc_1100 polypeptide having a Y259A mutation has the amino acid sequence set forth in SEQ ID NO:7. In some embodiments, the nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:7 is set forth in SEQ ID NO:6. In some embodiments, the Amuc_1100 polypeptide having a Y259S mutation has the amino acid sequence set forth in SEQ ID NO:9. In some embodiments, the nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:9 is set forth in SEQ ID NO:8.
[0087] In one embodiment, the Amuc_1100 polypeptide further comprises a tag or amino acid extension at the N-terminus or C-terminus. The tag can be used for purification of the Amuc_1100 polypeptide. The amino acid extension can be used for improving stability or reducing clearance. The tag or extension can be any suitable tag or extension, such as, for example, His-tag (e.g., 6xHis tag), protein A, lacZ (β-gal), maltose binding protein (MBP), calmodulin binding peptide (CBP), intein-chitin binding domain (intein-CBD) tag, streptavidin / biotin based tag, tandem affinity purification (TAP) tag, epitope tag, reporter gene tag, etc.
[0088] In some embodiments, the Amuc_1100 polypeptide further comprises an enzyme digestion site that separates the tag from the remainder of the Amuc_1100 polypeptide. The enzyme digestion site is used to remove the tag as needed. Examples of suitable enzyme digestion sites include an enterokinase recognition site (e.g., DDDDK), a factor Xa recognition site, a genenase I recognition site, a furin recognition site, and the like.
[0089] Amuc_1100 DNA sequence (SEQ ID NO:4) attgttaacagcaagcgtagcgagctggataagaaaatcagcattgcggcgaaagagatcaagagcgcgaacgcggcggaaattaccccgagccgtagcagcaacgaggaactggagaaagaactgaaccgttacgcgaaggcggttggtagcctggaaaccgcgtataaaaccgtttctggcgagcagcgcgctggtgccgaccaccccgaccgcg ttccaaaacgagctgaaaacctttcgtgacagcctgatcagcagctgcaagaaaaagaacatcctgattaccgataccagcagctggctggggcttccaggtttacagcacccaagcgccgagcgtgcaggcggcgagcaccctgggttttgagctgaaaagcgattaacagcctggttaacaagctggcggaatgcggcctgagcaaattcatcaag gtgtatcgtccgcagctgccgattgaaaacccggcgaacaacccggaggaaaagcgacgaagcggatcaggcgccgtggaccccgatgccgctggagatcgcgttccagggtgaccgtgaaagcgttctgaaagcgatgaacgcgattaccggcatgcaagattacctgtttaccgtgaacagcatccgtattcgtaacgaacgtatgatgccgccg ccaatcgcgaacccggctgcggcgaagccggctgcggcgcagccggcgaccggtgcggcgagcctgaccccggcggacgaggctgcggcgccgggctcgcccgggcgatccagcaagttattaaaccgtatatgggcaaggaacaggtgttcgttcaagtgagcctgaacctggtgcactttaaccagccgaaagcgcaagagccgagcgaagattga
[0090] Amuc_1100 の amino acid sequence(sequence number 5) IVNSKRSELDKKISIAAKEIKSANAAEITPSRSSNEELEKELNRYAKAVGSLETAYKPFLASSALVPTTPTAFQNELKTFRDSLISSCKKKNILITDTSSWLGFQVYSTQAPSVQAASTLGFELKAINSLVNKLAECGLSKFIK VYRPQLPIETPANNPEESDEADQAPWTPMPLEIAFQGDRESVLKAMNAITGMQDYLFTVNSIRIRNERMMPPPIANPAAAKPAAAQPATGAASLTPADEAAAPAAPAIQQVIKPYMGKEQVFVQVSLNLVHFNQPKAQEPSED*
[0091] DNA sequence of Amuc_1100(Y259A) (SEQ ID NO:6) Attgttaacagcaagcgtagcgagctggataagaaaatcagcattgcggcgaaagagatcaagagcgcgaacgcggcggaaattaccccgagccgtagcagcaacgaggaactggagaaagaactgaaccgttacgcgaaggcggttggtagcctggaaaccgcgtataaaaccgtttctggcgagcagcgcgctggtgccgaccaccccgaccgc gttccaaaacgagctgaaaacctttcgtgacagcctgatcagcagctgcaagaaaaagaacatcctgattaccgataccagcagctggctggggcttccaggtttacagcacccaagcgccgagcgtgcaggcggcgagcaccctgggttttgagctgaaagcgattaacagcctggttaacaagctggcggaatgcggcctgagcaaattcatca aggtgtatcgtccgcagctgccgattgaaaacccggcgaacaacccggaggaaaagcgacgaagcggatcaggcgccgtggaccccgatgccgctggagatcgcgttccagggtgaccgtgaaagcgttctgaaagcgatgaacgcgattaccggcatgcaagattacctgtttaccgtgaacagcatccgtattcgtaacgaacgtatgatgccg ccgccaatcgcgaacccggctgcggcgaagccggctgcggcgcagccggcgaccggtgcggcgagcctgaccccggcggacgaggctgcggcgccgggctcgcccggcgatccagcaagttattaaaacggctatgggcaaggaacaggtgttcgttcaagtgagcctgaacctggtgcactttaaccagccgaaagcgcaagagccgagcgaagat
[0092] Amuc_1100(Y259A) の amino acid sequence(sequence number7) IVNSKRSELDKKISIAAKEIKSANAAEITPSRSSNEELEKELNRYAKAVGSLETAYKPFLASSALVPTTPTAFQNELKTFRDSLISSCKKKNILITDTSSWLGFQVYSTQAPSVQAASTLGFELKAINSLVNKLAECGLSKFIK VYRPQLPIETPANNPEESDEADQAPWTPMPLEIAFQGDRESVLKAMNAITGMQDYLFTVNSIRIRNERMMPPPIANPAAAKPAAAQPATGAASLTPADEAAAPAAPAIQQVIKPAMGKEQVFVQVSLNLVHFNQPKAQEPSED*
[0093] DNA sequence of Amuc_1100(Y259S) (SEQ ID NO:8) attgttaacagcaagcgtagcgagctggataagaaaatcagcattgcggcgaaagagatcaagagcgcgaacgcggcggaaattaccccgagccgtagcagcaacgaggaactggagaaagaactgaaccgttacgcgaaggcggttggtagcctggaaaccgcgtataaaaccgtttctggcgagcagcgcgctggtgccgaccaccccgaccgc gttccaaaacgagctgaaaacctttcgtgacagcctgatcagcagctgcaagaaaaagaacatcctgattaccgataccagcagctggctggggcttccaggtttacagcacccaagcgccgagcgtgcaggcggcgagcaccctgggttttgagctgaaagcgattaacagcctggttaacaagctggcggaatgcggcctgagcaaattcatca aggtgtatcgtccgcagctgccgattgaaaacccggcgaacaacccggaggaaaagcgacgaagcggatcaggcgccgtggaccccgatgccgctggagatcgcgttccagggtgaccgtgaaagcgttctgaaagcgatgaacgcgattaccggcatgcaagattacctgtttaccgtgaacagcatccgtattcgtaacgaacgtatgatgccg ccgccaatcgcgaacccggctgcggcgaagccggctgcggcgcagccggcgaccggtgcggcgagcctgaccccggcggacgaggctcggcgcgggctcgcccgggcgatccagcaagttattaaaccgagcatgggcaaggaacaggtgttcgttcaagtgagcctgaacctggtgcactttaaccagccgaaagcgcaagagccgagcgaagat
[0094] Amuc_1100(Y259S) の amino acid sequence(sequence number9) IVNSKRSELDKKISIAAKEIKSANAAEITPSRSSNEELEKELNRYAKAVGSLETAYKPFLASSALVPTTPTAFQNELKTFRDSLISSCKKKNILITDTSSWLGFQVYSTQAPSVQAASTLGFELKAINSLVNKLAECGLSKFIK VYRPQLPIETPANNPEESDEADQAPWTPMPLEIAFQGDRESVLKAMNAITGMQDYLFTVNSIRIRNERMMPPPIANPAAAKPAAAQPATGAASLTPADEAAAPAAPAIQQVIKPSMGKEQVFVQVSLNLVHFNQPKAQEPSED*
[0095] In addition, Amuc_1100 is a membrane protein, and its N-terminal signal peptide sequence promotes membrane localization of the Amuc_1100 polypeptide. Therefore, in order to achieve the object of the present disclosure of secreting the Amuc_1100 polypeptide, it is necessary to replace the Amuc_1100's own signal peptide with another signal peptide of the present disclosure, such as the USP45 signal peptide, that can secrete the Amuc_1100 polypeptide outside the microorganism.
[0096] B. Cytokines The genetically modified microorganisms provided herein can also express and secrete one or more cytokines.
[0097] In some embodiments, the cytokines are IL-10 and IL-22.
[0098] In some embodiments, the cytokine may be IL-17A, IL-19, IL-23, IL-35, IL-37, or TGF-beta.
[0099] Interleukin-10 (IL-10) IL-10 is an anti-inflammatory cytokine that maintains the balance of immune responses and is synthesized by multiple types of cells, including B cells, monocytes, dendritic cells, natural killer cells, and T cells. IL-10 is recognized by a specific receptor expressed by hematopoietic cells and belongs to class II cytokines. IL-10 transmits signals through two receptors, IL-10R1 and IL-10R2, and the downstream JAK / STAT pathway, ultimately activating the expression of anti-inflammatory response genes. IL-10 suppresses the activity of macrophages and dendritic cells, and indirectly suppresses the activation and effector function of T cells. IL-10 has protective effects against inflammatory bowel disease and allergic reactions. Defects in IL-10 and / or its receptors are associated with IBD and intestinal hypersensitivity (Nielsen, 2014).
[0100] Interleukin-10 (IL-10) is a pleiotropic cytokine produced by several cells, including macrophages, monocytes, Th2-type and regulatory T cells, and B cells. IL-10 is a cytokine with immunosuppressive and anti-inflammatory properties, regulating the activity of many myeloid and lymphoid cells and directly suppressing the production of several inflammatory cytokines by T cells and NK (natural killer) cells.
[0101] IL-10 was originally described as a cytokine synthesis inhibitory factor (CSIF) produced by Th2 cells. Th2 cells suppress Th1 cells from producing proinflammatory cytokines such as gamma-interferon (IFN-γ), interleukin-1-α (IL-1α), interleukin-1-β (IL-1β), interleukin-2 (IL-2) and tumor necrosis factor α (TNF-α). It was demonstrated that IL-10, in addition to suppressing proinflammatory cytokine production, could suppress antigen-specific Th1 cell proliferation, thereby deregulating the expression of majorhistocompatibility complex (MHC)-II in these cells, resulting in a reduced capacity of monocyte antigen presentation.
[0102] The discovery that IL-10 has a strong inhibitory effect on the activation of Th1 cells and on the production of proinflammatory cytokines led to the hypothesis that IL-10 is a powerful immunosuppressant of cell-mediated immune responses. The use of this cytokine in the treatment of acute and chronic inflammation and in the treatment of autoimmune diseases has been proposed by other authors. For these reasons, this cytokine is used in some autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn's disease, etc. However, in other diseases such as infectious processes and cancer, for example leprosy, tuberculosis, leishmaniasis and viral infections, the induction of therapeutically beneficial Th1 responses is prevented, which may lead to side effects. It was then demonstrated that IL-10 was abundantly expressed in chronic infections with hepatitis C virus. This cytokine can be produced by Th2 cells as a result of stimulation by HCV antigens. It can also be produced by regulatory T cells (D4 and CD8) that suppress the formation of Th1-type antiviral effector cells. Furthermore, dendritic cells (DCs) or monocytes that have come into contact with and been infected with HCV proteins produce larger amounts of IL-10 than non-infected cells, which is advantageous for promoting the development of Th2 responses but hinders the clearance of the virus.
[0103] In some embodiments, the genetically modified microorganisms provided herein are capable of expressing and secreting IL-10.
[0104] The term "IL-10" as used herein broadly encompasses IL-10 and IL-10 polynucleotides, such as DNA or RNA sequences encoding IL-10. The term "IL-10" as used herein further encompasses wild-type IL-10 and functional equivalents that are functionally equivalent to wild-type IL-10. In the present application, a functional equivalent of wild-type IL-10 refers to any IL-10 variant that at least partially retains one or more biological functions of wild-type IL-10, despite having differences in amino acid sequence or polynucleotide sequence or chemical structure. The one or more biological functions of wild-type IL-10 include, but are not limited to, being able to bind to IL-10R1 / IL-10R2 and functioning through the receptor-JAK-STAT signaling pathway.
[0105] In some embodiments, the IL-10 comprises an amino acid sequence set forth in SEQ ID NO: 11 or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 11 and still retains immune cell (e.g., macrophage, dendritic cell) modulating activity. In some embodiments, the IL-10 comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 11 and still retains immune cell (e.g., macrophage, dendritic cell) modulating activity.
[0106] In some embodiments, the IL-10 has a P2A mutation, where the numbers are relative to SEQ ID NO:13, ie, has the amino acid sequence shown in SEQ ID NO:13.
[0107] In the present application, variants of IL-10 encompass all kinds of different forms of IL-10, including, but not limited to, IL-10 fragments, mutants, fusions, derivatives, mimetics, or any combination thereof.
[0108] In some embodiments, the genetically modified microorganisms provided herein may comprise any suitable gene encoding IL-10 (e.g., human IL-10). In some embodiments, the gene encoding IL-10 comprises the nucleotide sequence set forth in SEQ ID NO: 10 or a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 10, and wherein the protein encoded thereby still retains immune cell (e.g., macrophages, dendritic cells) modulating activity. In some embodiments, the gene encoding IL-10 comprises a nucleotide sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence set forth in SEQ ID NO:10, and wherein the protein encoded thereby still retains immune cell (e.g., macrophages, dendritic cells) modulating activity.
[0109] The gene encoding IL-10 may include modifications and / or mutations to, for example, increase stability under inducing conditions, increase expression of IL-10, and / or increase anti-inflammatory efficacy. In some embodiments, the gene encoding IL-10 comprises the nucleotide sequence set forth in SEQ ID NO:12.
[0110] In some embodiments, the genetically modified microorganisms provided herein are capable of producing IL-10 under induced conditions (e.g., conditions induced by microenvironmental factors in inflamed tissues). In some embodiments, the genetically modified microorganisms are capable of producing IL-10 under hypoxic or anaerobic conditions. In some embodiments, the genetically modified microorganisms are capable of producing IL-10 under 1×10 9 CFU of the microorganism may secrete at least 300 ng, at least 350 ng, at least 400 ng, at least 450 ng, at least 500 ng, at least 550 ng, at least 600 ng or at least 650 ng of IL-10.
[0111] DNA sequence of IL-10 (SEQ ID NO:10) agcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaactag
[0112] Amino acid sequence of IL-10 (SEQ ID NO: 11) SPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN*
[0113] DNA sequence of IL-10 (P2A) (SEQ ID NO: 12) agcgcgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaa gaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcg gagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcg gtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaact
[0114] Amino acid sequence of IL-10(P2A) (SEQ ID NO:13) SAGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN*
[0115] Interleukin-22 (IL-22) "Interleukin-22" or "IL-22" as used herein is a T cell-secreted glycoprotein that was named IL-10-related T cell-derived inducible factor (IL-TIF) upon discovery and has become one of the most intensively studied members of the IL-10 family due to its unique functions.
[0116] IL-22 is mainly secreted by adaptive immune cells (e.g., CD4+T cells, CD8+T cells) and innate immune cells (e.g., LTi cells, NK cells). It has been found that the expression of IL-22 can be influenced by many transcription factors, such as signal transduction and activation of transcription 3 (STAT3), retinoic acid-related orphan receptor γτ (RORγτ), and aryl hydrocarbon receptor (AhR), as well as cytokines, such as IL-23, IL-6, IL-17, TNF-α, and TNF-β.
[0117] IL-22 exerts its biological functions by binding to the IL-22RI and IL-10R2 receptors. Unlike other immune cytokines that act mainly on hematopoietic cells, IL-22 acts mainly on non-hematopoietic cells in tissues, such as endothelial cells, stromal cells, and fibroblasts. IL-22 is also widely distributed in many tissues, including the lung, liver, kidney, thymus, mammary gland, intestine, skin, and synovium.
[0118] IL-22 activates the STAT signaling pathway, which induces mucosal barrier maintenance and repair functions, involving downstream proliferation and anti-apoptotic effects. Although IL-22 can enhance epithelial cell repair after injury and enhance epithelial cell survival by anti-apoptosis and proliferation promotion, persistent high expression of IL-22 can actually cause pathogenic effects such as tissue damage and chronic inflammation in certain diseases such as tumors and autoimmune diseases. IL-22 can also work to resist microbial and parasitic invasion by inducing the production of antimicrobial peptides. As the protective and pathogenic functions of IL-22 are extensive and complex, many studies in recent years have demonstrated that IL-22 exerts unique effects in diseases such as infections, autoimmune diseases, and tumors.
[0119] In some embodiments, the genetically modified microorganisms provided herein express and secrete IL-22.
[0120] As used herein, the IL-22 includes a polypeptide having SEQ ID NO: 15 and its functional equivalents. As used herein, the term "IL-22" broadly encompasses IL-22 and IL-22 polynucleotides, such as DNA or RNA sequences encoding IL-22. As used herein, the term "IL-22" further encompasses wild-type IL-22 and functional equivalents that are functionally equivalent to wild-type IL-22. In the present application, a functional equivalent of wild-type IL-22 refers to any IL-22 variant that has a difference in amino acid sequence or polynucleotide sequence or chemical structure but at least partially retains one or more biological functions of wild-type IL-22. The one or more biological functions of wild-type IL-22 include, but are not limited to, substantial activity of binding to IL-22R1 / IL-10R2 and signaling through Janus kinase (associated with IL-22R subunit) and STAT molecules.
[0121] In some embodiments, the IL-22 comprises a sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 15 and still retains activity of binding to an IL-22 receptor and regulating a cell expressing an IL-22 receptor. In some embodiments, the IL-22 comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth in SEQ ID NO: 15 and still retains activity of binding to an IL-22 receptor and regulating a cell expressing an IL-22 receptor.
[0122] In the present application, variants of IL-22 may include any type of different form of IL-22, including but not limited to IL-22 fragments, mutants, fusions, derivatives, mimetics, or any combination thereof.
[0123] DNA sequence of IL-22 (SEQ ID NO: 14) gcgccgatcagcagccactgccgtctggacaaaagcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacac cgatgtgcgtctgatcggcgagaaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgc aaagcgatcgttttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgt aacgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgcgtgcatttag
[0124] Amino acid sequence of IL-22 (SEQ ID NO: 15) APISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI*
[0125] Interleukin-17A (IL-17A) As used herein, "interleukin-17" or "IL-17A" is produced by activated T cells and binds to IL-17R, which is generally expressed on all cell types, to mediate inflammatory responses. However, the exact mechanism of IL-17A signaling has not yet been fully elucidated. In chronic inflammation, including RA, IL-17A may cause tissue damage by directly degrading substrates or indirectly increasing activated inflammatory cells to allow other inflammatory cytokines, such as IL-1b and TNF-a, to enter the inflamed tissue. IL-17A activates all three members of the MAPKs (mitogen-activated protein kinases): extracellular signal-regulated kinases (ERK1 and ERK2) p44 and p42, Jun protein N-terminal kinase (JNK), and p38. IL-17A has been shown to induce activation of NF-kb in human fibroblasts, intestinal epithelial cells, and cultured chondrocytes, and it is believed that this inductive effect must be related to TNF receptor-associated factor (TRAF)-6. In the human monocytic leukemia cell line U937, IL-17A can induce tyrosine phosphorylation of some members of the Janus kinase (JAN) and signal transduction and activator of transcription (STAT) pathways, including Tyk2, JAK1, 2 and 3, and STAT1, 2, 3 and 4, suggesting that the JAK / STAT pathway must be involved in regulating the biological effects of IL-17A.
[0126] DNA sequence of IL-17A (SEQ ID NO:217) ggtattacaatcccgcgtaatccgggttgtccgaatagtgaagataaaaattttccgcgtacagttatggttaatctgaatattcataaccgtaacacaaacaccaatccgaaacgtagtagcgattattataatcgtagcacaagcccgtggaatctgcatcgtaacgaagatccggaacgttatccaagcgttatc tgggaagcaaaatgccgccatctgggttgtatcaatgcagatggtaacgttgattatcatatgaatagcgtgccgattcagcaggaaattctggttctg cgtcgtgaaccgccgcattgtccgaatagctttcgtctggaaaaaattctggttagcgttggttgtacctgtgttaccccgattgttcatcatgttgca
[0127] IL-17 A amino acid sequence (SEQ ID NO:218) GITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA
[0128] Interleukin-19 (IL-19) As used herein, "interleukin-19" or "IL-19" plays a biological role by transmitting biological signals through a pair of receptor complexes, IL-20R1 / R2. Although IL19 is a member of the cytokine IL-10 family, the role of IL-19 has not yet been clarified, and there is still debate and uncertainty as to whether IL-19 is a pro-inflammatory or anti-inflammatory cytokine. Some studies believe that IL-19 may have anti-inflammatory effects similar to IL-10, and that there may be a phenotype that induces lymphocytes to transition from Th1 to Th2. Some studies also believe that IL-19 upregulates the production of IL-6 and TNF-α in monocytes, indicating that IL-19 has pro-inflammatory properties. Although the expression of IL-20R1 was not detected in immune cell populations, many studies have clearly shown the effects of IL-19 on these cells. Most studies have shown that IL-19 is part of the Th2 system. Studies have also shown that IL-19 exerts an anti-inflammatory effect in myocarditis. Since endogenous IL-19 shows protective effects in the inflammatory intestinal tract, some scholars established an IL-19 mouse DSS colitis model and found that these mice were more susceptible to colitis than immune-competent mice. In active Kahn's disease, defective expression of IL-19 and the corresponding lack of response make the disease more susceptible to inflammation. In addition, when adenovirus-mediated IL-19 fusion gene is introduced into rats, it effectively reduces damage and activates MAPK. In addition, it has been found that the production of IL-19 can be induced by some cellular inflammatory factors. Meanwhile, IL-19 can reduce the inflammatory response of vascular smooth muscle by reducing the stability of mRNA species encoding inflammatory proteins. Several in vitro experimental studies have shown that IL-19 can induce the production of Th2 cytokines by CD4+ T cells, IL-19 increases the production of IL-10 in peripheral blood monocytes, and T cells exposed to IL-19 for a long time can downregulate IFN-γ and upregulate IL-4 and IL-13.However, some controversial studies have found that IL-19 in monocytes upregulated the production of the pro-inflammatory factors IL-6 and TNF-α, and that the expression of IL-19 and its two receptor chains IL-20R1 / IL-20R2 in the skin of psoriasis patients. Further studies have found that treatments that reduced IL-19 levels were effective.
[0129] DNA sequence of IL-19 (SEQ ID NO:219) ctgcgtcgttgtctgattagcaccgatatgcatcatattgaagaaagctttcaggaaattaaacgtgccattcaggcaaaagatacctttccgaatgttaccattctgagcacc ctggaaaccctgcagattatcaaaccactggatgtttgttgtgttaccaaaaatctgctggccttttatgttgatcgtgtttttaaagatcatcaggaaccgaatccgaaaattc tgcgtaaaattagtagcattgccaatagctttctgtatatgcagaaaaccctgcgccagtgtcaggaacagcgtcagtgtcattgtcgtcaggaagcaaccaatgcaacccgtgt gattcatgataactatgatcagctggaagttcatgcagcagcgattaaaagcctgggtgaactggatgtgtttctggcatggattaataaaaatcatgaagtgatgtttagcgca
[0130] Amino acid sequence of IL-19 (SEQ ID NO:220) LRRCLISTDMHHEESFQEIKRAIQAKDTFPNVTILSTELETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNPKILRKISSIANSFLYMQKTLRQCQEQRQCHCRQEATNATRVIHDNYDQLEVHAAAIKSLGELDVFLAWINKNHEVMFSA
[0131] Interleukin-23 (IL-23) "Interleukin-23" or "IL-23" as used herein is a heterodimeric cytokine consisting of IL-12p40 and IL-23p19 subunits. Here, the p40 subunit is shared by IL-23 and IL-12. The functional receptor for IL-23 was identified to consist of IL-12R β1 and IL-23R. IL-23 functions in the immune response of type 1 polarized T cells. Although IL-12 can potently activate naive T cells, initial reports believed that IL-23 could preferentially act on memory T cells to promote IFN-γ secretion and proliferation, indicating that IL-23 plays an important role in controlling bacterial infection. IL-23 has been further described as an important cytokine in controlling inflammation in peripheral tissues. Overexpression of p19 has been associated with inflammation in multiple organs and epithelial tissues, including the skin. IL-23 has also been implicated in inflammation in the central nervous system and in a variety of autoimmune diseases.
[0132] DNA sequence of IL-23 (IL-12p40 subunit) (SEQ ID NO:221) atctgggaactgaaaaaggatgtttatgtggttgaactggattggtatccggatgcaccgggcgaaatggtggttctgacgtgtgatacgccggaagaagatggtattacctggacactggatcagagcagcgaagttctgggcagtggtaaaacctgacgattcaggttaaagaatttggtgatgcaggtcagtatacctcataaaggtggtgaagttctgagcc attccctgctgctgctgcataaaaaggaagatggtatctggagcaccgatatctgaaagatcagaaagaaccgaaaaacaaaacctttctgcgttgcgaagcgaaaaaattattcaggccgttttacctgttggtggctgacgaccattagcacagatctgacctttagcgtgaaaagcagccgtggtagcagcgatccgcagggtgttacttgtggtgcagcaacgctg tctgcagaacgtgttcgtggtgataataaagaatatgaatatagcgtggaatgccaggaagattcagcatgtccggcagcagaagaaagcctgccgattgaagtgatggttgatgcagttcataaactgaaatatgaaaactataccagcagcttttttatccgtgatatattaataaaccggaccctccgaaaatctgcagctgaaacctctgaaaaatagtcgtcagg tggaagtgtcctgggaatatccggatacctggagcaccccacatagcttatttagtctgaccttttgtgttcaggttcagggcaaatcaaaacgcgaaaaaaaagatcgtgtttttaccgataaaaaccagcgcaaccgttatttgtcgtaaaaaatgcaagcattagcgttcgtgcacaggatcgttattatagcagcagctggagcgaatgggcaagcgttccgtgtagc
[0133] Amino acid sequence of IL-23(IL-12p40 subunit) IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATL SAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS
[0134] DNA sequence of IL-23 (IL-23p19 subunit) (SEQ ID NO:223) cgtgcagttccgggtggtagcagcccggcatggacccagtgtcagcagctgagccagaaactgtgtaccctggcatggagcgcacatccgctggttggtcatatggatctgcgtgaagaaggtgatg aagaaaccaccaatgatgttccgcatattcagtgtggtgatggttgtgatccgcagggtctgcgtgataatagccagttttgtctgcagcgtattcatcagggtctgattttttatgaaaaactgctg ggtagcgatatttttaccggtgaaccgagcctgctgccggatagcccggttggtcagctgcatgcaagcctgctgggtctgagccagctgctgcagccggaaggtcatcattgggaaacccagcaga ttccgagcctgagcccgagccagccgtggcagcgtctgctgctgcgttttaaaattctgcgtagcctgcaggcatttgttgcagttgcagcacgtgtttttgcacatggtgcagcaaccctgagcccg
[0135] Amino acid sequence of IL-23 (IL-23p19 subunit) (SEQ ID NO:224) RAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEGDEETTNDVPHIQCGGGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSPVGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVFAHGAATLSP
[0136] Interleukin-35 (IL-35) As used herein, "interleukin-35" or "IL-35" is a heterodimer consisting of Epstein-Barr virus-induced gene 3 (EBI3) protein and IL-12p35 (IL-12A) subunit, which constitutes the IL-12 cytokine family together with IL-12, IL-23 and IL-27 and plays an important regulatory role in T cell proliferation activation and cytokine production. Research has demonstrated that IL-35 is mainly secreted by regulatory T cells (Treg), is one of the major cytokines that Treg exerts negative immune regulation, and is involved in the immune regulation of inflammation in various diseases (experimental colitis, collagen-induced arthritis, autoimmune demyelitis, chronic hepatitis, diabetes, tumors, etc.), and is closely related to the development, progression and progression of diseases.
[0137] DNA sequence of IL-35 (EBI3 protein) (SEQ ID NO: 225) cgcaaaggtccgccggcagcactgaccctgccgcgtgttcagtgtcgtgcatcccgctatccgattgcagttgattgtagttggaccctgccgccggcaccgaattccacctcaccggttagctttattgctacctatcgtctgggtatggccgca cgtggtcattcatggccttgtctgcagcagaccccgaccagcacgagctgtaccatcaccgatgttcagctgttttctatggcaccgtatgttctgaatgttacggcagttcatccgtggggttcaagcagctcttttgttccatttattaccgaac atatcatcaaaccggaccctccggaaggtgttcgtctgagcccgctggcagaacgtcagctgcaggttcagtgggaaccgccaggttcatggccgtttcctgaaatttttagcctgaaatattggattcgttataaacgtcagggtgcggcccgttt tcatcgtgttggtcctattgaagcaacctcatttattctgcgtgcggtccgtcctcgtgcccgttattatgttcaggtcgccgcacaggatctgaccgattatggtgaactgagcgattggtcactgccggcaaccgcgaccatgtccctgggtaaa
[0138] Amino acid sequence of IL-35 (EBI3 protein) (SEQ ID NO: 226) RKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPVSFIATYRLGMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSFVPFITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYWIRYKRQGAARFHRVGPIEATSFILRAVRPRARYYVQVAAQDLTDYGELSDWSLPATATMSLGK
[0139] DNA sequence of IL-35 (IL-12p35 subunit) (SEQ ID NO:227) cgtaacctgccggttgcgaccccggaccctggcatgtttccgtgtctgcatcattctcagaatctgctgcgtgcagtctctaatatgctgcagaaagcacgtcagaccctggaattttatccgtgtaccagtgaagaaatcgatcat gaagatattaccaaagataaaaccagcaccgtggaagcatgtctgccgctggaactgaccaaaaacgaaagctgtctgaacagccgcgaaaccagttttattacaaatggtagttgtctggcaagccgcaaaaccagctttatgatgg cgctgtgtctgagctcaatttatgaagatctgaaaatgtatcaggtggaatttaaaaccatgaatgccaaactgctgatggaccctaaacgtcagatttttctggatcagaatatgctggcagttatcgatgaactgatgcaggcact gaactttaatagcgaaaccgttccgcagaaaagctccctggaagaaccggatttttataaaaccaaaatcaaactgtgcatcctgctgcatgcatttcgtattcgtgcagttaccattgatcgtgtgatgagctatctgaatgcaagc
[0140] Amino acid sequence of IL-35 (IL-12p35 subunit) (SEQ ID NO:228) RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS
[0141] Interleukin-37 (IL-37) As used herein, "interleukin-37" or "IL-37" has five different subtypes (IL-37a-e). Current research has shown that only IL-37b has biological function and has anti-inflammatory effects in various diseases. IL-37 may be secreted outside the cell as a cytokine that binds to receptors and regulates cell activity, or it may enter the cell nucleus as a transcription factor. IL-37 has high homology with L-18, binds to IL-18 binding protein (IL-18BP), and has a certain inhibitory effect on the IL-18 signaling pathway.
[0142] DNA sequence of IL-37 (SEQ ID NO: 229) gttcataccagtccgaaagtgaaaaatctgaatccgaaaaagtttagcatccatgatcaggatcataaagttctggtactggatagcggtaatctgattgcagtgccggataaaaattatattcgtccg gaaatttttttgccctggcaagcagcctgagttcagcctcagcggaaaaaggtagcccgattctgctgggtgttagtaaaggtgaattttgtctgtattgtgataaagataaaggccagagccatccga gtctgcagctgaaaaaggaaaaactgatgaaactggcagcacagaaagaaagcgctcgtcgtccgtttattttttatcgtgcacaggtgggtagctggaatatgctggaaagcgcagcccatccaggttg gtttatttgcaccagctgcaattgtaatgaaccggtgggtgttaccgataaatttgaaaatcgtaaacatatcgaatttagctttcagccggtttgtaaagcagaaatgagcccgagcgaagttagtgat
[0143] Amino acid sequence of IL-37 (SEQ ID NO:230) VHTSPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD
[0144] TGF-β "Transforming growth factor beta" or "TGF-β" as used herein is a multifunctional cellular hormone. Many types of cells in the human body have the ability to produce and secrete such cellular hormones. TGF-β is involved in the mechanisms of various diseases and plays a dual role in suppressing or promoting the disease. Wound healing, tissue fibrosis, atherosclerosis, cancer development and metastasis, autoimmune diseases, diabetic complications, and neurological damage due to Alzheimer's disease are all closely related to TGF-β. There are two immune responses in the human body. The normal immune defense response mediated by type 1 helper T cells (TH1) is responsible for the immune defense mechanism against infectious microorganisms. When the function of TH1 cells is too strong, cellular hormones that cause inflammatory reactions, such as interleukin-2 (IL-2) and interferon-γ (IFN-γ), are secreted, and the cellular immune response is enhanced, attacking specific tissues and special cells in the human body, resulting in long-term damage to these specific tissues and organs, especially autoimmune diseases and organ transplant rejection. The allergic immune defense response mediated by type 2 helper T cells (TH2) is responsible for the immune defense mechanism against parasites, stinging insects, allergens and irritants in the barrier layer organs. When the function of TH2 cells is too strong, the secretion of TH2 cellular hormones becomes excessive, promoting B cells to produce large amounts of the allergic antibody IgE. IgE induces the release of inflammatory substances such as histamine, interleukin, cellular hormones, and platelet activating factor from mast cells and basophils, and acts on cells and blood vessels to cause vasodilation and smooth muscle contraction, causing allergic symptoms such as allergic asthma, allergic rhinitis, and atopic dermatitis. These two types of immunity exist in the human body as a balance between the two, and TH1 and TH2 are balanced by each other and are jointly controlled by regulatory cells (Treg) and immune regulators (TGF-β). By maintaining the balance between TH1 and TH2, which are the body's immune defense system, the effect of preventing autoimmune diseases and allergy-related diseases is realized. In common genetic allergic diseases such as atopic dermatitis, asthma, and allergic rhinitis, the TGF-β immune regulator is lacking in the body.Research has shown that long-term supplementation with TGF-β can increase body levels, improve physical condition, reduce inflammation, alleviate allergy symptoms, repair tissues, prolong the protective power of breast milk for infants and young children, improve the body's tolerance to foods, and maintain gastrointestinal function.
[0145] DNA sequence of TGF-β (SEQ ID NO:231) gcactggataccaattattgtttttcaagcaccgaaaaaaattgttgtgttcgtcagctgtatattgattttcgtaaagatctgggttggaaatggattcatgaaccgaaaggttatcatgcaaatttttgtctgggtccgtgtccgtatatttggagcctggatacc cagtatagcaaagttctggcactgtataatcagcataatccgggtgcaagcgcagcaccgtgttgtgttccgcaggcactggaaccgctgccgattgtttattatgttggtcgtaaaccgaaagttgaacagctgagcaatatgattgttcgtagctgtaaatgtagc
[0146] Amino acid sequence of TGF-β (SEQ ID NO:232) ALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS
[0147] C. Expression Cassette The term "expression cassette" as used herein refers to a DNA sequence capable of directing the expression of a particular nucleotide sequence in a suitable microorganism, and includes a promoter operably linked to a nucleotide sequence of interest that is operably linked to a termination signal. It also generally includes sequences necessary for proper translation of the nucleotide sequence. The coding region usually encodes a protein of interest, but can also encode a functional RNA of interest, such as an antisense RNA or a non-translated RNA in the antisense orientation. An expression cassette containing a nucleotide sequence of interest may be chimeric, meaning that at least one of its constituent units is heterologous to at least one of the other constituent units.
[0148] As used herein, the term "recombinant" refers to a polynucleotide that has been synthesized or otherwise manipulated in vitro (e.g., a "recombinant expression cassette"), to a method of producing a product using a recombinant polynucleotide or recombinant expression cassette in a cell or other biological system, or to a polypeptide encoded by a recombinant polynucleotide. A "recombinant expression cassette" encompasses nucleic acid molecules from different sources that are linked into an expression cassette or vector to express a protein produced, for example, by inducible or constitutive expression of a fusion protein or polypeptide. A recombinant expression cassette encompasses a recombinant polynucleotide operably linked to one or more regulatory elements.
[0149] In some embodiments, in the genetically modified microorganisms described herein, the at least two exogenous genes are contained in (at least one) exogenous expression cassette.
[0150] In some embodiments, the genetically modified microorganism described herein comprises at least one, at least two, or all three exogenous expression cassettes selected from the first to third exogenous expression cassettes described below. The first exogenous expression cassette (also referred to as "Amuc_1100 expression cassette", "exogenous expression cassette A" or "expression cassette A" used interchangeably and with the same meaning in this disclosure) contains a nucleotide sequence encoding an Amuc_1100 polypeptide. The second exogenous expression cassette (also referred to as "IL-10 expression cassette", "exogenous expression cassette B" or "expression cassette B" used interchangeably and with the same meaning in this disclosure) contains a nucleotide sequence encoding an IL-10. The third exogenous expression cassette (also referred to as "IL-22 expression cassette", "exogenous expression cassette C" or "expression cassette C" used interchangeably and with the same meaning in this disclosure) contains a nucleotide sequence encoding an IL-22.
[0151] In some embodiments, the at least one exogenous expression cassette comprises one or more regulatory elements (or "expression regulatory elements" having the same meaning herein) operably linked to the exogenous gene.
[0152] In some embodiments, the regulatory element comprises one or more elements selected from the group consisting of a promoter, a ribosome binding site (RBS), a mistron, a terminator, and any combination thereof.
[0153] i. Promoter The term "promoter" as used herein refers to a non-translated DNA sequence that contains a binding site for RNA polymerase and initiates DNA transcription, usually upstream of a coding region. The promoter region may also contain other elements that act as regulators of gene expression. In some embodiments, the promoter is suitable for initiating a polynucleotide encoding an Amuc_1100 polypeptide, IL-10 and / or IL-22 in a genetically modified microorganism. In some embodiments, the promoter is a constitutive promoter or an inducible promoter.
[0154] The term "constitutive promoter" refers to a promoter capable of promoting the continuous transcription of a coding sequence or gene under its control and / or operably linked thereto. Constitutive promoters and variants thereof are well known in the art and include, for example, BBa_J23119, BBa_J23101, BBa_J23102, BBa_J23103, BBa_J23109, BBa_J23110, BBa_J23114, BBa_J23117, USP45_promoter, Amuc_1102_promoter, OmpA_promoter, BBa_J23100, BBa_J23104, BBa_J23105, BBa_I14018, BBa_J45992, BBa_J23118, BBa_J23116, BBa_J23117 ...2, BBa_J23119, BBa_J23103, BBa_J23109, BBa_J23110, BBa_J23114, BBa_J2 These include, but are not limited to, J23115, BBa_J23113, BBa_J23112, BBa_J23111, BBa_J23108, BBa_J23107, BBa_J23106, BBa_I14033, BBa_K256002, BBa_K1330002, BBa_J44002, BBa_J23150, BBa_I14034, Oxb19, oxb20, BBa_K088007, Ptet, Ptrc, PlacUV5, BBa_K292001, BBa_K292000, BBa_K137031 and BBa_K137029. Exemplary constitutive promoter nucleotide sequences include nucleotide sequences selected from the group consisting of SEQ ID NOs: 16-56 shown in Table 3, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In some embodiments, the constitutive promoter includes a nucleotide sequence shown in any of SEQ ID NOs: 16-56. In some embodiments, the promoter is active under in vitro conditions, e.g., culture, amplification, and / or production. In some embodiments, the promoter is active in an in vivo environment, e.g., the intestinal tract and / or an inflammatory microenvironment. Exemplary constitutive promoter nucleotide sequences are shown in Table 3.
[0155] [Table 3-1] [Table 3-2]
[0156] As used herein, the term "inducible promoter" refers to a regulated promoter that can be activated in one or more cell types by an external stimulus, such as a chemical, light, hormone, stress, or pathogen. Inducible promoters and variants thereof are well known in the art and include, but are not limited to, PLteto1, galP1, PLlacO1, Pfnrs, Psal, Pvan. In some embodiments, the nucleotide sequence of an exemplary inducible promoter comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 57-61 shown in Table 4, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity.
[0157] [Table 4]
[0158] In some embodiments, the promoter is an endogenous promoter or an exogenous promoter. An exogenous promoter refers to a promoter that is operably linked to a coding region, provided that the promoter is not the promoter that is naturally associated with the coding region in the genome of an organism. A promoter in a genome that is naturally associated with or linked to a coding region is referred to as an endogenous promoter of the coding region. In some embodiments, the promoter is operably linked upstream or downstream of the transcription start site of a gene of interest.
[0159] In some embodiments, the promoter is selected from BBa_J23101, BBa_J23108, BBa_J23110, PfnrS, Psal, Pvan, BBa_J23119, BBa_J23102, or BBa_J23114.
[0160] ii. Ribosome binding site The term "ribosome binding site" ("RBS"), as used herein, refers to a sequence in an mRNA to which a ribosome binds to initiate translation of a protein. The RBS has a length of approximately 35 nucleotides and contains three distinct domains: (1) the Shine-Dalgarno (SD) sequence, (2) the spacer region, and (3) the first 5-6 codons of the coding sequence (CDS). RBSs and variants thereof are well known in the art and include, but are not limited to, USP45, Synthesized, Amuc_1102, and OmpA. Exemplary RBS nucleotide sequences include nucleotide sequences selected from the group consisting of SEQ ID NOs:62-65 shown in Table 5, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In one embodiment, the ribosome binding site is operably linked 8 to 13 nucleotides upstream of the coding region of the gene of interest.
[0161] [Table 5]
[0162] iii. Mistron The term "mistron" as used herein refers to a segment of a nucleic acid sequence that is transcribed and encodes a polypeptide. Mistrons and variants thereof are well known in the art and include, but are not limited to, GFP, BCD2, luciferase, MBP. Exemplary nucleotide sequences of mistrons include nucleotide sequences selected from the group consisting of SEQ ID NOs: 66-75 shown in Table 6, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In one embodiment, a mistron is operably linked to the N-terminus of the coding region of a gene of interest.
[0163] [Table 6]
[0164] iv. Terminator The term "terminator" as used herein refers to a nucleotide sequence that provides an RNA polymerase transcription termination signal, which subsequently prevents incorporation of nucleotides into the resulting polynucleotide chain, thereby disrupting polymerase-mediated elongation. In some embodiments, the terminator used in this disclosure is a T7 terminator. In some embodiments, the terminator comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 76-79 shown in Table 7, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In some embodiments, the terminator is operably linked to the 3' end of the encoding gene. In some embodiments, the terminator used in the present disclosure is a rrnB_T1_T7Te_terminator comprising a sequence in which a rrnB_T1_terminator and a T7Te_terminator are linked in tandem, and the specific sequence is caaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcg (sequence number 242).
[0165] [Table 7]
[0166] D. Secretion and / or Export Pathways in Microorganisms In certain embodiments, the polynucleotide sequence encoding the Amuc_1100 polypeptide, IL-10 and / or IL-22 in the exogenous expression cassettes provided herein is operably linked to a signal peptide.
[0167] The term "signal peptide" or "signal sequence" as used herein refers to a peptide that can be used to secrete a heterologous polypeptide into the periplasm or medium of cultured bacteria, or to secrete an Amuc_1100 polypeptide, IL-10 and / or IL22 into the periplasm. The signal of the heterologous polypeptide may be homologous or heterologous to the bacterium, including signals derived from the polypeptide produced in the bacterium. For Amuc_1100, IL-10 and / or IL22, the signal sequence is generally endogenous to the bacterial cell, but need not be endogenous, so long as it is effective for its purpose. Non-limiting examples of secretory peptides include USP45, OppA (ECOLIN_07295), OmpA, OmpF, cvaC, TorA, fdnG, dmsA, PelB, HlyA, adhesin (ECOLIN_19880), DsbA (ECOLIN_21525), Gltl (ECOLIN_03430), GspD (ECOLIN_16495), HdeB (ECOLIN_19410), MalE (ECOLIN_22540), PhoA (ECOLIN_02255), PpiA (ECOLIN_18620), TolB, tort, mglB, and lamB. In some embodiments, the secretory peptide is USP45.
[0168] In certain embodiments, the signal peptide for Amuc_1100, IL-10 and / or IL22 secretion provided herein comprises USP45, OmpA, DsbA, pelB, Cel-CD, sat or the endogenous signal peptide of Amuc_1100, IL-10 and / or IL22 (or referred to as "its own signal peptide", as used herein, "endogenous signal peptide" and "its own signal peptide" have the same meaning and both refer to the original or naturally occurring signal peptide sequence in the wild-type polypeptide sequence). Exemplary signal peptide nucleotide sequences include nucleotide sequences selected from the group consisting of SEQ ID NOs: 123-135 shown in Table 9, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In some embodiments, the signal peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-122 shown in Table 8, and homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity. In some embodiments, the signal peptide is operably linked to the N-terminus of the expressed target protein. In some embodiments, for protein secretion, the target protein (e.g., Amuc_1100, IL-10 and / or IL-22) is linked at its N-terminus to a selected signal peptide (a first signal peptide, a second signal peptide or a third signal peptide described herein, e.g., USP45 signal peptide) after its own signal peptide sequence is removed (i.e., its own signal peptide is replaced with the selected signal peptide).
[0169] In some embodiments, the expression cassette comprises a nucleotide sequence encoding Amuc_1100, IL-10 and / or IL-22 operably linked to a signal peptide and an autotransporter domain, wherein the signal peptide and the autotransporter domain are operably linked to both ends of Amuc_1100, IL-10 and / or IL-22. For example, the signal peptide is operably linked to the N-terminus of Amuc_1100, IL-10 and / or IL-22, and the autotransporter domain is operably linked to the C-terminus of Amuc_1100, IL-10 and / or IL-22. The construct is useful for type V autocrine mediated secretion. The N-terminal signal peptide is removed when the precursor protein is transported from the cytoplasm to the periplasmic compartment by the native secretion system (e.g., the Sec system), and the C-terminal autotransporter domain is removed, e.g., by autocatalytic or protease-catalyzed OmpT cleavage, once the precursor protein has crossed the outer membrane, thus releasing the mature protein (e.g., Amuc_1100 polypeptide, IL-10 and / or IL-22) into the extracellular environment.
[0170] [Table 8-1] [Table 8-2]
[0171] [Table 9]
[0172] In some embodiments, the signal peptide can be processed by an export pathway and / or secretion system present in the genetically engineered microorganism (e.g., genetically modified bacteria). Typically, the signal peptide is at the N-terminus of the exported precursor protein and can direct the precursor protein to an export pathway at the plasma membrane of the bacterial cell. The secretion system can remove the signal peptide from the precursor protein before secreting the mature protein from the genetically engineered microorganism (e.g., bacteria).
[0173] As used herein, the term "secretion system" is used interchangeably with "export system" and "export pathway" herein and refers to a native or non-native secretion mechanism capable of secreting or exporting an expressed polypeptide product (e.g., Amuc_1100 polypeptide) from a microorganism (e.g., bacterial cytoplasm). From outside to inside, Gram-negative bacteria such as E. coli have the outer membrane (OM), peptidoglycan cell wall, periplasm, inner membrane (IM), and cytoplasmic compartments. The OM is a highly effective and selective permeability barrier. The OM is a lipid bilayer composed of phospholipids in the inner leaflet and glycolipids in the outer leaflet, as well as lipoproteins and β-barrel proteins. The OM is anchored to the underlying peptidoglycan by a lipoprotein called Lpp. The periplasm is densely packed with proteins and is more viscous than the cytoplasm. The IM is a phospholipid bilayer that primarily houses membrane proteins that function in energy production, lipid biosynthesis, protein secretion, and transport.
[0174] There are two common protein export pathways in bacteria, including the common secretion (or Sec) pathway and the twin-arginine transport (or Tat) pathway. The Sec pathway usually processes unfolded high molecular weight precursor proteins, and a signal peptide targets the substrate protein to the membrane-bound Sec translocase. The precursor target protein is delivered to the translocase and passes through the SecYEG pore via SecA, SecD, and SecF. The chaperones SecB, GroEL-GroES, and DnaK-DnaJ-GrpE assist in the transport of the target protein. The Tat pathway usually transports fully folded or oligomeric proteins and is composed of TatA, TatB, and TatC in both Gram-negative and Gram-positive bacteria. After membrane translocation, the signal peptide is removed by a signal peptidase, and the mature protein is secreted.
[0175] Gram-negative bacteria have dedicated one-step secretion systems. Non-limiting examples of secretion systems include the Sat secretion system, type I secretion system (T1SS), type II secretion system (T2SS), type III secretion system (T3SS), type IV secretion system (T4SS), type V secretion system (T5SS), type VI secretion system (T6SS), and the resistance-nodulation-division (RND) family of multidrug efflux pumps, various single membrane secretion systems.
[0176] In some embodiments, the secretion system is native or non-native to the genetically modified microorganism. "Native" to the microorganism means that the secretion system is normally present in the microorganism, and "non-native" to the microorganism means that the secretion system is not normally present in the microorganism, such as a secretion system from a different species, strain or substrain of bacteria or virus, or an additional secretion system that is modified and / or mutated compared to an unmodified secretion system from a microorganism of the same subtype.
[0177] In some embodiments, the genetically modified microorganism of the present disclosure further comprises one or more genetic modifications in the genome of the microorganism, in some embodiments, the one or more genomic manipulations comprise engineering and / or optimizing a secretion system such that at least one gene encoding an outer membrane protein is deleted, inactivated or silenced.
[0178] In some embodiments, the secretion system has been engineered and / or optimized such that at least one gene encoding an outer membrane protein in the genetically modified microorganism is deleted, inactivated or silenced, in some embodiments, the outer membrane protein is selected from the group consisting of OmpC, OmpA, OmpF, OmpT, pldA, pagP, tolA, Pal, To1B, degS, mrcA and lpp.
[0179] To produce a Gram-negative bacterium (e.g., EcN) capable of secreting a therapeutic protein or peptide of interest, it is necessary to genetically modify the bacterial host to have a "leaky" or destabilized outer membrane without affecting the chemical and physical activity of the host bacterium. For example, a "leaky" outer membrane can be generated by deleting or mutagenizing genes such as lpp, ompC, ompA, ompF, ompT, pldA, pagP, tolA, to1B, pal, degS, degP, and nlpI. Lpp is the most abundant polypeptide in bacterial cells and serves as the major "staple" of the bacterial cell wall and peptidoglycan. Deletion of lpp has minimal effect on bacterial growth but increases the secretion of Amuc_1100, for example, by at least two-fold. Inducible promoters can be used to replace the endogenous promoter of one or more selected genes with minimal adverse effects on cell viability.
[0180] "Deletion / deletion" or "inactivation" or "suppression" of a gene or coding region means that the enzyme or protein encoded by said gene or coding region is not produced, is produced in an inactive form in a microorganism, or is produced in a microorganism at a level lower than that found in the wild-type form of the microorganism under the same or similar growth conditions. This can be achieved, for example, by one or more of the following methods: (1) homologous recombination, (2) RNA interference-based technologies, (3) ZFN and TALEN, and (4) CRISPR / Cas systems.
[0181] In some embodiments, the secretion system is engineered such that at least one gene encoding a chaperone is amplified, overexpressed, or activated.
[0182] Chaperones are involved in many important biological processes, such as protein folding and aggregation of oligomeric protein complexes, maintain protein precursors in an unfolded state to facilitate transmembrane transport of proteins, and allow depolymerization and repair of denatured proteins. Chaperones primarily perform normal physiological functions by helping other peptides maintain their normal conformation and form correct oligomeric structures. Various chaperones are known in the art. In some embodiments, the chaperone is selected from the group consisting of dsbA, dsbC, dnaK, dnaJ, grpE, groES, groEL, tig, fkpA, surA, skp, PpiD, and DegP. In some embodiments, the chaperone is selected from the group consisting of Ssa1p, Ssa2p, Ssa3p and Ssa4p of the cytoplasmic SSA subfamily of 70 kDa heat shock proteins (Hsp70), BiP, Kar2, Lhs1, Sil1, Sec63, protein disulfide bond isomerase Pdi1p, and in some embodiments, the chaperone is composed of dsbA, dsbC, dnaK, dnaJ, grpE, groES, groEL, tig, fkpA and surA.
[0183] "Overexpressed" or "overexpression" of a gene or coding region means that an enzyme or protein encoded by said gene or coding region is produced in a microorganism at a level higher than that found in the wild type of the microorganism under the same or similar growth conditions. This can be achieved, for example, by one or more of the following methods: (1) placement of a stronger promoter, (2) placement of a stronger ribosome binding site, such as a DNA sequence of 5'-AGGAGG located approximately 4-10 bases upstream of the translation initiation codon, (3) placement of a terminator or stronger terminator, (4) improved codon selection at one or more sites in the coding region, (5) improved stability of the mRNA, and (6) increased copy number of the gene by introducing multiple copies into the chromosome or placing the cassette in a multicopy plasmid. The enzyme or protein produced by an overexpressed gene is referred to as "overproduced." An "overexpressed" gene or an "overproduced" protein may be native to the microorganism or may be transferred to the microorganism from a different organism by methods of genetic modification. In the latter case, the enzyme or protein and the gene or coding region encoding the enzyme or protein are said to be "foreign" or "heterologous." Foreign or heterologous genes and proteins are not present in the non-genetically engineered microorganism and are therefore overexpressed or overproduced.
[0184] The secretory system of yeast mainly consists of nascent protein translocation, protein folding in the endoplasmic reticulum (ER), glycosylation, protein sorting, and transport. When the signal peptide emerges from the ribosome during translation, the newly synthesized membrane or secreted protein is recognized by the signal recognition particle (SRP) and subsequently targeted for translation through the Sec61 or Ssh1 translocon pore for secretion. To improve heterologous protein production in yeast, various approaches have been implemented, including (1) engineering signal peptides and increasing promoter strength or plasmid copy number, and (2) engineering post-translational pathways in the host strain, such as overexpression of ER folding chaperones or vesicular transport components, to reduce intracellular and extracellular protein hydrolysis. Exemplary yeast secretory signal peptides for secreting heterologous proteins include the Saccharomyces cerevisiae α-Mating Factor (α-MF) pre pro-peptide, the signal peptide of inulinase from Kluyveromyces marxianus, the signal peptide of PHAE from Phaseolus vulgaris agglutinin, the signal peptide of a prepro toxin, the signal peptide of Rhizopus oryzae amylase or the signal sequence of the hydrophobic protein from Trichoderma reesei.
[0185] E. Genomic integration site In some embodiments, the exogenous expression cassette is integrated into the genome of the genetically modified microorganism.
[0186] In some embodiments, the exogenous expression cassette is contained in a plasmid, and the plasmid has been introduced into the microorganism and is suitable for expression in the microorganism.
[0187] In some embodiments, the genetically modified microorganisms described herein allow for the stable growth and expression of non-native genetic material, such as genes encoding Amuc_1100, IL-10 and / or IL-22, or exogenous expression cassettes expressing these polypeptides / proteins. In some embodiments, the non-native genetic material is introduced into the genome of the microorganism or replicated on an extrachromosomal plasmid, thereby allowing the non-native genetic material to be maintained, transcribed and expressed.
[0188] In some embodiments, the stable microorganism (e.g., bacteria) may be a genetically modified microorganism that expresses and secretes Amuc_1100, IL-10, and / or IL-22. A plasmid or chromosome carrying an exogenous expression cassette encoding Amuc_1100, IL-10, and / or IL-22 is stably maintained in the genetically modified microorganism, such that the exogenous expression cassette is expressed in the genetically modified microorganism, allowing the genetically modified microorganism to survive and / or grow in vitro and / or in vivo. A stable microorganism can survive and grow in vitro (e.g., in a culture medium) or in vivo (e.g., in the digestive tract).
[0189] In some embodiments, the copy number affects the stability of expression of the non-natural genetic material. In some embodiments, the copy number affects the level of expression of the non-natural genetic material. In embodiments where the genetically modified microorganism comprises one or more gene sequences and one or more gene cassettes, the gene sequences may be present on one or more plasmids and the gene cassettes may be present in the chromosome of the microorganism, or vice versa. Also, multiple copies (e.g., 1, 2, 3, 4, 5, 6 or more) of any gene, gene cassette or regulatory region may be present in the microorganism, provided that one or more copies of the gene, gene cassette or regulatory region may be mutated or otherwise altered as described herein. In some embodiments, the genetically modified microorganism is engineered to include multiple copies of the same gene, gene cassette or regulatory region to increase the copy number. In some embodiments, the genetically modified microorganism is engineered to include multiple different units of a gene cassette that perform multiple different functions. In some embodiments, the genetically modified microorganism is engineered to contain one or more copies of different genes, gene cassettes, or regulatory regions to produce a genetically modified microorganism that expresses one or more therapeutic molecules and / or performs one or more functions. In some embodiments, the copy number affects the stability of expression of the non-native genetic material. In some embodiments, the copy number affects the level of expression of the non-native genetic material.
[0190] In some embodiments, the two or more gene sequences are multiple copies of the same gene. In some embodiments, the two or more gene sequences are sequences encoding different genes. In some embodiments, the two or more gene sequences are sequences encoding multiple copies of one or more different genes. In some embodiments, the genetically modified microorganism comprises one or more gene cassettes of a molecule used to treat or prevent an inflammatory disease or an autoimmune disease. For example, the genetically modified microorganism may comprise two or more gene cassettes of a molecule used to treat or prevent an inflammatory disease or an autoimmune disease. In some embodiments, the two or more gene cassettes are multiple copies of the same gene cassette. In some embodiments, the two or more gene cassettes are different gene cassettes for producing the same or different molecules for treating or preventing an inflammatory disease or an autoimmune disease. In some embodiments, the two or more gene cassettes are gene cassettes for multiple copies of a molecule.
[0191] Also, multiple copies of any regulatory region, promoter, gene, and / or gene cassette may be present in the genetically modified microorganism, although one or more copies of the regulatory region, promoter, gene, and / or gene cassette may be mutated or otherwise altered as described herein. In some embodiments, the genetically modified microorganism is engineered to contain multiple copies of the same regulatory region, promoter, gene, and / or gene cassette to increase the copy number, or to contain multiple different constituent units of a gene cassette that perform multiple different functions, or to contain one or more copies of different regulatory regions, promoters, genes, and / or gene cassettes to produce a genetically modified microorganism that expresses one or more therapeutic molecules and / or performs one or more functions.
[0192] In some embodiments, the exogenous expression cassette is integrated into the genome of the genetically modified microorganism by a CRISPR-Cas genome editing system. Any suitable microorganism provided herein can be engineered to integrate an exogenous expression cassette into its genome.
[0193] In some embodiments, the genetically modified microorganism is the Nissle 1917 (EcN) strain of E. coli, and the exogenous expression cassette is integrated into a site in the EcN genome. In some embodiments, suitable integration sites in the EcN genome are integration sites agaI / rsmI, lacZ, kefB, malP / T, yicS / nepl, rhtB / C, maeB, malE / K, yieN, lldD, maeA, pflB, or araB / C. Amuc_1100, IL-10, and / or IL-22 used in the present invention are integrated into a genomic site in EcN. Without wishing to be bound by any theory, the genomic site of EcN disclosed herein is believed to be advantageous for insertion of expression cassettes for Amuc_1100, IL-10 and / or IL-22 because it has at least one of the following characteristics: (1) one or more bacterial genes affected by genetic engineering at said site are not essential for the growth of EcN and the biochemical and physiological activities of the host bacterium are not altered; (2) said site is easily editable; and (3) the Amuc_1100 gene cassette, IL-10 and / or IL-22 gene cassette at said site can be transcribed.
[0194] F. Auxotrophs In some embodiments, the microorganism of the present disclosure further comprises an inactivation or deletion of at least one of the auxotrophy-associated genes.
[0195] To produce environmentally friendly bacteria, genetically engineered bacteria can be made auxotrophic by gene editing to delete or inactivate essential genes required for the survival of some bacterial cells. As used herein, the term "auxotroph" refers to a microorganism (e.g., a microbial strain) that requires an external source of a particular metabolite for growth that it cannot synthesize due to an acquired genetic defect.
[0196] As used herein, the term "auxotrophy-associated gene" refers to a gene required for the survival of a microorganism (e.g., a microorganism such as a bacterium). The auxotrophy-associated gene may be required for the microorganism to produce a nutrient required for survival or growth, or may be required for the microorganism to detect a signal in the environment that regulates the activity of a transcription factor, the absence of which leads to cell death.
[0197] In some embodiments, auxotrophic modifications are made so that the microorganism will die in the absence of an exogenously added nutrient required for survival or growth (because the microorganism lacks one or more genes required to produce the essential nutrient). In some embodiments, any of the genetically modified bacteria described herein also contains a deletion or mutation in a gene required for cell survival and / or growth.
[0198] Various auxotrophy-related genes in bacteria are well-known in the art. Exemplary auxotrophy-related genes include thyA, cysE, glnA, ilvD, leuB, lysA, serA, metA, glyA, hisB, ilvA, pheA, proA, thrC, trpC, tyrA, uraA, dapF, flhD, metB, metC, proAB, yhbV, yagG, hemB, secD, secF, ribD, ribE, thiL, dxs, ispA, dnaX, adk, hemH, IpxH, cysS, fold, rplT, infC, thrS, nadE, gapA, yeaZ, aspS, argS, pgsA, yeflA, metG, folE, yejM, gyrA, nrdA, nrdB, folC, accD, fabB, gltX, ligA, zipA, dapE, dapA, der, hisS, ispG, suhB, tadA, acpS, era, rnc, fisB, eno, pyrG, chpR, Igt, fbaA, pgk, yqgD, metK, yqgF, plsC, ygiT, pare, ribB, cca, ygjD, tdcF, yraL, yihA, ftsN, murl, murB, birA, secE, nusG, rplJ, rplL, rpoB, rpoC, ubiA, plsB, lexA, dnaB, ssb, alsK, groS, psd, orn, yjeE, rpsR, chpS, ppa, valS, yjgP, yjgQ, dnaC, ribF, IspA, ispH, dapB, folA, imp, yabQ, flsL, flsl, murE, murF, mraY, murD, ftsW, murG, murC, ftsQ, ftsA, ftsZ, IpxC, secM, secA, can, folK, hemL, yadR, dapD, map, rpsB, infB, nusA, ftsH, obgE, rpmA, rplU, ispB, murA, yrbB, yrbK, yhbN, rpsl, rplM, degS, mreD, mreC, mreB, accB, accC, yrdC, def, fint, rplQ, rpoA, rpsD, rpsK, rpsM, entD, mrdB, mrdA, nadD, hlepB, rpoE, pssA, yfiO, rplS, trmD, rpsP, ffh, grpE, yfjB, csrA, ispF, ispD, rplW, rplD, rplC,rpsJ, fusA, rpsG, rpsL, trpS, yrfF, asd, rpoH, ftsX, ftsE, ftsY, frr, dxr, ispU, rfaK, kdtA, coaD, rpmB, djp, dut, gmk, spot, gyrB, dnaN, dnaA, rpmH, rnpA, yidC, tnaB, glmS, glmU, wzyE, hemD, hemC, yigP, ubiB, ubiD, hemG, secY, rplO, rpmD, rpsE, rplR, rplF, rpsH, rpsN, rplE, rplX, rplN, rpsQ, rp mC, rplP, rpsC, rplV, rpsS, rplB, cdsA, yaeL, yaeT, lpxD, fabZ, IpxA, IpxB, dnaE, accA, tilS, proS , yafF, tsf, pyrH, olA, rlpB, leuS, Int, glnS, fldA, cydA, infA, cydC, ftsK, lolA, serS, rpsA, msbA , IpxK, kdsB, mukF, mukE, mukB, asnS, fabA, mviN, rne, yceQ, fabD, fabG, acpP, tmk, holB, lolC, lol D, lolE, purB, ymflC, minE, mind, pth, rsA, ispE, lolB, hemA, prfA, prmC, kdsA, topA, ribA, fabi, r Examples include, but are not limited to, acR, dicA, ydB, tyrS, ribC, ydiL, pheT, pheS, yhhQ, bcsB, glyQ, yibJ and gpsA. ,
[0199] In one modification, the essential gene thyA is deleted or replaced with another gene, thereby rendering the genetically modified bacteria dependent on exogenous thymine for growth or survival. The addition of thymine to the growth medium or the human intestinal tract, which has a naturally high thymine content, can support the growth and survival of thyA auxotrophic bacteria. This modification is made to ensure that the genetically modified bacteria cannot grow and survive outside the intestinal tract or in an environment lacking the auxotrophic gene product.
[0200] In some embodiments, the microorganism is an auxotroph for one or more substances selected from the group consisting of uracil, thymine, diaminopimelic acid, leucine, histidine, tryptophan, lysine, methionine, adenine, and a non-naturally occurring amino acid sequence, in some embodiments, the non-naturally occurring amino acid sequence is selected from the group consisting of l-4,4'-biphenylalanine, p-acetyl-l-phenylalanine, p-iodo-l-phenylalanine, and p-azido-l-phenylalanine.
[0201] In some embodiments, the microorganism comprises an allosteric regulatory transcription factor capable of detecting a signal in the environment that regulates the activity of the transcription factor, where absence of said signal results in cell death. The "signaling molecule-transcription factor" pair may comprise one or more selected from the group consisting of tryptophan-TrpR, IPTG-LacI, benzoic acid ester derivative-XylS, ATc-TetR, galactose-GalR, estradiol-estrogen receptor hybrid protein, cellobiose-CelR, and homoserine lactone-luxR.
[0202] G. Deletion of endogenous plasmids In some embodiments, the genetically modified bacteria is deleted for one or more endogenous plasmids.
[0203] Some chassis bacterial hosts contain one or more endogenous plasmids that consume significant resources for transcription, and without wishing to be bound by any theory, it is believed that these endogenous plasmids are deleted to free up resources that are more readily available for heterologous gene expression.
[0204] One or more endogenous plasmids can be removed from the target microorganism by methods known in the art. For example, the two endogenous plasmids pMUT1 and pMUT2 contained in EcN can be removed from EcN by any suitable method. One exemplary approach is by CRISPR-Cas9-mediated DNA double-strand breaks. Briefly, pMUT1 or pMUT2 can be destroyed in EcN through Cas9 protein-mediated DNA double-strand breaks by introducing a guide RNA (gRNA or single-stranded guide RNA, i.e., sgRNA) that specifically binds to pMUT1 or pMUT2 and a nucleic acid sequence (e.g., a plasmid) that expresses Cas9 protein into EcN. In another embodiment, pMUT2 in EcN can be replaced with a recombinant pMUT2 plasmid that expresses a specific resistance gene (e.g., kanamycin resistance gene) first, for example by screening for a recombinant EcN that has resistance. Next, a nucleic acid sequence (e.g., a plasmid) expressing a gRNA or sgRNA that specifically binds to the resistance gene and a Cas9 protein is introduced, thereby destroying the replaced recombinant pMUT2 plasmid by a Cas9 protein-mediated DNA double-strand break in EcN.
[0205] The inventors of the present application have surprisingly discovered that the genetically modified microorganisms (e.g., bacteria) described in the present disclosure not only stably grow and maintain vitality, but also can simultaneously integrate at least two exogenous genes into their genomes, and can stably and efficiently express and secrete the polypeptides / proteins encoded by these at least two exogenous genes. More importantly, the microorganisms expressing and secreting the novel combinations of exogenous polypeptides (at least two combinations of Amuc_1100 / IL-10 / IL-22) have shown therapeutic effects against various inflammatory or autoimmune diseases (e.g., inflammatory bowel disease) in animal models after being administered via the intestinal tract, and even showed unexpected synergistic effects. Thus, the genetically engineered microorganisms of the present disclosure have a broad clinical application prospect as live drugs.
[0206] The present invention also provides a method for producing the genetically modified microorganism, comprising the steps of introducing a nucleotide sequence capable of exogenously expressing Amuc_1100, IL-10 and / or IL-22 of the present invention into a microorganism, thereby enabling the exogenous gene in the nucleotide sequence to be expressed in the microorganism, thereby obtaining the genetically modified microorganism.
[0207] In some embodiments, an exemplary optimized Amuc_1100 expression cassette of the present invention has a structure shown in any one of the following sequences, SEQ ID NO: 139 to SEQ ID NO: 143. An IL-10 expression cassette has a structure shown in any one of the following sequences, SEQ ID NO: 144 to SEQ ID NO: 156 and 235. An IL-22 expression cassette has a structure shown in any one of the following sequences, SEQ ID NO: 157 to SEQ ID NO: 163.
[0208] Examples of Amuc_1100 sequences containing different regulatory elements In some embodiments, the present application provides sequences of various Amuc_1100 specific expression cassettes containing different regulatory elements (e.g., different promoters, different signal peptides, different mistrons, etc.) as shown below. In some embodiments, the present application also provides genetically modified microorganisms (e.g., EcN) containing any of the Amuc_1100 specific expression cassette sequences. Examples of sequences of Amuc_1100 specific expression cassettes provided in the present application are as follows:
[0209] BBa_J23101_USP45_Amuc_1100(Y259A)_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4101, CBT4103 and CBT4108 in the examples of the present disclosure, SEQ ID NO: 139)
[0210] BBa_J23110_USP45_Amuc_1100(Y259A)_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4102, CBT4107, CBT4108 and CBT4109 in the examples of the present disclosure, SEQ ID NO: 140)
[0211] BBa_J23101_USP45_Amuc_1100(WT)_rrnB_T1(mutant)_T7Te (corresponding expression cassette contained in strains CBT4068, CBT4069, CBT4067 and CBT4070 in the examples of the present disclosure, SEQ ID NO: 141)
[0212] BBa_J23110_USP45_Amuc_1100(WT)_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4105, CBT4106, CBT4068, CBT4069, CBT4067 and CBT4070 in the examples of the present disclosure, SEQ ID NO: 142)
[0213] PfnrS_USP45_Amuc_1100(WT)_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4080, CBT4096, CBT4088, CBT4098 and CBT4111 in the examples of the present disclosure, SEQ ID NO: 143)
[0214] Examples of IL-10 sequences containing regulatory elements In some embodiments, the present application provides various IL-10 specific expression cassette sequences that contain different regulatory elements (e.g., different promoters, different signal peptides, different mistrons), as shown below. In some embodiments, the present application also provides genetically modified microorganisms (e.g., EcN) that contain any of the above IL-10 specific expression cassette sequences. Examples of IL-10 specific expression cassette sequences provided in the present application are as follows:
[0215] BBa_J23101_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4003 in the examples of the present disclosure, SEQ ID NO: 144) tctagagcttgtcgacgtctcgagtttacagctagctcagtcctaggtattatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0216] BBa_J23110_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassettes contained in strains CBT4005, CBT4071, CBT4072, CBT4073, CBT4074, CBT4112, CBT4020, CBT4075, CBT4076 and CBT4077 in the examples of the present disclosure, SEQ ID NO: 145) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagatcatta gcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccact tcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaagg agagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacc cggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaag gcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatg accatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcct ttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0217] BBa_J23108_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4004 in the examples of the present disclosure, SEQ ID NO: 146) tctagagcttgtcgacgtctcgagctgacagctagctcagtcctaggtataatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagatcatta gcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccact tcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaagg agagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacc cggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaag gcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatg accatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcct ttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0218] BBa_J23101_DsbA_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4007 in the examples of the present disclosure, SEQ ID NO: 147) tctagagcttgtcgacgtctcgagtttacagctagctcagtcctaggtattatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaatctggc tggcgctggcgggtctggtgctggcgttcagcgcgagcgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccga acatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggagg acttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaagg cgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaa caggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatg aaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttc gttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0219] BBa_J23101_OmpA_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4009 in the examples of the present disclosure, SEQ ID NO: 148) tctagagcttgtcgacgtctcgagtttacagctagctcagtcctaggtattatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaccgcgat tgcgattgcggtggcgctggcgggtttcgcgaccgttgcgcaggcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctg ccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctg gaggacttcaaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatatta aggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtgg aacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccat gaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggccttt cgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0220] BBa_J23101_PelB_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4011 in the examples of the present disclosure, SEQ ID NO: 149) tctagagcttgtcgacgtctcgagtttacagctagctcagtcctaggtattatgctagcctcgaggaaagaggagaaagaagcttatgaagtacctgctgcc gaccgcggcggcgggtctgctgctgctggcggcgcagccggcgatggcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaac ctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgc tggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatat taaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtg gaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgacca tgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggccttt cgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0221] BBa_J23101_YebF_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4013 in the examples of the present disclosure, SEQ ID NO: 150)
[0222] BBa_J23110_T7g10_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4026 in the examples of the present disclosure, SEQ ID NO: 151) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgagttaagtttagaaagaggagaaagaagcttatgaagaaaaa gatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgc acccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgc tgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaacca agacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagc aaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtata tgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcc tttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0223] BBa_J23110_BCD2_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4028, CBT4067, CBT4068, CBT4063 and CBT4062 in the examples of the present disclosure, SEQ ID NO: 152) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgaaagcaattttcgtactgaaacatcttaatcatgctaaggaggttttctaatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0224] BBa_J23110_GFP_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4029 in the examples of the present disclosure, SEQ ID NO: 153) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgcgtaaaggcgaagagaagga ggttaactgatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtaccc aaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaact ggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcag gcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgag aacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgagg cgtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgg gcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0225] BBa_J23110_Luciferase_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4030 in the examples of the present disclosure, SEQ ID NO: 154) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgattatgtccggttataagga ggttaactgatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtaccc aaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaact ggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcag gcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgag aacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgagg cgtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgg gcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0226] PfnrS_BCD2_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4078 in the examples of the present disclosure, SEQ ID NO: 155) Tctagagcttgtcgacgtctcgagaaaaacgccgcaaagtttgagcgaagtcaataaactctctacccattcagggcaatatctctcttctcgaggaaagaggagaaagaagcttatgaaagcaattttcgtactgaaacatcttaatcatgctaaggaggttttctaatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0227] PfnrS_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4084, CBT4088, CBT4110 and CBT4111 in the examples of the present disclosure, SEQ ID NO: 156) Tctagagcttgtcgacgtctcgagaaaaacgccgcaaagtttgagcgaagtcaataaactctctacccattcagggcaatatctctcttctcgaggaaagaggagaaa gaagcttatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaa agcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactg gataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcagg cggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgaga acaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggc gtatatgaccatgaaaattcgtaactagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgg gcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0228] Psal_sTRSV-HHRz_USP45_IL-10_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4113 in the examples of the present disclosure, SEQ ID NO: 235) ggggcctcgcttgggttattgctggtgcccggccgggcgcaatattcatgttgatgatttattatatatcgagtggtgtatttatttatattgtttgctccgttaccgttattaacagctgtcaccggatgtgctttccggtctgatgagtccgtgaggacgaaacagcctctacaaataattttgtttaatactagagaaagaggggaaatactagatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgagcccgggtcagggtacccaaagcgaaaacagctgcacccacttcccgggcaacctgccgaacatgctgcgtgacctgcgtgatgcgttcagccgtgtgaaaaccttcttccagatgaaagaccaactggataacctgctgctgaaggagagcctgctggaggacttcaaaggttacctgggctgccaggcgctgagcgaaatgatccaattttatctggaggaagtgatgccgcaggcggagaaccaagacccggatattaaggcgcacgttaacagcctgggcgagaacctgaaaaccctgcgtctgcgtctgcgtcgttgccaccgtttcctgccgtgcgagaacaaaagcaaggcggtggaacaggttaagaacgcgtttaacaaactgcaagagaagggcatctataaagcgatgagcgaattcgatatctttattaactacatcgaggcgtatatgaccatgaaaattcgtaactaggagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0229] Examples of IL-22 sequences containing different regulatory elements In some embodiments, the present application provides various IL-22 specific expression cassette sequences that contain different regulatory elements (e.g., different promoters), as shown below. In some embodiments, the present application also provides genetically modified microorganisms (e.g., EcN) that contain any of the above IL-22 specific expression cassette sequences. Examples of IL-22 specific expression cassette sequences provided in the present application are as follows:
[0230] BBa_J23119_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4038 in the examples of the present disclosure, SEQ ID NO: 157) tctagagtctcgagttgacagctagctcagtcctaggtataatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagatcattagcgc gatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaaagcaact tccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgagaaactg ttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgttttcag ccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgtaacgt gcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgcgt gcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgtt ttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0231] BBa_J23101_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4041 in the examples of the present disclosure, SEQ ID NO: 158) tctagagcttgtcgacgtctcgagtttacagctagctcagtcctaggtattatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagat cattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaa agcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgag aaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgtt ttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgta acgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgc gtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0232] BBa_J23102_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4042 in the examples of the present disclosure, SEQ ID NO: 159) tctagagcttgtcgacgtctcgagttgacagctagctcagtcctaggtactgtgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagat cattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaa agcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgag aaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgtt ttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgta acgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgc gtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0233] BBa_J23108_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4043 in the examples of the present disclosure, SEQ ID NO: 160) tctagagcttgtcgacgtctcgagctgacagctagctcagtcctaggtataatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagat cattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaa agcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgag aaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgtt ttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgta acgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgc gtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0234] BBa_J23110_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4039, CBT4016, CBT4110 and CBT4111 in the examples of the present disclosure, SEQ ID NO: 161) tctagagcttgtcgacgtctcgagtttacggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagat cattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaa agcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgag aaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgtt ttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgta acgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgc gtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0235] BBa_J23114_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4040, CBT4066, CBT4069, CBT4063 and CBT4067 in the examples of the present disclosure, SEQ ID NO: 162) tctagagcttgtcgacgtctcgagtttatggctagctcagtcctaggtacaatgctagcctcgaggaaagaggagaaagaagcttatgaagaaaaagat cattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatcagcagccactgccgtctggacaaa agcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccgatgtgcgtctgatcggcgag aaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcccgcaaagcgatcgtt ttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgcacattcagcgta acgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctgcgtaacgc gtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgt tttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0236] PfnrS_USP45_IL-22_rrnB_T1_T7Te (corresponding expression cassette contained in strains CBT4095 and CBT4098 in the examples of the present disclosure, SEQ ID NO: 163) Tctagagcttgtcgacgtctcgagaaaaacgccgcaaagtttgagcgaagtcaataaactctctacccattcagggcaatatctctcttctcgaggaaagagg agaaagaagcttatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcgccgatca gcagccactgccgtctggacaaaagcaacttccagcaaccgtatattaccaaccgtacctttatgctggcgaaagaggcgagcctggcggacaacaacaccga tgtgcgtctgatcggcgagaaactgttccacggcgttagcatgagcgaacgttgctacctgatgaagcaggtgctgaactttaccctggaggaagttctgttcc cgcaaagcgatcgttttcagccgtatatgcaagaggtggttccgttcctggcgcgtctgagcaaccgtctgagcacctgccacatcgaaggtgacgatctgca cattcagcgtaacgtgcaaaaactgaaggacaccgttaaaaagctgggcgagagcggcgaaatcaaagcgattggcgaactggatctgctgtttatgagcctg cgtaacgcgtgcatttagtaacgagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctt tcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0237] Examples of IL-17A sequences containing different regulatory elements An example of an IL-17A specific expression cassette sequence provided in this application is as follows:
[0238] Psal_USP45_IL-17A_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 236) ggggcctcgcttgggttattgctggtgcccggccgggcgcaatattcatgttgatgatttattatatatcgagtggtgtatttatttatattgtttgctccgttaccgttat taacagctgtcaccggatgtgctttccggtctgatgagtccgtgaggacgaaacagcctctacaaataattttgtttaatactagagaaagaggggaaatactagatgaagaa aaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgggtattacaatcccgcgtaatccgggttgtccgaatagt gaagataaaaattttccgcgtacagttatggttaatctgaatattcataaccgtaacacaaacaccaatccgaaacgtagtagcgattattataatcgtagcacaagcccgtg gaatctgcatcgtaacgaagatccggaacgttatccaagcgttatctgggaagcaaaatgccgccatctgggttgtatcaatgcagatggtaacgttgattatcatatgaat agcgtgccgattcagcaggaaattctggttctgcgtcgtgaaccgccgcattgtccgaatagctttcgtctggaaaaaattctggttagcgttggttgtacctgtgttacccc gattgttcatcatgttgcacatcatcatcatcatcattaagagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaaga ctgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0239] Examples of IL-19 sequences containing different regulatory elements Examples of sequences of specific IL-19 expression cassettes provided in the present application are as follows:
[0240] Psal_USP45_IL-19_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 237) ggggcctcgcttgggttattgctggtgcccggccgggcgcaatattcatgttgatgatttattatatatcgagtggtgtatttatttatattgtttgctccgttaccgttattaacagctgtcaccggatgtgctttccggtctgatgagtccgtgaggacgaaacagcctctacaaataattttgtttaatactagagaaagaggggaaatactagatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcgctgcgtcgttgtctgattagcaccgatatgcatcatattgaagaaagctttcaggaaattaaacgtgccattcaggcaaaagatacctttccgaatgttaccattctgagcaccctggaaaccctgcagattatcaaaccactggatgtttgttgtgttaccaaaaatctgctggccttttatgttgatcgtgtttttaaagatcatcaggaaccgaatccgaaaattctgcgtaaaattagtagcattgccaatagctttctgtatatgcagaaaaccctgcgccagtgtcaggaacagcgtcagtgtcattgtcgtcaggaagcaaccaatgcaacccgtgtgattcatgataactatgatcagctggaagttcatgcagcagcgattaaaagcctgggtgaactggatgtgtttctggcatggattaataaaaatcatgaagtgatgtttagcgcacatcatcatcatcatcattaagagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0241] Examples of IL-23 sequences containing different regulatory elements Examples of sequences of specific IL-23 expression cassettes provided in the present application are as follows:
[0242] Psal_USP45_IL-12p40_linker1_IL-23p19_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 238)
[0243] Examples of IL-35 sequences containing different regulatory elements Examples of sequences of specific IL-35 expression cassettes provided in the present application are as follows:
[0244] Psal_USP45_EBI3_linker2_IL-12p35_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 239)
[0245] Examples of IL-37 sequences containing different regulatory elements Examples of sequences of specific IL-37 expression cassettes provided in the present application are as follows:
[0246] Psal_USP45_IL-37_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 240)
[0247] Examples of TGF-β sequences containing different regulatory elements Examples of sequences of specific TGF-β expression cassettes provided in this application are as follows:
[0248] Psal_sTRSV-HHRz_USP45_TGF-β_rrnB_T1_T7Te (corresponding expression cassette contained in strain CBT4114 in the examples of the present disclosure, SEQ ID NO: 241) ggggcctcgcttgggttattgctggtgcccggccgggcgcaatattcatgttgatgatttattatatatcgagtggtgtatttatttatattgtttgctccgttaccgttattaacagctgtcaccggatgtgctttccggtctgatgagtccgtgaggacgaaacagcctctacaaataattttgtttaatactagagaaagaggggaaatactagatgaagaaaaagatcattagcgcgatcctgatgagcaccgtgattctgagcgcggcggcgccgctgagcggtgtttatgcggcactggataccaattattgtttttcaagcaccgaaaaaaattgttgtgttcgtcagctgtatattgattttcgtaaagatctgggttggaaatggattcatgaaccgaaaggttatcatgcaaatttttgtctgggtccgtgtccgtatatttggagcctggatacccagtatagcaaagttctggcactgtataatcagcataatccgggtgcaagcgcagcaccgtgttgtgttccgcaggcactggaaccgctgccgattgtttattatgttggtcgtaaaccgaaagttgaacagctgagcaatatgattgttcgtagctgtaaatgtagccatcatcatcatcatcattaagagctcgatagtgctagtgtagatcgctactagagccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaacgctctctactagagtcacactggctcaccttcgggtgggcctttctgcgtttatatactagaagcggccgctgcag
[0249] In some embodiments, the present application also provides various genetically modified EcN strains having the genotypes shown in Table 10 below. As shown in Table 10, each strain is named by its genotype name, where EcN represents E. coli Nissle 1918, ΔmaeB represents the maeB site for insertion in said strain, and the underlined portion represents the specific expression cassette name described in the application, such as: BBa_J23101_USP45_IL-10 indicates that the expression cassette has a BBa_J23101 promoter operably linked to a coding sequence for a USP45 signal peptide and a coding sequence for an IL-10 polypeptide. The nucleic acid sequences of specific expression cassettes are shown in SEQ ID NOs: 139 to 163 in this application. In some strains, the genotype name reflects the additional deficiency of one or more outer membrane proteins. For example, ΔLPP indicates the deficiency of the LPP outer membrane protein. In some strains, the genotype name reflects the additional overexpression of one or more molecular chaperones. For example, ΔyicS / nepI::BBa_J23114_dsbA_dsbC_dnaK_dnaJ_grpE indicates that an expression cassette with an operably linked BBa_J23114 promoter sequence therein is inserted at the yicS / nepI site, which expresses molecular chaperone_dsbA_dsbC_dnaK_dnaJ_grpE. Those skilled in the art can know and determine the specific genetic modifications contained in each strain by following the instructions in this application and referring to the genotype names listed in Table 10. For example, the specific genetic modifications can be detected and identified by designing primers or probes to the specific insertion sequence or sequence at the insertion site.
[0250] [Table 10-1] [Table 10-2] [Table 10-3]
[0251] III. Compositions and Kits In another aspect, the present invention provides a composition comprising (a) a genetically modified microorganism according to the present invention and (b) a physiologically acceptable vector.
[0252] As used herein, a "composition" refers to a formulation of the genetically modified bacteria of the invention with other components, such as a physiologically suitable vector. The interchangeably used phrase "physiologically acceptable vector" refers to a vector or diluent that does not cause significant irritation to the organism and does not eliminate the biological activity and properties of the genetically modified microorganism to which it is administered.
[0253] Bacteria are about 10 4 About 10 13 The microorganism may be present in the composition in an amount ranging from about 10 to about 10 colony forming units (CFU). For example, an effective amount of the microorganism may be about 10 5 CFU to about 10 13 Up to about 10 CFU, preferably 6 CFU to about 10 13 Up to about 10 CFU, preferably 7 CFU to about 10 12 CFU, more preferably about 10 8 CFU to about 10 12 The amount of the microorganism may be up to CFU. The microorganism may be a live or dead cell. The effectiveness of the microorganism correlates with the presence of Amuc_1100, IL-10 and / or IL-22 as provided herein.
[0254] In some embodiments, the compositions disclosed herein may be formulated for oral administration, e.g., nutritional or nutritious compositions, such as food or food supplements, feed or feed supplements, or dairy products, such as fermented dairy products, such as yogurt or yogurt drinks. In this case, the composition may include a nutritionally acceptable carrier and may be a suitable food base. Those skilled in the art will recognize that many formulations of food supplements (e.g., pills, tablets, etc.) or functional foods (e.g., beverages, fermented yogurt, etc.) may be included that contain live or dead microorganisms. The compositions disclosed herein may also be formulated as capsules, pills, or medicines in solution, e.g., encapsulated freeze-dried bacteria, etc. In some embodiments, the composition is a probiotic composition.
[0255] The compositions disclosed herein can be formulated to be effective in a given individual via a single dose or multiple doses, for example, a single dose is effective to substantially reduce monitored symptoms of a target disease state in a mammalian individual to which the composition is administered.
[0256] In some embodiments, the composition comprises at least about 1×10 4 CFU of bacterial and / or fungal entities. Typically, a single oral dose contains about or at least 1 x 10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 Bacterial and / or fungal entities are included. If known, for example, the cell concentration of a given strain or the total concentration of all strains is greater than or equal to 1×10 per gram of composition or unit dose. 4 , 1×10 5 , 1×106 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 In some embodiments, the composition comprises 1×10 live bacterial entities (e.g., CFU). 8 ~1×10 12 CFU of the genetically modified microorganism according to the present invention.
[0257] In some formulations, the composition contains at least about 0.5%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more than 90% by mass of a microorganism of the present disclosure. In some formulations, the administered dose does not exceed 200, 300, 400, 500, 600, 700, 800, 900 mg or 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 or 1.9 g by mass of a microorganism provided in the present application.
[0258] Physiologically acceptable carriers used in the compositions disclosed herein may include, for example, physiologically acceptable liquid, gel or solid carriers, aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonicity agents, buffers, antioxidants, suspending / dispersing agents, sequestering / chelating agents, diluents, adjuvants, excipients or non-toxic auxiliary substances, other ingredients known in the art, or various combinations thereof. In some embodiments, the compositions described herein are liquid formulations, solid formulations, semi-solid formulations. In some embodiments, the liquid formulations are selected from the group consisting of solution products or suspension products.
[0259] To further illustrate, aqueous vehicles include, for example, sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, and dextrose-lactated Ringer's injection. Non-aqueous vehicles include, for example, fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents may be added to the compositions in multi-dose containers at concentrations that inhibit bacteria or fungi, and / or include phenol or cresol, mercurials, benzyl alcohol, chlorobutanol, methyl or propyl paraben, thimerosal, benzalkonium chloride, and benzethonium chloride. Isotonic agents include, for example, sodium chloride or dextrose. Buffers include, for example, phosphate or citrate buffers. Antioxidants include, for example, sodium bisulfate. Suspending and dispersing agents include, for example, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone. Chelating agents include, for example, ethylenediaminetetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA), ethanol, polyethylene glycol, propylene glycol, sodium hydroxide, hydrochloric acid, citric acid, or lactic acid. Suitable excipients include, for example, water, saline, dextrose, glycerin, or ethanol. Suitable non-toxic auxiliary substances include, for example, wetting or emulsifying agents, pH buffers, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrins.
[0260] In some embodiments, the compositions provided herein may be pharmaceutical compositions. In some embodiments, the compositions provided herein may be food supplements. The compositions provided herein may include, in addition to the genetically modified microorganisms provided herein, a pharma- ceutical, nutritionally / alimentarily, or physiologically acceptable carrier. The preferred form is determined by the desired mode of administration and (therapeutic) use. The carrier may be any compatible, physiologically acceptable, non-toxic substance suitable for delivering the genetically modified microorganisms provided herein to the gastrointestinal tract of a mammal (e.g., human), preferably near or within the intestinal mucosal barrier (more preferably the colonic mucosal barrier) of the mammal. In some embodiments, the dosage form of the pharmaceutical composition is selected from the group consisting of powders, powders, tablets, dragees, capsules, granules, suspensions, solutions, syrups, drops, sublingual tablets, and combinations thereof.
[0261] The composition may be a solution, suspension, emulsion, pill, capsule, tablet, sustained release formulation, or powder. Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinylpyrrolidone, sodium saccharin, cellulose, magnesium carbonate, etc. In another aspect, the present invention provides a kit containing the composition according to the present invention.
[0262] Optionally, the kit may further include one or more of various conventional pharmaceutical kit components, such as a container with one or more pharma- ceutically acceptable carriers, additional containers, etc., as will be apparent to one of skill in the art. The kit may also include instructions, either as an insert or label, indicating the amounts of the components to be administered, the method of administration, and / or how to mix the components.
[0263] IV. Indications and Treatments In another aspect, the present invention provides a method for treating or preventing an inflammatory or autoimmune disease in an individual in need thereof, the method comprising administering to the individual an effective amount of a genetically modified microorganism as described in the present invention, or a composition as described in the present invention. In one embodiment, the genetically modified microorganism expresses at least one exogenous gene selected from the group consisting of an exogenous gene encoding and expressing an Amuc_1100 polypeptide, an exogenous gene encoding and expressing an IL-10 polypeptide, an exogenous gene encoding and expressing an IL-22 polypeptide, and any combination thereof.
[0264] In one aspect, the present invention provides a method for improving the therapeutic effect of a drug, including a drug for treating an inflammatory disease or an autoimmune disease, in an individual undergoing treatment with the drug, the method comprising administering to the individual an effective amount of a genetically modified microorganism described in the present invention or a composition described in the present invention. In one embodiment, the genetically modified microorganism expresses at least one exogenous gene selected from the group consisting of an exogenous gene encoding and expressing an Amuc_1100 polypeptide, an exogenous gene encoding and expressing an IL-10 polypeptide, an exogenous gene encoding and expressing an IL-22 polypeptide, and any combination thereof.
[0265] In another aspect, the present invention also provides the use of a genetically modified microorganism according to the present invention or a composition of the present invention in the preparation of a medicament for the treatment or prevention of an inflammatory disease or an autoimmune disease.
[0266] In some embodiments, the inflammatory disease or autoimmune disease is inflammatory bowel disease (IBD). In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0267] In some embodiments, the inflammatory disease or autoimmune disease is systemic lupus erythematosus (SLE). In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0268] In some embodiments, the inflammatory or autoimmune disease is arthritis. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0269] In some embodiments, the inflammatory or autoimmune disease is asthma. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0270] In some embodiments, the inflammatory disease or autoimmune disease is graft-versus-host disease (GvHD). In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide. In some embodiments, the genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
[0271] In some embodiments, the subject has an inflammatory or autoimmune disease / condition (e.g., as described herein) or disorder, or has a trigger for said disease / condition, and the goal is to treat, cure, alleviate, relieve, alter, remedy, mitigate, ameliorate, or affect the disease / condition or the trigger that causes the disease / condition.
[0272] As used herein, "treatment" of a disease, disease, or condition includes preventing or alleviating the disease, disease, or condition, slowing the onset or rate of progression of the disease, disease, or condition, reducing the risk of onset of the disease, disease, or condition, preventing or slowing the progression of symptoms associated with the disease, disease, or condition, reducing or terminating symptoms associated with the disease, disease, or condition, completely or partially attenuating the disease, disease, or condition, curing the disease, disease, or condition, or some combination thereof.
[0273] The term "effective amount" as used herein refers to the amount and / or dose and / or dosing regimen of one or more agents required to produce a desired result, such as, for example, an amount sufficient to alleviate in an individual one or more symptoms associated with the disease state for which the individual is being treated, or an amount sufficient to reduce the severity or delay the progression of the disease state in an individual (e.g., a therapeutically effective amount), an amount sufficient to reduce the risk or delay the onset and / or reduce the ultimate severity of the disease state in an individual (e.g., a prophylactically effective amount). The effective amount will vary depending on the severity of the disease state being treated, individual patient parameters including age, physical condition, height, sex and weight, duration of treatment, the nature of said concurrent treatment (if any), and other factors within the knowledge and experience of the general practitioner or other physician. These factors are well known in the art and can be determined by only routine experimentation. Usually, it is preferable to use the maximum dose of each component or combination used that is safe as determined by reasonable medical judgment. However, as will be appreciated by those skilled in the art, a patient may require a lower or tolerable dose for medical reasons, psychological reasons, or virtually any other reason.
[0274] As used herein, the term "individual" includes both human and non-human animals. Non-human animals include vertebrates, such as mammals and non-mammals, e.g., non-human primates, mice, rats, cats, rabbits, sheep, dogs, cows, chickens, amphibians, reptiles, etc. Unless otherwise indicated, the terms "patient" or "individual" are used interchangeably herein.
[0275] The term "inflammatory or autoimmune disease" as used herein includes, but is not limited to, inflammatory disease and autoimmune disease. The inflammatory disease includes, for example, autoimmune disease such as inflammatory bowel disease. "Inflammatory bowel disease" or "IBD" is used interchangeably herein and refers to a type of disease associated with gastrointestinal inflammation, characterized by prominent local inflammation and impaired epithelial barrier function in the gastrointestinal tract, usually driven by T cells and activated macrophages (Ghishan et al., 2014), including, but not limited to, Crohn's disease, ulcerative colitis, Behcet's disease, lymphocytic colitis, collagenous colitis, metastatic colitis, and indeterminate colitis.
[0276] "Autoimmune diseases" as referred to herein further include graft-versus-host disease (GvHD), systemic lupus erythematosus, arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis), asthma (e.g., allergic asthma or neutrophilic asthma).
[0277] The term "graft versus host" or "GVH" as used herein refers to when transplanted (donor) cells develop an immune response against microorganisms and tissues. The term "graft versus host disease" or "GvHD" as used herein refers to an abnormal condition (including acute and chronic) resulting from the effects of transplanted (graft) cells produced from GVH on microorganisms and tissues. For example, patients who receive blood or bone marrow transplants from other people are at risk of developing acute GvHD. Acute graft versus host disease (GvHD) is a disease caused by donor immune cells in patients who receive allogeneic bone marrow or blood cells. The intestinal epithelium and liver are commonly affected tissues. In severe cases, GvHD can cause skin blisters, excessive diarrhea, and weight loss. Inflammation in the liver caused by donor immune cells can lead to blockages that cause jaundice. Other tissues such as the lungs and thymus can also be affected. The diagnosis of GvHD can usually be confirmed by looking at a small piece of skin, liver, stomach or intestine under a microscope and observing certain features of inflammation.
[0278] Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease (AID) that has a complex and diverse clinical presentation with repeated onset and remission throughout the disease. The main clinical features are the appearance of multiple antibodies in serum, represented by antinuclear antibodies, and the involvement of multiple systems. Symptoms of SLE vary from individual to individual and range from mild to severe. Common symptoms include joint pain and swelling, fever, chest pain, hair loss, stomatitis, swollen lymph nodes, fatigue, and a red rash, often on the face. There is usually a period of onset of the disease and a period of remission with fewer symptoms. The etiology of SLE is unknown. Genetic and environmental factors are thought to be involved. If one identical twin is affected, there is a 24% chance that the other twin will also be affected. The risk is thought to be increased by female sex hormones, sunlight, smoking, vitamin D deficiency, and certain infections. SLE is difficult to diagnose and is primarily based on a combination of symptoms and laboratory tests.
[0279] Rheumatoid arthritis (RA) is a long-term autoimmune disease that primarily affects the joints. RA often causes fever, swelling, and pain in the joints, and the pain and stiffness tend to worsen with rest. The wrists and hands are commonly affected, and joints on both sides of the body are usually affected as well. RA can also affect the skin and other parts of the body, such as the eyes, lungs, heart, nerves, and blood. This can lead to a decrease in red blood cell count and inflammation around the lungs and heart, which can also cause fever and lethargy. Symptoms usually develop gradually over a period of weeks to months. The etiology of rheumatoid arthritis is still unknown, but it is thought to involve a combination of genetic and environmental factors. Potential mechanisms of development include the body's immune system attacking the joints, which causes inflammation and thickening of the joint capsule, and potentially also affects bone and cartilage. RA is primarily diagnosed based on the patient's signs and symptoms. A specific diagnosis may involve a combination of x-rays and laboratory tests to support the diagnosis or rule out other diseases with similar symptoms.
[0280] In some embodiments, the autoimmune disease is selected from the group consisting of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), graft-versus-host disease (GvHD), systemic lupus erythematosus, arthritis (e.g., rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis), asthma (e.g., allergic asthma or neutrophilic asthma), and combinations thereof. In some embodiments, the autoimmune disease includes graft-versus-host disease (GvHD). In some embodiments, the autoimmune disease includes inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), systemic lupus erythematosus, asthma, multiple sclerosis, and / or rheumatoid arthritis.
[0281] Approximately 70% of the human immune system is located in the gastrointestinal tract. There are many correlations and common disease signals between intestinal autoimmune diseases (e.g., inflammatory bowel disease) and non-intestinal autoimmune diseases (e.g., multiple sclerosis), including 1) changes in cytokine signals, 2) changes in immune cell activity, and 3) abnormalities in the intestinal microbiota. Abnormalities in the intestinal microbiota are closely related to the pathogenesis of autoimmune diseases in both animal models and humans. For example, changes in microbial components are observed in the early stages of rheumatoid arthritis and inflammatory bowel disease. Several independent studies have pointed out that abnormalities in the intestinal microbiota exist in SLE patients from Spain and China. The balance of intestinal bacteria is important for the regulation and development of the immune system. In addition, in inflammatory conditions, the intestinal barrier function is impaired, promoting the leakage of bacteria from the mucosal layer into the blood vessels, thereby stimulating local and systemic autoimmune pathways.
[0282] Multiple targets in the intestinal inflammatory signaling pathway, innate immune system and adaptive immune system have become research hotspots for new drug development using small molecules, antibodies, gene therapy or intestinal microbe therapy. Recently, bacterial vector gene therapy using genetically modified bacteria has been recognized as promising in the industry. However, the efficacy of these genetically modified microbes has not yet been confirmed in patients, although it has been shown in some preclinical models.
[0283] Without wishing to be bound by any existing theory, in order to solve the above unmet clinical needs, the inventors of the present application construct genetically engineered microorganisms (e.g., engineered E. coli EcN) as live drugs and administer them to the intestinal tract to introduce exogenous polypeptide factors or combinations thereof. Since the genetically engineered bacteria can continuously express and secrete exogenous polypeptide factors in the intestine, they can continuously act on intestinal cells for a certain period of time, thereby strengthening the intestinal barrier and / or enhancing intestinal immunity, and further improving the symptoms of immune diseases in the organism. If the lesion is located in the intestine, the genetically modified microorganisms of the present disclosure are expected to be distributed near the lesion, and the polypeptide factors they secrete may also directly act on the cells at the lesion site, thereby exerting a therapeutic effect. When the polypeptide-based drug is orally ingested, the polypeptide is decomposed in the intestine, reducing the therapeutic effect, so that the polypeptide-based drug cannot achieve the mechanism of action as in the present application. Even if the effect of oral polypeptides can be improved to some extent by using a better delivery vector, it is still difficult to meet the therapeutic needs and there is also the problem of high cost. In the case of serum injection, there is a serious problem of patient compliance, and since the cytokine-based drug directly enters the blood circulation, it may cause many side effects.
[0284] First, the inventors screened for a combination of exogenous genes suitable for expression and secretion by microorganisms and capable of exerting therapeutic effects in local delivery to the intestinal tract. It should be noted that while live drugs need to maintain the vitality of microorganisms so that they can grow normally and exert therapeutic effects in the body, when microorganisms continuously express exogenous polypeptides, especially two or more kinds of exogenous polypeptides, it will inevitably bring about a certain pressure on the stability of cells, so it is necessary that the exogenous polypeptides expressed by the microorganisms should not have an excessively adverse effect on the vitality of the microorganisms themselves. Otherwise, it should be noted that the condition of the microorganisms will deteriorate, affecting their ability to express and secrete therapeutic exogenous polypeptides, and furthermore, the microorganisms may reduce or even stop the expression of exogenous genes through internal stress mechanisms, thus causing the construction of genetically engineered microorganisms to fail. However, it is still unclear and difficult to predict what exogenous genes are suitable for expression in therapeutic genetically engineered microorganisms. Many of the exogenous genes that were thought to be suitable for microbial expression in the field of non-living drugs are rather unusable when constructing genetically engineered bacteria for therapeutic purposes. During screening, the inventors found that some exogenous factors were not suitable for expression and secretion using the genetically engineered microorganisms of the present disclosure, and ultimately abandoned them (e.g., IL-19, IL-23, IL-37, etc.). After the inventors determined Amuc_1100, IL-10, and / or IL-22 polypeptides as the basis for the combination, they further comprehensively optimized the signal peptides of these polypeptides (replacing their own signal peptides), the expression regulatory elements in the expression cassette (e.g., selecting appropriate promoters, mistrons, ribosome binding sites, etc.), and the structure of the chassis bacteria (selecting to knock out specific membrane proteins to increase membrane permeability), etc., so that the genetically engineered bacteria were able to efficiently and stably express the above new combinations of exogenous genes.We also confirmed that in multiple animal disease models, all or part of the genetically modified bacteria expressing combinations of exogenous factors showed unexpected therapeutic and even synergistic effects against various inflammatory and autoimmune diseases, and have the prospect of broad clinical application.
[0285] The following examples are provided to further illustrate the invention described in the claims and should not be construed as limiting the scope of the invention. All specific compositions, materials and methods described below in whole or in part are included within the scope of the invention. These specific compositions, materials and methods are not intended to limit the invention, but are merely to illustrate specific examples within the scope of the invention. Those skilled in the art may develop equivalent compositions, materials and methods without departing from the scope of the invention without the exercise of inventive ability. It will be understood that within the scope of the invention, a number of modifications may be made to the processes described herein. The inventors intend such modifications to be included within the scope of the invention. EXAMPLES
[0286] Example 1: Bacterial genome editing procedure 1.1 Design of sgRNA We found a 20 bp sequence (N20NGG) with NGG PAM sequence on both strands of the target integration site sequence and blasted it against the EnN genome. A unique 20 bp sequence was selected as the sgRNA for the target integration site. 300-500 bp sequences upstream and downstream of the sgRNA were selected as the left homology arm (LHA) and right homology arm (RHA).
[0287] 1.2 Construction of sgRNA plasmid The sgRNA sequence was appended to the 5' end of the reverse primer of the gRNA backbone, amplified by PCR, digested with restriction endonucleases PstI and SpeI, and the digested PCR product fragment was ligated with similarly digested plasmid pCBT003 (SEQ ID NO: 137) to form the pCBT003_sgRNA plasmid.
[0288] 1.3 Preparation of donor gene fragments The exogenous gene to be integrated into the EcN genome was synthesized on a cloning plasmid (e.g., pUC57) using GeneScript. The exogenous gene was amplified using the synthesized plasmid as a template, and the LHA and RHA of the selected integration site were amplified using the EcN genome as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they can be linked by overlap PCR, and the resulting PCR product containing LHA-exogenous gene-RHA was used as the donor gene fragment.
[0289] Example 2: Plasmid transformation procedure 2.1 Preparation of electroporation competent cells for EcN / pCBT001 100-200 ng of pCBT001 plasmid (a plasmid expressing Cas9 protein, SEQ ID NO: 136) was added to 100 μL of EcN electroporation competent cells, and the mixture was transferred to a 2 mm electroporation cup, and the electroporation conditions were set to 2.5 kV, 25 μF, and 200 Ω. After electroporation, the cells were suspended in 1 mL of SOC and incubated at 30 ° C for 2 hours with shaking (220 rpm). Then, all the cells were spread on an LB agar plate supplemented with 50 μg / mL of spectinomycin and streptomycin, and incubated overnight at 30 ° C. The colonies that grew on the plate were EcN containing the pCBT001 plasmid (EcN / pCBT001).
[0290] A single EcN / pCBT001 colony on the resistant LB agar plate was inoculated into 3 mL of LB liquid medium supplemented with 50 μg / mL of spectinomycin and streptomycin and incubated overnight at 30° C. with shaking (220 rpm). Then, 300 μL of this overnight culture was inoculated into 30 mL of LB liquid medium supplemented with 50 μg / mL of spectinomycin and streptomycin and incubated at 30° C. with shaking (220 rpm). After 1 h, IPTG was added to the culture at a concentration of 1 mM. OD 600 When the NA reached approximately 0.6, the cells were washed three times with 20 mL, 10 mL, and 5 mL of 10% glycerol (4 °C), finally resuspended in 300 μL of 10% glycerol (4 °C), and separated into 1.5 mL centrifuge tubes at 100 μL per tube.
[0291] 2.2 Transformation of pCBT003-sgRNA plasmid and donor gene fragment Approximately 2 μg of the donor gene fragment PCR product containing LHA-exogenous gene-RHA and 100-200 ng of pCBT003_sgRNA expressing the sgRNA at the integration site were transformed into electroporation competent cells for EcN / pCBT001. After electroporation, the cells were suspended in 1 mL of SOC and incubated for 2 h with shaking (220 rpm) at 30 °C. Then, all the cells were plated on LB agar plates supplemented with 50 μg / mL spectinomycin, streptomycin and 100 μg / mL ampicillin. A schematic diagram of the EcN genome with the exogenous gene expression cassette inserted is shown in Figure 1.
[0292] Example 3: Procedure for removing excess plasmid 3.1 Verification of exogenous gene integration The primers used for verification were designed upstream of LHA and downstream of RHA. Single colonies that grew on the transformation plates were selected and colony PCR was performed using the verification primers. Clones with correctly integrated exogenous genes into the genome were selected based on the size of the PCR products.
[0293] 3.2 Removal of pCBT003_sgRNA and pCBT001 plasmids The selected correct clone was inoculated into 3 mL of LB liquid medium supplemented with 50 μg / mL spectinomycin, streptomycin, and 10 mM arabinose, and incubated overnight at 30° C. with shaking (220 rpm). The culture was then diluted with water and diluted with ethanol. 6 After 2-fold dilution, 100 μL of the culture was plated onto LB agar plates supplemented with 50 μg / mL spectinomycin and streptomycin and incubated overnight at 30° C. Single colonies were then selected and simultaneously spotted onto LB agar plates supplemented with 50 μg / mL spectinomycin, streptomycin and 100 μg / mL ampicillin, and LB agar plates supplemented with 50 μg / mL spectinomycin and streptomycin. Colonies that grew only on the LB agar plate supplemented with 50 μg / mL spectinomycin and streptomycin were pCBT003_sgRNA plasmid-cured colonies.
[0294] The pCBT003_sgRNA-removed clone was inoculated into LB liquid medium and incubated overnight at 42 °C with shaking (220 rpm), after which the culture was divided into 10 6 The culture was diluted 2-fold and 100 μL of the culture was plated on an LB agar plate. Single colonies were selected and simultaneously spotted on LB agar plates and LB agar plates supplemented with 50 μg / mL spectinomycin and streptomycin. Colonies that grew only on the LB agar plates were pCBT001 cured colonies.
[0295] 3.3 Removal of endogenous plasmids 3.3.1 Removal of pMUT1 The plasmid pCBT003_pMUT1_sgRNA expressing the sgRNA of pMUT1 was transformed into EcN / pCBT001. The primers for verifying the removal of pMUT1 are specifically homologous to pMUT1 but are not homologous to the genome of EcN. Therefore, PCR was performed using the primers for verifying pMUT1. Colonies that did not produce PCR products were pMUT1-removed colonies.
[0296] 3.3.2 Removal of pMUT2 The kanamycin resistance gene was ligated into pMUT2 to obtain plasmid pMUT2-kana, the nucleotide sequence of which is shown in SEQ ID NO: 138. Plasmid pMUT2-kana was transformed into EcNΔpMUT1, and the transformed cells were plated on an LB agar plate supplemented with 10 μg / mL kanamycin, and the colonies that grew were EcNΔpMUT1 containing plasmid pMUT2-kana. After EcNΔpMUT1 / pMUT2-kana was subcultured several times in LB liquid medium supplemented with 10 μg / mL kanamycin, the plasmid was extracted, and electrophoretic bands were used to confirm whether pMUT2 was completely replaced with pMUT2-kana. Next, pCBT001 was transformed into EcNΔpMUT1 / pMUT2-kana in which pMUT2 was completely replaced, and the plasmid pCBT003_Kana-sgRNA expressing the kanamycin resistance gene sgRNA was transformed into EcNΔpMUT1 / pMUT2-kana / pCBT001. PCR was performed on the resulting colonies using primers specific to the kanamycin resistance gene, and colonies that did not produce PCR products were pMUT2-kana removal colonies.
[0297] In this example, the sequence of the sgRNA targeting pMUT1 is shown in SEQ ID NO: 164, and the sequence of the sgRNA targeting the kanamycin resistance gene is shown in SEQ ID NO: 165.
[0298] sgRNA sequence targeting pMUT1 (SEQ ID NO: 164): gctgccgctattctgccgct
[0299] sgRNA sequence targeting the kanamycin resistance gene (SEQ ID NO: 165): atgaaggagaaaactcaccg
[0300] Example 4: Membrane protein knockout procedure The design method of the target membrane protein sgRNA to be knocked out and the construction method of the sgRNA plasmid were the same as those described in 1.1 and 1.2 of Example 1. As the left homology arm (LHA) and the right homology arm (RHA), 300 to 500 bp sequences upstream and downstream of the target membrane protein coding gene were selected. The genome of EcN was used as a template to amplify the selected knockout sites LHA and RHA. The PCR primers for amplifying these fragments have a homologous sequence of 15 to 20 bp each other, so they can be linked by overlap PCR, and the resulting PCR product containing LHA-RHA was used as the donor fragment. The PCR product of the obtained donor fragment and the pCBT003_sgRNA plasmid expressing the knockout site sgRNA were simultaneously transformed into competent cells containing pCBT001. The obtained single colony was amplified with a primer for verifying the knockout site, and clones in which the target protein was knocked out from the genome were screened by the size of the amplified band.
[0301] The membrane proteins knocked out in this example include tolQ, tolR, tolA, pal, lpp, mrcA, and ompT. The sequence of the sgRNA for the tolQ knockout site is set forth in SEQ ID NO: 166, and the sequences of the homology arms on either side of the tolQ knockout site are set forth in SEQ ID NO: 167 and 168, respectively. The sequence of the sgRNA for the tolR knockout site is set forth in SEQ ID NO: 169, and the sequences of the homology arms on either side of the tolR knockout site are set forth in SEQ ID NO: 170 and 171, respectively. The sequence of the sgRNA for the tolA knockout site is set forth in SEQ ID NO: 172, and the sequences of the homology arms on either side of the tolA knockout site are set forth in SEQ ID NO: 173 and 174, respectively. The sequence of the sgRNA for the pal knockout site is set forth in SEQ ID NO: 175, and the sequences of the homology arms on either side of the pal knockout site are set forth in SEQ ID NO: 176 and 177, respectively. The sequence of the sgRNA for the lpp knockout site is set forth in SEQ ID NO: 178, with the sequences of the homology arms on either side of the lpp knockout site set forth in SEQ ID NOs: 179 and 180, respectively. The sequence of the sgRNA for the mrcA knockout site is set forth in SEQ ID NO: 181, with the sequences of the homology arms on either side of the mrcA knockout site set forth in SEQ ID NOs: 182 and 183, respectively. The sequence of the sgRNA for the ompT knockout site is set forth in SEQ ID NO: 184, with the sequences of the homology arms on either side of the ompT knockout site set forth in SEQ ID NOs: 185 and 186, respectively.
[0302] sgRNA sequence targeting tolQ site (SEQ ID NO: 166): gggaaacgggataatctgag
[0303] Sequence of the left homology arm (LHA) of the tolQ site (SEQ ID NO: 167): gtgaatacaacgctgtttcgatggccggttcgtgtctactatgaagataccgatgccggtggtgtggtgtaccacgccagttacgtcgctttttatgaaagagcacgcacagagatgctgcgtcatcatcatttcagtcaacaggcgctgatggctgaacgcgttgcctttgtggtacgtaaaatgacggtggaatattacgcacctgcgcggctcgacgatatgctcgaaatacagactgaaataacatcaatgcgtggcacctctttggttttcacgcaacgtattgtcaacgccgagaatactttgttgaatgaagcagaggttctggttgtttgcgttgacccactcaaaatgaagcctcgtgcgcttcccaagtctattgtcgcggagtttaagcagtga
[0304] Sequence of the right homologous arm (RHA) of the tolQ region (SEQ ID NO: 168): gccatggccagagcgcgtggacgaggtcgtcgcgatctcaagtccgaaatcaacattgtaccgttgctggacgtactgctggtgctgttgctgatctttatggcgacagcgcccatcatcacccagagcgtggaggtcgatctgccagacgctactgaatcacaggcggtgagcagtaacgataatccgccagtgattgttgaagtgtctggtattggtcagtacaccgtggtggttgagaaagatcgtctggagcgtttaccaccagagcaggtggtggcggaagtgtccagccgtttcaaggccaacccgaaaacggtctttctgatcggtggcgcaaaagatgtgccttacgatgaaataattaaagcactgaacttgttacatagtgcgggtgtgaaatcggttggtttaatgacgcagcctatctaaacatctgcgtttcccttgcttgaaagagagcgggtaacaggcgaacagtttttggaaaccgaga
[0305] sgRNA sequence targeting tolR site (SEQ ID NO: 169): tggtattggtcagtacaccg
[0306] Sequence of the left homology arm (LHA) of the tolR site (SEQ ID NO: 170): gcatcgtgccaatagccatgcgccggaagccgtagtggaaggggcgtcgcgtgcgatgcgtatttccatgaatcgtgaacttgaaaatctggaaacgcacatt ccttcctcggtacggttggctccatcagcccgtatattggtctgtttggtacggtctgggggatcatgcacgcctttatcgccctcggggcggtaaaacaagc aacactgcaaatggttgcgcccggtatcgcagaagcgttgattgcgacggcaattggtttgttcgccgcaattccggcggtaatggcttataaccgcctcaacc agcgcgtaaacaaactggaactgaattacgacaactttatggaagagtttaccgcgattctgcaccgccaggcgtttaccgttagcgagagcaacaaggggtaa
[0307] Sequence of the right homology arm (RHA) of the tolR site (SEQ ID NO: 171): acatctgcgtttcccttgcttgaaagagagcgggtaacaggcgaacagtttttggaaaccgagagtgtcaaaggcaaccgaacaaaacgacaagctcaagcgggcgataattatttca gcagtgctgcatgtcatcttatttgcggcgctgatctggagttcgttcgatgagaatatagaagcttcagccggaggcggcggtggttcgtccatcgacgctgtcatggttgattcagg tgcggtagttgaacagtacaaacgtatgcaaagccaggaatcaagcgcgaagcgttctgatgagcagcgcaagatgaaggagcagcaggctgctgaagaactgcgtgagaaacaagcg gctgaacaggaacgcctgaagcaacttgagaaagagcggttagcggctcaggagcagaaaaagcaggctgaagaagccgcaaaacaggccgagttaaagcagaagcaagcggaagaggc
[0308] sgRNA sequence targeting tolA site (SEQ ID NO: 172): agaactgcgtgagaaacaag
[0309] Sequence of the left homology arm (LHA) of the tolA point (SEQ ID NO: 173): gccatggccagagcgcgtggacgaggtcgtcgcgatctcaagtccgaaatcaacattgtaccgttgctggacgtactgctggtgctgttgctgatctttatggcgacagcgcccatcatcaccc agagcgtggaggtcgatctgccagacgctactgaatcacaggcggtgagcagtaacgataatccgccagtgattgttgaagtgtctggtattggtcagtacaccgtggtggttgagaaagatcg tctggagcgtttaccaccagagcaggtggtggcggaagtgtccagccgtttcaaggccaacccgaaaacggtctttctgatcggtggcgcaaaagatgtgccttacgatgaaataattaaagca ctgaacttgttacatagtgcgggtgtgaaatcggttggtttaatgacgcagcctatctaaacatctgcgtttcccttgcttgaaagagagcgggtaacaggcgaacagtttttggaaaccgaga
[0310] Sequence of the right homology arm (RHA) of the tolA site (SEQ ID NO: 174): tcgcgatgttgactgttccgacggtcaacatcaggcaccggttgccacggggttctggtagttttgtgtattttagtttgttaacattctgctaaattatcgtgggccatcggtccagataaggg agatatgatgaagcaggcattacgagtagcatttggttttctcatactgtgggcatcagttctgcatgctgaagtccgcattgtgatcgacagcggtgtagattccggtcgtcctattggtgttg ttcctttccagtgggcggggcctggtgcggcacctgaagatattggcggcatcgttgctgctgacttgcgtaacagcggtaaatttaatccgttagatcgtgctcgtttgccacagcagccgggt agtgcgcaggaagtacaaccagctgcatggtccgcgctgggcattgacgctgtggttgtcggtcaggtcactccgaatccggatggttcttacaatgttgcttatcaacttgttgacactggcgg
[0311] sgRNA sequence targeting pal site (SEQ ID NO: 175): agtcaccgtagaaggtcacg
[0312] Sequence of the left homology arm (LHA) of the pal site (SEQ ID NO: 176): tggtcgcagtaacaataccgaaccgacctggttcccggacagccagaacctggcatttacttctgaccaggccggtcgtccgcaggtttataaagtgaatatcaacggcggtgcgcca caacgtattacctgggaaggttcgcagaaccaggatgcggatgtcagcagcgacggtaaatttatggtaatggtcagctccaacggtgggcagcagcacattgccaaacaagatctgg caacgggaggcgtacaagttctgtcgtccacgttcctggatgaaacgccaagtctggcacctaacggcactatggtaatctacagctcttctcaggggatgggatccgtgctgaattt ggttctacagatgggcgtttcaaagcgcgtcttccggcaactgatggacaggtcaaattccctgcctggtcgccgtatctgtgataataattaattgaatagtaaaggaatcattgaa
[0313] Sequence of the right homology arm (RHA) of the pal site (SEQ ID NO: 177): gagaattgcatgagcagtaacttcagacatcaactattgagtctgtcgttactggttggtatagcggccccctgggccgcttttgctcaggcaccaatcagtagtgtcggctcaggc tcggtcgaagaccgcgtcactcaacttgagcgtatttctaatgctcacagccagcttttaacccaactccagcaacaactctctctgataatcaatccgatattgattccctgcgtggtc agattcaggaaaatcagtatcaactgaatcaggtcgtggagcggcaaaagcagatcctgttgcagatcgacagcctcagcagcggtggtgcagcggcgcaatcaaccagcggcgatca aagcggtgtggcggcatcaacgacgccgacagctgatgctggtactgcgaatgctggcgcgccggtgaaaagcggtgatgcaaacacggattacaatgcagctattgcgctggtgcag
[0314] sgRNA sequence targeting lpp site (SEQ ID NO:178): acgttcaggctgctaaagat
[0315] Sequence of the left homology arm (LHA) of the lpp site (SEQ ID NO: 179): aatacttcccggatgccaccatcctggcactgaccaccaacgaaaaaacggctcaccagttagtactgagcaaaggtgttgtgccgcagctggttaaagagatcacatctactgatgact tctaccgtctgggtaaagaactggctctgcagagcggtctggcacacaaaggtgatgtcgtagttatggtttctggtgcactggtaccgagcggcactactaacaccgcatctgttcacgt cctgtaatattgcttttgtgaattaatttgtatatcgaagcgccctgatgggcgcttttttatttaatcgataaccagaagcaataaaaaatcaaatcggatttcactatataatctca ctttatctaagatgaatccgatggaagcatcctgttttctctcaatttttttatctaaaacccagcgttcgatgcttctttgagcgaacgatcaaaaataagtgccttcccatcaaaaaaa
[0316] Sequence of the right homology arm (RHA) of the lpp site (SEQ ID NO: 180): cctgtgaagtgaaaaatggcgcacattgtgcgccatttttttgcctgctatttaccgctactgcgtcgcgcgtaacatattcccttgctctggttccccattctgcgct gactctactgaaggcgcattgctggctgcgggagttgctccactgctcaccgcaaccggataccctgcccgacgatacaacgctttatcgactaacttctgatctacagc cttattctctttaaattgcgtaaagcctgctggcagcgtgtacggcattgtctgaacgttctgctgttcttctgccgatagtggtcgatgtacttcaacataacgcatc ccgttaggttccacggaatatttcaccggttcgttgatcactttcaccggtgttcccgtccgcacgctggagaataaagctttaatatccggtgcattcatgcgaataca
[0317] sgRNA sequence targeting mrcA site (SEQ ID NO:181): caaaccgttcctctacaccg
[0318] Sequence of the left homology arm (LHA) of the mrcA site (SEQ ID NO: 182): gacagccaggccatttgctcccgctcaccgagggacatcgacgggcgtggaaatgaccgctgtaatgtgcgactggcgggaaacgccaacataatgtgatgacgctgcggcagttcacgactccacggtaacaacgtgttagccagccgctgcacatcaacaatccgcccatctttgataatgtcgttctccagtggcaaccgccaccagcggtgcaataagcattcttttgcgctccgcacgatagcaaccgctaccgcttcttgctgttgtaaatgcaaaccaatttgccagttcttaaatgccattgtgatgatctccttatcacccgtcactctgacgggtatatcaatgcgtctggcttgcctttatactaccgcgcgtttgtttataaactgcccaaatgaaactaaatgg
[0319] Sequence of the right homology arm (RHA) of the mrcA site (SEQ ID NO: 183): ttaaaaaggcgcttcggcgcctttttcagtttgctgacaaagtgcacttgtttatgccagatgcgggtgaacgcgttatccggccaacaaaaaattgaaaattcaataaattgcaggaacttcgtaagcctgataagcgttgtgcatcaggcaaacttcacgcatttacactcgcccctgccctttcaaccattcgcgcacgaggaacagcgcgctgacattacgcgcttcgttgaagtcaggggcttccagcaaatccatcatatgcgccagcggccagcgcacctgtggtagcggctctggctcatcgccttccagtgattccgggtagagatcttgcgctaccacgatattcattttgctggaaaagtaagacggtgccatgctgagcttcttcaaaaaagtcagatcgttcgcaccaaatccaacctcttcttttagctcgcggttagcggcttca
[0320] sgRNA sequence targeting ompT site (SEQ ID NO:184): cctgggactcatggccggat
[0321] Sequence of the left homology arm (LHA) of the ompT site (SEQ ID NO: 185): cccagcccttgtcgatgccgcgttcaggctagcttcgttcaaatccattaaagatatcagactactctcaggtacgtgagtaaggtaaaacccagttccaacgccaatatccagatggttgttacctaa atgttccagaaagtgtggaagaaggtgttcctttgtaggacatccccatgcaagccgatttgatactcccaaaacccaccagtcataaagctttagggtaagtggtgtgtaaattttagccccatcatc tgtgtttttttcattagtttcaccgtgttatagttttatttgtgaattaaatcaattatagagatgaattacaaggggttaaatgatgccacggcataacgaatttgaatatattgggtcttgtgttg cggtaagaggttacacgccaggacgcaggttaaatgcttacaatattaggggatattgtttgcttttaacggtaaacaaattccccggggctatacaataccaccggggagaaaatctatttaacgttg
[0322] Sequence of the right homology arm (RHA) of the ompT site (SEQ ID NO: 186): aaaaggtctccattcaatcgttttaatgattgagtatgtattttttatatctaacttaatgagtcaattgtatattgccccactgtttatattttgtttaacattgaatttttgtcacaatgcgctgtcagttttttagtttaattgtctgtttg tgttttgtattgtggttttatgggctaattatttttttctttgtggagtttttatctattcaagtgccatgcctttagatgcatattagcgataatagcatgaggtttatcctcaattgctgtgtttttagtataaaaaagaggaacaaaactga gacacataaggcctcgcaatggcttgcaaggttttacatattttgaggtggtggaacgtgtgaacgcagagatggcgcggtaatttgttgatttaaaatgtcgttcttggagtttctaagtcgtgggctacaggttcgaatcctgcagggcgagcc atttcctcgccatttatttgttcccttttacaaattacaccatcactttgttgtcgcggttttgctaaataattggaacacgtcagacgaataaaatgaaaacagaaattctgctaaacaattcatcttgccaggattttgattaggaaagtgaaa
[0323] Example 5: Procedure for overexpressing molecular chaperones 5.1 Selection of molecular chaperones Various combinations of molecular chaperones were expressed in recombinant bacteria CBT4020 using plasmids, and the yields of IL-10 expressed in the culture supernatant and cells after culturing the recombinant bacteria in LB for 24 hours are shown in Table 11. The results showed that the yield of IL-10 could be increased by expressing molecular chaperones, and the best effect was obtained by simultaneously expressing molecular chaperones dsbA, dsbC, dnaK, dnaJ, grpE, groES, groEL, tig, fkpA, and surA.
[0324] [Table 11]
[0325] 5.2 Construction of molecular chaperone plasmids 5.2.1 Construction of plasmid pCBT012 The promoter BBa_J23114 and ribosome binding site (RBS) were amplified using the synthetic plasmid as a template. The groES, groEL, and tig coding sequences were amplified using the plasmid pG-TF2 as a template. The fkpA and surA coding sequences and the LHA and RHA of the insertion site yieN were amplified using the genome of EcN as a template. The transcription terminator was amplified using the plasmid pCBT003 as a template. The sgRNA expression sequence targeting the yieN site was amplified using the sgRNA expression plasmid pCBT003_yieN_sgRNA as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were linked by overlap PCR to obtain expression cassettes of donor gene fragments linked to the LHA and RHA-yieN_sgRNA sequences on both sides, respectively. Each element of the molecular chaperone expression cassette is arranged in the following order from 5' to 3': 5'-promoter-ribosome binding site (RBS)-groES-groEL-tig-fkpA-surA coding sequence-terminator. The pCBT012 plasmid backbone was amplified using the plasmid pCBT010 as a template. The PCR primers for amplifying the pCBT012 plasmid backbone have 15-20 bp of homology with the molecular chaperone expression cassette, so they could be ligated to the molecular chaperone expression cassette using the kit ClonExpress Ultra One Step Cloning Kit (Vazyme) to form the plasmid pCBT012 (SEQ ID NO: 215).
[0326] The sequence of plasmid pCBT010 (SEQ ID NO:187):
[0327] 5.2.2 Construction of plasmid pCBT013 The promoter BBa_J23114 and ribosome binding site (RBS) were amplified using a synthetic plasmid as a template. The dnaK, dnaJ, and grpE coding sequences were amplified using the plasmid pKJE7 as a template. The dsbA and dsbC coding sequences and the LHA and RHA of the insertion site yicS / nepI were amplified using the genome of EcN as a template. The transcription terminator was amplified using the plasmid pCBT003 as a template. The sgRNA expression sequence targeting the yicS / nepI site was amplified using the sgRNA expression plasmid pCBT003_yicS / nepI_sgRNA as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were linked by overlap PCR to obtain expression cassettes of donor gene fragments with both sides linked to the LHA and RHA-yicS / nepI_sgRNA sequences, respectively. Each element of the molecular chaperone expression cassette is arranged in the following order from 5' to 3': 5'-promoter-ribosome binding site (RBS)-dsbA-dsbC-dnaK-dnaJ-grpE coding sequence-terminator. The pCBT013 plasmid backbone was amplified using the plasmid pCBT010 as a template. The PCR primers for amplifying the pCBT013 plasmid backbone have 15-20 bp of homology with the molecular chaperone expression cassette, so they could be ligated to the molecular chaperone expression cassette using the kit ClonExpress Ultra One Step Cloning Kit (Vazyme) to form the plasmid pCBT013 (SEQ ID NO: 216).
[0328] 5.3 Genomic integration of molecular chaperones Plasmids pCBT012 and pCBT013 expressing molecular chaperones were transformed into competent cells containing pCBT001. The resulting single colonies were amplified with primers for verifying the insertion site, and clones in which the molecular chaperone expression cassette was inserted into the genome were screened based on the size of the amplified band. The sequence accession numbers of each molecular chaperone are shown in Table 12.
[0329] [Table 12]
[0330] The sequence of the sgRNA targeting the yieN insertion site is shown in SEQ ID NO: 188. The sequences of the homology arms on either side of the yieN insertion site are shown in SEQ ID NO: 189 and 190, respectively. The sequence of the sgRNA targeting the yicS / nepI insertion site is shown in SEQ ID NO: 191. The sequences of the homology arms on either side of the yicS / nepI insertion site are shown in SEQ ID NO: 192 and 193, respectively.
[0331] sgRNA sequence targeting the yieN site (SEQ ID NO:188): gagggtgagccataatgaag
[0332] Sequence of the left homology arm (LHA) of the yieN site (SEQ ID NO: 189): tccgagacataaggcgcatccggtaatttatccagttgctggcgcagcataaaaatcagctcaaatacatgatcgggcagcgtaatttcaccaatctctttctgccagcgttcatattcttcatctgtgatctgcaaggaggcaggaaccggattgtcattttcatcctgttgactggtcagcatggagcggaaattcgctttatcctgcactttatctaaccacagacgaatcagcatgcgatcatataacgcttccagactgctgtctgcttccggcagctcgttggaggccgccaccagcagacgcatcgggattttttctacgagtgcgccgttgcggaactggcgctcgttaatggcggtgagcagggtattaagaattgccggacccgctttccagatctcatccagaaagacgatttcagcttccggcaggtaaccgctggttaaacgttcatagcgcccttcatcttttagcgcctgaatagaaaggggaccaaaaacttcttccggcgtggagaagcgggtcatcagatattcaaacgcgcggg
[0333] Sequence of the right homologous arm (RHA) of the yieN site (SEQ ID NO: 190): aatgtggccgcatttaggagtacgattttgccgttaatcgtgcatactgtgcgcttttttgtgggccaagggactaagcacacatttcatatttcaacgaaagactagtctatgagcactgataataagcaatcattgcccgcgattaccctcgcggcgattggagttgtctacggcgatattggtaccagcccgttatatacacttcgtgaatgtttgtccggccagtttggttttggcgttgaacgcgatgccgtgtttggctttttatcgctgatcttctggctgctaatctttgtggtttccattaaatatctcaccttcgtgatgcgggcagata
[0334] sgRNA sequence targeting the yicS / nepI site (SEQ ID NO:191): ctgaccaacgcttctttacc
[0335] Sequence of the left homology arm (LHA) of the yicS / NepI site (SEQ ID NO: 192): aacgaaacgctatcgataagaataaaaaggaataaaagtggaatataaagtctggcacttcttactgaccacgcaaacacctttcgtacagcatgatgagagcggcaaaagcaaacta cacttatgcttcattcgatgcacatttgcagaaggttgccgctatgaagccaacgatgctactcatgattaccgtattcctgatttttccagccatttctcaggccgagtcgccattc agttctctacagtcggcaaaagagaaaaccacggtattgcaagatttacgtaaaatttgcacgccacaggcgtcattatcagatgaagcgtgggaaaagttaatgttgtcagatgaaa acaataaacaacatatacgcgaggccatcgtggcgatggaacgtaataatcagagcaattattgggaagcgttgggtaaggtagaatgcccggatatgtaagaacggcaacaaccactg
[0336] Sequence of the right homology arm (RHA) of the yicS / NepI site (SEQ ID NO: 193): accaacgcttctttacctgatatcaggatttcttcattttcacctttgcagtcaccaacaatgcagtcagcaacatcaatgtgccggacaacatcagcggcgaagtcagaccaatg ttatccaacgcataaccgccgattgccgcaccgcaggtgttagcaagctgaataacggccacctgaatagatccagccttttctgcctgatcggccaatgagcgagtgatccacgt tgaccaaccaacgggaattaaagcaaaggtcagcccccagataatcgcaacaccagtagcaacaattttatagcttccccacagcgtcagtaccagcgcgctcagggcgagcacaa acggtgcgcccgctaaggccagtttcaccgaacgtttgagaataaacgacgaaagcgatgtcccgacaaagctggcgataccaaaactcagcagcaccagggttaagccatcaaca
[0337] Example 6: Strain construction 6.1 Construction of IL-10-expressing strains 6.1.1 Procedure for constructing expression cassettes for IL-10 donor gene fragments The IL-10 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were synthesized on a cloning plasmid (e.g., pUC57) by GeneScript. The IL-10 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were amplified using the synthetic plasmid as a template. The insertion sites LHA and RHA were amplified using the EcN genome as a template. The transcription terminator was amplified using the plasmid pCBT003 as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were linked by overlap PCR to obtain an expression cassette of the donor gene fragment linked to the LHA and RHA sequences on both sides. Each element of the expression cassette is arranged in the following order from 5' to 3': 5'-promoter-ribosome binding site (RBS)-mistron-signal peptide-IL-10 coding sequence-terminator (the sequence structure of the constructed expression cassette for each donor gene fragment is shown in SEQ ID NOs: 144 to 156, 235). The PCR product of the expression cassette for the donor gene fragment having LHA and RHA sequences on both sides and the pCBT003_maeB_sgRNA plasmid expressing sgRNA were simultaneously transformed into competent cells containing pCBT001. The resulting single colony was amplified with a primer for verifying the insertion site, and clones in which IL-10 had been inserted into the genome were screened based on the size of the amplified band. The yield of IL-10 was detected with an ELISA kit (Sino Biological, KIT10947A).
[0338] In this example, all IL-10 coding sequences were sequences encoding wild-type human IL-10 (SEQ ID NO: 11). The inserted site was maeB in the EcN genome. The sequence of the sgRNA targeting the maeB site is shown in SEQ ID NO: 194. The sequences of the homology arms on both sides of this maeB site are shown in SEQ ID NO: 195 and 196, respectively.
[0339] sgRNA sequence targeting the maeB site (SEQ ID NO:194): gaaggggaagaggcgcgcgt
[0340] Sequence of the left homology arm (LHA) of the maeB site (SEQ ID NO: 195): gtggtggatgacggtaaacgtaccctcgatgatgtgattgaaggcgcggatattttcctcggctgttccggcccgaaagtgctgacccaggaaatggtgaagaa aatggcccgtgcgccaatgatcctggcgctggcgaacccggaaccggaaattctgccgccgctggcgaaagaagtgcgtccggatgccatcatctgtaccggccg ttccgactacccgaaccaggtgaacaacgtcctttgcttcccgtttatcttccgtggcgcgctggacgttggcgcaaccgccatcaacgaagagatgaaactggc ggcagtacgcgcgattgcagaactggcccatgcggaacagagtgaagtggtggcttcagcgtatggcgatcaggatctgagctttggtccggaatacatcattcc
[0341] Sequence of the right homology arm (RHA) of the maeB site (SEQ ID NO: 196): gcgaaaccgatccttattggtcgtccgaacgtgatcgaaatgcgcattcagaaactgggcttgcagatcaagtcgggcgttgattttgagatcgtcaataacgaatccgatccgcgctttaaagagtactggaccgaatacttccagatcatgaagcgtcgcggtgtcactca ggagcaggcgcagcgtgcgctgatcagtaacccgacagtgatcggcgcgatcatggttcagcgtggcgaagccgatgcaatgatttgcggtacggtgggcgattatcatgaacactttagcgtggtgaaaaatgtctttggttatcgcgatggcgttcacaccgcaggtgcaat
[0342] The information on each of the IL-10-expressing strains obtained in this example and their insertion elements and knockout elements is shown in Table 13 below. The sequences of the relevant elements are shown in Tables 2 to 9. [Table 13]
[0343] 6.1.2 Optimization of IL-10 expression conditions After culturing recombinant bacteria using different signal peptides in LB for 24 hours, the yields of IL-10 expressed in the culture supernatant and in the cells are shown in Table 14. The dsbA signal peptide was used in strain CBT4007, the ompA signal peptide in strain CBT4009, the pelB signal peptide in strain CBT4011, the yebF signal peptide in strain CBT4013, and the USP45 signal peptide in strain CBT4003. At the same dilution, the concentrations of IL-10 in recombinant bacteria samples using OmpA, PelB, and YebF signal peptides were lower than the lower limit of detection. The yield of IL-10 using the SP45 signal peptide was significantly higher than that using the DsbA signal peptide.
[0344] [Table 14]
[0345] After culturing recombinant bacteria using different promoters in LB for 24 hours, the yields of IL-10 expressed in the culture supernatant and in the cells are shown in Table 15. The BBa_J23101 promoter was used in strain CBT4003, the BBa_J23108 promoter in strain CBT4004, and the BBa_J23110 promoter in strain CBT4005. The results showed that the yield of IL-10 could be adjusted by selecting an appropriate promoter (e.g., the BBa_J23101 promoter).
[0346] [Table 15]
[0347] After culturing recombinant bacteria using different mistrons in LB for 24 hours, the yield of IL-10 expressed in the culture supernatant is shown in Table 16. Mistron T7g10 was used in strain CBT4026, Mistron BCD2 in strain CBT4028, Mistron GFP in strain CBT4029, and Mistron Lucifierase in strain CBT4030. The results showed that the yield of IL-10 could be adjusted by selecting different mistrons.
[0348] [Table 16]
[0349] The yields of IL-10 expressed in the culture supernatant and cells after culturing recombinant bacteria with different membrane proteins knocked out and overexpressing molecular chaperones in LB for 12 hours are shown in Table 17. The membrane proteins tolQ, tolR, tolA, pal and lpp were knocked out in strains CBT4071, CBT4072, CBT4073, CBT4074 and CBT4020, respectively. The control was strain CBT4005, whose outer membrane was not engineered. The results showed that the yield and secretion efficiency of IL-10 could be significantly increased by knocking out tolQ, tolR, tolA, pal and lpp alone.
[0350] CBT4062 was a genetically engineered strain that knocked out the membrane protein lpp and overexpressed molecular chaperones. Overexpression of molecular chaperones was achieved by inserting dsbA, dsbC, dnaK, dnaJ, and grpE driven by the BBa_J23114 promoter into the strain yicS / nepI site, and groES, groEL, tig, fkpA, and surA driven by the BBa_J23114 promoter into the yieN site. The sequence accession numbers of the individual molecular chaperones are shown in Table 12. Compared with the control strain CBT4028, which only knocked out lpp but did not overexpress molecular chaperones, overexpression of molecular chaperones could obviously increase the yield of IL-10 in CBT4062. The recombinant CBT4075 strain, which simultaneously knocked out lpp and mrcA and overexpressed molecular chaperones, and the recombinant CBT4076 strain, which simultaneously knocked out lpp and ompT and overexpressed molecular chaperones, significantly increased the yield and secretion level of IL-10 by knocking out lpp and mrcA or ompT in combination, compared with CBT4062, which only knocked out lpp and overexpressed molecular chaperones. However, the recombinant CBT4077 strain, which simultaneously knocked out the three membrane proteins lpp, mrcA, and ompT, and overexpressed molecular chaperones, did not show higher IL-10 yield. The recombinant CBT4112 strain, which simultaneously knocked out pal and mrcA, showed no obvious change in IL-10 yield, compared with CBT4074, which only knocked out pal. Therefore, mrcA can increase the efficiency of protein secretion only when it is knocked out in combination with lpp.
[0351] [Table 17]
[0352] The expression levels of IL-10 in LB (pH adjusted to 8.0 with phosphate citrate buffer system) + 1% w / v glucose medium under aerobic and anaerobic conditions were compared for the strain CBT4078 (EcNΔmaeB::PfnrS_BCD2_USP45_IL-10ΔLPPΔyicS / nepI::BBa_J23114_dsbA_dsbC_dnaK_dnaJ_grpEΔyieN::BBa_J23114_groES_groEL_tig_fkpA_surA) using an anaerobic promoter are shown in Figure 2. As a result, it was shown that the yield of IL-10 obtained by anaerobic culture using an anaerobic promoter was clearly higher than that obtained by aerobic culture.
[0353] 6.2 Construction of IL-22-expressing strains 6.2.1 Procedure for constructing expression cassettes for IL-22 donor gene fragments The IL-22 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were synthesized on a cloning plasmid (e.g., pUC57) by GeneScript. The IL-22 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were amplified using the synthetic plasmid as a template. The insertion sites LHA and RHA were amplified using the EcN genome as a template. The transcription terminator was amplified using the plasmid pCBT003 as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were linked by overlap PCR to obtain an expression cassette of the donor gene fragment linked to the LHA and RHA sequences on both sides. Each element of the expression cassette is arranged in the following order from 5' to 3': 5'-promoter-ribosome binding site (RBS)-mistron-signal peptide-IL-22 coding sequence-terminator (the sequence structure of the constructed expression cassette for each donor gene fragment is shown in SEQ ID NOs: 157 to 163). The PCR product of the expression cassette for the donor gene fragment having LHA and RHA sequences on both sides and the pCBT003_kefB_sgRNA plasmid or pCBT003_maeB_sgRNA plasmid expressing sgRNA were simultaneously transformed into competent cells containing pCBT001. The resulting single colony was amplified with a primer for verifying the insertion site, and clones in which IL-22 had been inserted into the genome were screened based on the size of the amplified band. The yield of IL-22 was detected using an ELISA kit (Sino Biological, KIT13059).
[0354] All IL-22 coding sequences in this example were sequences encoding wild-type human IL-22 (SEQ ID NO: 15). The inserted sites were the maeB site (CBT4038) or the kefB site (CBT4041, CBT4042, CBT4043, CBT4039, CBT4040, CBT4016) of the EcN genome. The sequence of the sgRNA targeting the maeB site is shown in SEQ ID NO: 194. The sequences of the homology arms on both sides of the maeB site are shown in SEQ ID NO: 195 and 196, respectively. The sequence of the sgRNA targeting the kefB site is shown in SEQ ID NO: 197. The sequences of the homology arms on both sides of the kefB site are shown in SEQ ID NO: 198 and 199, respectively.
[0355] sgRNA sequence targeting kefB site (SEQ ID NO:197): gccggaagacactatgaagc
[0356] Sequence of the left homology arm (LHA) of the kefB site (SEQ ID NO: 198): ttgtttatggatgcgctggggttgtcgatggcgctcggtacgtttattgcgggtgtgctactggcggaaagtgaatatcgccatgaactggaaa cggctatcgatcccttcaaaggcttgctgctcggtttgttctttatctctgtcggcatgtcgctcaacctcggggtgctttatacccatctgtt gtgggtagtgataagtgtggttgtgctggtggcggtgaaaattctcgtgctgtatctgctggcgcgattgtatggcgtgcgcagttctgagcgg atgcagtttgctggcgtgttgagtcagggcggtgagtttgcctttgtcctcttttctaccgcttcttcacaacgcttattccagggcgaccagat
[0357] Sequence of the right homology arm (RHA) of the kefB site (SEQ ID NO: 199): ttgcatattcttgcgcgagcgcgcggacgtgtggaagcgcatgagttattacaggcaggggtgacgcagttttcccgtgaaacattctccagtgcgttagagctggggcgcaagacgctggtcacgcttggcatgcatccgcatcaggcgcagcgcgcgcaactg cattttcgccgcctggatatgcgaatgctgcgggagttaatcccgatgcatgctgataccgtacaaatttctcgcgccagggaagcccgacgtgaactggaagagattttccagcgtgaaatgcaacaagaacgacgccagctggacggctgggatgaatttgagt
[0358] [Table 18]
[0359] 6.2.2 Optimization of IL-22 expression conditions After culturing recombinant bacteria using different promoters in LB for 24 hours, the yield of IL-22 expressed in the culture supernatant and in the cells is shown in Table 19. The BBa_J23119 promoter (inserted into the ΔmaeB site) was used in strain CBT4038, the BBa_J23101 promoter in strain CBT4041, the BBa_J23102 promoter in strain CBT4042, the BBa_J23108 promoter in strain CBT4043, the BBa_J23110 promoter in strain CBT4039, and the BBa_J23114 promoter in strain CBT4040. The results showed that the yield of IL-22 could be adjusted by selecting an appropriate promoter (e.g., the BBa_J23119 promoter).
[0360] [Table 19]
[0361] After culturing recombinant bacteria with different membrane proteins knocked out and recombinant bacteria overexpressing molecular chaperones in LB for 24 hours, the yields of IL-22 expressed in the culture supernatant and cells are shown in Table 20. The results showed that the strain CBT4016, in which the membrane protein LPP was knocked out, had a significantly higher IL-22 secretion rate than the strain CBT4039, in which only LPP was knocked out.
[0362] [Table 20]
[0363] 6.3 Construction of strain expressing Amuc_1100 6.3.1 Procedure for constructing expression cassettes for Amuc_1100 donor gene fragments The Amuc_1100 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were synthesized on a cloning plasmid (e.g., pUC57) by GeneScript. The Amuc_1100 coding sequence, signal peptide, promoter, ribosome binding site (RBS), and mistron were amplified using the synthetic plasmid as a template. The insertion sites LHA and RHA were amplified using the EcN genome as a template. The transcription terminator was amplified using the plasmid pCBT003 as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were linked by overlap PCR to obtain an expression cassette of the donor gene fragment linked to the LHA and RHA sequences on both sides. Each element of the expression cassette is arranged in the 5' to 3' direction in the following order: 5'-promoter-ribosome binding site (RBS)-mistron-signal peptide-Amuc_1100 coding sequence-terminator (the sequence structure of the constructed expression cassette for each donor gene fragment is shown in SEQ ID NOs: 139 to 143). The PCR product of the expression cassette for the donor gene fragment having the LHA and RHA sequences on both sides and the pCBT003_agaI / rsmI_sgRNA plasmid or pCBT003_malP / T_sgRNA plasmid or pCBT003_pflB_sgRNA plasmid or pCBT003_lldD_sgRNA plasmid or pCBT003_maeA_sgRNA plasmid expressing sgRNA were simultaneously transformed into competent cells containing pCBT001. The obtained single colonies were amplified with primers for verifying the insertion site, and clones in which Amuc_1100 had been inserted into the genome were screened based on the size of the amplified band.
[0364] In this example, the Amuc_1100 coding sequence was a sequence encoding wild-type Amuc_1100 (SEQ ID NO: 5, designated WT in Table 21) or Y259A mutant Amuc_1100 (the number at position 259 is based on the sequence shown in SEQ ID NO: 5, designated Y259A in Table 21). When a single copy of Amuc_1100 was inserted, the inserted site was the agaI / rsmI site of the EcN genome. When two copies of Amuc_1100 were inserted, the first and second inserted sites were the agaI / rsmI site and the malP / T site of the EcN genome, respectively. When three copies of Amuc_1100 were inserted, the first, second and third inserted sites were the agaI / rsmI site, the malP / T site and the pflB site of the EcN genome, respectively.
[0365] The sequence of the sgRNA targeting the agaI / rsmI site is shown in SEQ ID NO: 200. The sequences of the homology arms on both sides of the agaI / rsmI site are shown in SEQ ID NO: 201 and 202, respectively. The sequence of the sgRNA targeting the malP / T site is shown in SEQ ID NO: 203. The sequences of the homology arms on both sides of the malP / T site are shown in SEQ ID NO: 204 and 205, respectively. The sequence of the sgRNA targeting the pflB site is shown in SEQ ID NO: 206. The sequences of the homology arms on both sides of the pflB site are shown in SEQ ID NO: 207 and 208, respectively. The sequence of the sgRNA targeting the lldD site is shown in SEQ ID NO: 209. The sequences of the homology arms on both sides of the lldD site are shown in SEQ ID NO: 210 and 211, respectively. The sequence of the sgRNA targeting the maeA site is shown in SEQ ID NO: 212. The sequences of the homology arms on both sides of the maeA site are shown in SEQ ID NO: 213 and 214, respectively.
[0366] Sequence of sgRNA targeting agaI / rsmI sites (SEQ ID NO:200): ggcgagttaacgacgacaca
[0367] Sequence of the left homology arm (LHA) of the agaI / rsmI site (SEQ ID NO:201): gcgctaaaagctattgaagcggagccgcgcacgctgattttttatgaatctacccaccgtctgttagatagcctggaagatatcgttgcggtattaggcgaatcccgttacgtggttctggcgcgtgagctaaccaaaacctgggaaaccattcacggcgcgcccgttggcgagctgctggcgtgggtaaaagaagatgaaaaccgtcgcaaaggcgaaatggtgctgattgtcgaaggccataaagcgcaggaaaatgacttgcctgctgatgccctgcgcacgctggcgctgctacaggcagaactgccgctgaaaaaagcggcggcgctggccgcagaaattcacggcgtgaagaaaaatgcgctgtataagtatgcgctggagcagcagggagagtgattacaggcgtcgcagcaggaatagcgctac
[0368] Sequence of the right homologous arm (RHA) of the agaI / rsmI site (SEQ ID NO: 202): tcacgcatgtgaaatggttatgcagccataaaaatgaagccgggatagcggtggagactttagccgtgagaaaacgttctgtcgcatcctgttttccttcgccagtcaccagtaacaaaacttcgcgggcattgagaatatccttcaggcctaaggtgatcccacgagtcacgggacggtccgcggtttttaacatctcatgttgctgtgttctggcatcaagttgactgatatggcaggctggttgcaggctttctcccggttcgttcagcccaagatgaccgtttttccccaatccgagaacgcataaatccagaccgcctttgcgcgcaatcaggttcgttacccgttcgcactctgtctcatttatctcttcggagcgaaagctgatgagctggtcttcacgcagccccagcggctgcacgatatgctgttgtaggaaagtttcgcaggtg
[0369] Sequence of sgRNA targeting malP / T site (SEQ ID NO: 203): ttgcgtattttcaaaaagcg
[0370] Sequence of the left homology arm (LHA) of the malP / T site (SEQ ID NO: 204): accagccgagattcaacaggttgttgcccgtcaggcgaccaatcaaaaactccattgagatgtagttaacatgtcgctgattcgccactggcttggcgaatggctgagcacgcagcatt tcggccagtgcttcgctcactgccagccaccactggcgaggagtcatttcagccgcagaatttaagccataacgctgccactgacgtgaaagcgcttcctgaaattgcttatcgttaaa aataggttgtgacataggagttccacttttcttagattttcaacacaacgttatcgctagtttgccaggctcgatgttgaccttcctcatcctgcgggggattaggcagggaggagttg cggggatgagcaaggaaatgtgatctcgaccacttaaagctagtgcaatccacaggattagcagcaaatcaatgccataccgcgcagaaaatctgtatctaagtgcaaaaaatggccgtt
[0371] Sequence of the right homology arm (RHA) of the malP / T site (SEQ ID NO: 205): cgtattttcaaaaagcggaaggtaactctataaattaagtaaaggagtgaaacagtttcacaagtaaaatatcaagtgtgctccatctcattcttaatagatttattaagatca tctttttagatggcactttcatcagaaatgaagaagaaacccttgcttaaatgaaactgatgaacataaggaaaataccgtacaacccagtattcacgctggatcagcgtcgtt ttaggtgagttgttaataaacatttggaattgtgacacagtgcaaattcagacacataaaaaaacgtcatcgcttgcattagaaaggtttctggccgaccttataaccattaat tacgaagcgcaaaaaaaataatatttcctcattttccacagtgaagtgattaactatgctgattccgtcaaaattaagtcgtccggttcgactcgaccataccgtggttcgtga
[0372] Sequence of sgRNA targeting pflB site (SEQ ID NO:206): ccgtgacgttatccgcacca
[0373] Sequence of the left homology arm (LHA) of the pflB site (SEQ ID NO:207): acgatgacctgatgcgtccggacttcaacaacgatgactacgctattgcttgctgcgtaagcccgatgatcgttggtaaacaaatgcag ttcttcggtgcgcgtgcaaacctggcgaaaaccatgctgtacgcaatcaacggcggcgttgacgaaaaactgaaaatgcaggttggtcc gaagtctgaaccgatcaaaggcgatgtcctgaactatgatgaagtgatggagcgcatggatcacttcatggactggctggctaaacagtacatcactgcactgaacatcatccactacatgcacgacaagtacagctacgaagcctctctgatggcgctgcacgaccgtgacgttatcc
[0374] Sequence of the right homology arm (RHA) of the pflB site (SEQ ID NO:208): gtgacgctatcccgactcagtctgttctgaccatcacttctaacgttgtgtatggtaagaaaactggtaacaccccagacggtcgtcgtgctggcgcgccgttcgggaccg ggtgctaacccgatgcacggtcgtgaccagaaaggtgctgtagcgtctctgacttccgttgctaaactgccgtttgcttacgctaaagatggtatctcctacaccttctct atcgttccgaacgcactgggtaaagacgacgaagttcgtaagaccaacctggctggtctgatggatggttacttccaccgaagcatccatcgaaggtggtcagcacct gaacgttaacgtgatgaaccgtgaaatgctgctcgacgcgatggaaaacccggaaaaatatccgcagctgaccatccgtgtatctggctacgcagtacgtttcaactcgct
[0375] Sequence of sgRNA targeting lldD site (SEQ ID NO:209): gttatcgtgatgcgcattct
[0376] Sequence of the left homology arm (LHA) of the lldD site (SEQ ID NO:210): tttccgcagccagcgattatcgcgccgcagcgcaacgcattctgccgccgttcctgttccactatatggatgggggggcatattctgaatacacgctgcgccgcaacgtggaagatttgtcagaagtggcgctgcgccagcgtattctgaaaaacatgtctgacttaagcctggaaacgacgctgtttaatgagaaattgtcgatgccggtggcgctaggtccggtaggtttgtgtggcatgtatgcgcgacgcggcgaagttcaggctgccaaagcagcagatgcgcatggcattccgtttactctctcgacggtttccgtttgcccgattgaagaagtggctccggctatcaaacgtccgatgtggttccagctttatgtgctgcgcgatcgcggctttatgcgtaacgccctggagcgagcaaaagccgcgggttgttcgacgctggttttcacc
[0377] Sequence of the right homology arm (RHA) of the lldD region (SEQ ID NO: 211): gatccgcgatttctgggatggcccgatggtgatcaaagggatcctcgatccggaagatgcgcgcgatgcagtacgttttggtgctgatggaattgtggtttctaaccacggtggccgccagttagatggcgtactctcttctgctcgtgcactgcctgctattgcggatgcggtgaaaggtgatatcgccattctggcggatagcggaatacgtaacgggcttgatgtcgtgcgtatgattgcgctcggtgccgacaccgtactgctgggtcgtgctttcctgtatgcactggcaacagcgggccaggcgggtgtagctaatctgctaaatctgatcgaaaaagagatgaaagtggcgatgacgctgactggcgcgaaatcgattagcgaaattacgcaagattcgctggtgcaggggctgggtaaagagttgcctgcggca
[0378] Sequence of sgRNA targeting the maeA site (SEQ ID NO:212): taacacccagcccgatgccc
[0379] Sequence of the left homology arm (LHA) of the maeA site (SEQ ID NO:213): ttctgcatagcaggtgaggcaaatgagatttattcgccactacccagtatggatgagatctgaaaaagggagaggaaaattgcccggtagccttcactaccgggcgcaggcttagatggaggtacggcggtagtcgcggtattcggcgtgccagaaattatcatcaatggcctgttgc agagcttcggcagacgttttcaccgccacgccttgctgctgcgccattttgccaaccgcaaaggcaattgcgcgggagactttctgaatatctttcagttccggcagtaccagaccttcgccgttcaggaccagcggcgaatactgagcaagcatttcacttgccgacatcagcatctc
[0380] Sequence of the right homology arm (RHA) of the maeA site (SEQ ID NO:214): gagattttcgcgcttctgcaccagtttggtctggaaaggcagcaggttcggcatcttgtcggtcagcaggccaaagcgatcgaccataaagactttctgccgcgccgcttcctcgcttaatccttcgcgctgggtctgggcga tgatcatttcggcaatgccgcatcccgctgaacctgcgccaaggaagacgatttttttctcgcttaactgaccacctgccgcgcggctggctgcgatcagtgtgccgactgttaccgccgcggtgccctgaatgtcatcgttaa aagaacaaatttcattgcgatagcggttaagtaacggcatcgcatttttttgtgcgaagtcttcaaactgcaacagtacgtccggccagcgttgtttcacagcctggataaattcatcaacaaattcatagtattcgtcgtca gtgatacgcggattacgccagcccatatacagcggatcgttaagcagctgttggttgttggtgccgacatccagcaccacggaagggtataggccggactgatgccgccacaggcggtatagagcgacagtttaccgatcgga
[0381] The yield of Amuc_1100 was detected by Western blotting. The strain information is shown in Table 21. The sequences of the relevant elements are shown in Tables 2 to 9. [Table 21]
[0382] 6.3.2 Optimization of Amuc_1100 expression conditions The results of comparing the expression levels of Amuc_1100(Y259A) with different copy numbers are shown in Figure 3A. In the figure, lanes A and B are strain CBT4101 expressing a single copy of Amuc_1100(Y259A) using the BBA_J23101 promoter, lane C is strain CBT4107 expressing a single copy of Amuc_1100(Y259A) using the BBA_J23110 promoter, lane D is strain CBT4102 expressing two copies of Amuc_1100(Y259A) using the BBA_J23110 promoter, and lane E is strain CBT4103 expressing two copies of Amuc_1100(Y259A) using the BBA_J23110 promoter. Lane A is strain CBT4103 expressing 3 copies of Amuc_1100(Y259A) using 1 promoter, lane B is strain CBT4108 expressing 3 copies of Amuc_1100(Y259A), of which a single copy uses the BBA_J23101 promoter and the other two copies use the BBA_J23110 promoter, and lane G is strain CBT4109 expressing 3 copies of Amuc_1100(Y259A) using the BBA_J23110 promoter. The results showed that the expression level of Amuc_1100 could be increased by increasing the copy number.
[0383] The stability of Amuc_1100 was improved by engineering the outer cell membrane, and the results of the comparison are shown in Figure 3B, where the membrane proteins LPP and ompT were knocked out in strain CBT4106, and only the membrane protein LPP was knocked out in strain CBT4105. The results showed that knocking out ompT could reduce the degradation of Amuc_1100 in the supernatant.
[0384] 6.4 Construction of strains expressing combinations of IL-10, IL-22 and / or Amuc_1100 The methods for producing the IL-10, IL-22 and Amuc_1100 donor gene fragments were similar to those described in Examples 6.1, 6.2 and 6.3. The construction of the two combination strains expressing IL-10 and IL-22 simultaneously was by transforming the IL-22 donor gene fragment into a strain expressing IL-10, the construction of the two combination strains expressing IL-10 and Amuc_1100 simultaneously was by transforming the Amuc_1100 donor gene fragment into a strain expressing IL-10, the construction of the two combination strains expressing IL-22 and Amuc_1100 simultaneously was by transforming the Amuc_1100 donor gene fragment into a strain expressing IL-22, and the construction of the three combination strains expressing IL-10, IL-22 and Amuc_1100 simultaneously was by transforming the Amuc_1100 donor gene fragment into a strain expressing IL-10 and IL-22 simultaneously. The information of each combination strain obtained in this embodiment and its insertion element and knockout element is shown in Table 21 below, and the sequences of the related elements are shown in the sequences of Tables 2 to 9.
[0385] [Table 22]
[0386] In the figure, a schematic diagram of the location of each gene on the EcN chromosome in the three combination strains simultaneously expressing IL-10, IL-22, and Amuc_1100 is shown in FIG. 4A.
[0387] 6.5 Determination of strain growth status The growth curves of the strains expressing Amuc_1100 alone, two-gene combination, and three-gene combination are shown in Figure 4B. In the figure, CBT4070 expresses Amuc_1100 alone, CBT4062 expresses IL-10 alone, CBT4068 expresses IL-10 and Amuc_1100 simultaneously, CBT4066 expresses IL-22 alone, CBT4069 expresses IL-22 and Amuc_1100 simultaneously, CBT4063 expresses IL-10 and IL-22 simultaneously, and CBT4067 expresses IL-10, IL-22, and Amuc_1100 simultaneously. The strain information is shown in Table 10.
[0388] The results showed that the growth of the recombinant bacteria expressed alone, in combination with two genes, and in combination with three genes was not significantly affected.
[0389] 6.6 Measurement of exogenous gene expression The results of the expression levels of IL-10 and IL-22 in the supernatants of the strains expressed alone, in a combination of two genes, and in a combination of three genes are shown in Table 23. In the table, CBT4062 expressed IL-10 alone. CBT4068 expressed IL-10 and Amuc_1100 simultaneously. CBT4066 expressed IL-22 alone. CBT4069 expressed IL-22 and Amuc_1100 simultaneously. CBT4070 expressed Amuc_1100 alone. CBT4063 expressed IL-10 and IL-22 simultaneously. CBT4067 expressed IL-10, IL-22, and Amuc_1100 simultaneously. As a result, it was shown that the expression of IL-10, IL-22, and Amuc_1100 by the genetically modified bacteria expressing in combination was not reduced by the combination. [Table 23]
[0390] Example 7: Activity detection of expressed proteins 7.1 Detection of IL-10 activity The samples to be detected were diluted to the appropriate concentration in whole cell culture medium. 20 μL of the diluted samples and IL-10 standard were added to a flat-bottom 96-well plate, respectively, and the EcN sample was used as a negative control. ~280,000 cells / mL of HEK-Blue TM A cell suspension of IL-10 Cells (InvivoGen, Cat#hkb-il10) was prepared, and 180 μL of this suspension (~50,000 cells) was quickly added to the wells to which the samples were added. After incubating the 96-well plate at 37°C with 5% CO2 for 22 hours, 20 μL of the supernatant was added to a new flat-bottom 96-well plate, and 180 μL of QUANTI-Blue reagent was added per well, and incubated at 37°C for 1 hour before A620 The numerical value was read.
[0391] The cellular activity of secreted IL-10 in the supernatants of the strains expressing alone, two-gene combination, and three-gene combination is shown in Figure 4C. In the figure, the negative control was EcN supernatant that does not express IL-10. The concentration of the IL-10 standard was 30ng / mL. CBT4062 expressed IL-10 alone, and the sample concentration was diluted to 21ng / mL. CBT4068 expressed IL-10 and Amuc_1100 simultaneously, and the sample concentration was diluted to 28ng / mL. CBT4063 expressed IL-10 and IL-22 simultaneously, and the sample concentration was diluted to 21ng / mL. CBT4067 expressed IL-10, IL-22, and Amuc_1100 simultaneously, and the sample concentration was diluted to 29ng / mL.
[0392] The results showed that the IL-10 expressed and secreted by the recombinant recombinant strains was biologically active and its activity was comparable to that of the standard.
[0393] 7.2 Detection of IL-22 activity The samples to be detected were diluted to the appropriate concentration with whole cell culture medium. 20 μL of the diluted samples and IL-22 standard were added to a flat-bottom 96-well plate, respectively, and the EcN sample was used as a negative control. ~280,000 cells / mL of HEK-Blue TM A cell suspension of IL-22 Cells (InvivoGen, Cat#hkb-il22) was prepared, and 180 μL of this suspension (~50,000 cells) was quickly added to the wells to which the samples were added. After incubating the 96-well plate at 37°C with 5% CO2 for 22 hours, 20 μL of the supernatant was added to a new flat-bottom 96-well plate, and 180 μL of QUANTI-Blue reagent was added per well, and incubated at 37°C for 1 hour before addition of A 620 The numerical value was read.
[0394] The cellular activity of secreted IL-22 in the supernatants of the strains expressing alone, two-gene combination, and three-gene combination is shown in Figure 4D. In the figure, the negative control was EcN supernatant that does not express IL-22. CBT4066 expressed IL-22 alone. CBT4069 simultaneously expressed IL-22 and Amuc_1100. CBT4063 simultaneously expressed IL-22 and IL-10. CBT4067 simultaneously expressed IL-10, IL-22, and Amuc_1100. The IL-22 standard and sample concentrations of each strain were diluted to 0.33ng / mL, 1ng / mL, and 3ng / mL.
[0395] The results showed that IL-22 expressed and secreted by the recombinant recombinant strains was biologically active and its activity was comparable to that of the standard.
[0396] 7.3 Detection of Amuc_1100 activity The samples to be detected were diluted to appropriate concentrations in whole cell culture medium. 20 μL of the diluted samples and Amuc_1100 standard were added to a flat-bottom 96-well plate, respectively, and the EcN sample was used as a negative control. ~280000 cells / mL of HEK-Blue TM A cell suspension of hTLR2 Cells (InvivoGen, Cat#hkb-htlr2) was prepared, and 180 μL of this suspension (~50,000 cells) was quickly added to the wells to which the samples were added. After incubating the 96-well plate at 37°C with 5% CO2 for 22 hours, 20 μL of the supernatant was added to a new flat-bottom 96-well plate, and 180 μL of QUANTI-Blue reagent was added per well, and incubated at 37°C for 1 hour before the A 620 The numerical value was read.
[0397] The strain CBT4080 was selected as the measurement subject, and the activity of secreted Amuc_1100 in the supernatant was detected, as shown in Figure 4E. In the figure, the negative control was a purified product of EcN supernatant that does not express Amuc_1100. The concentration of the Amuc_1100 standard was 40 μg / mL. The CBT4080 purified sample had a purity of about 70% and a concentration of 28.8 μg / mL. The results showed that Amuc_1100 expressed and secreted by the recombinant bacteria had biological activity, and its activity was comparable to that of the standard.
[0398] Example 8: Construction of strains expressing combinations of IL-10, IL-22 and / or Amuc_1100 upon anaerobic induction The methods for producing IL-10, IL-22 and Amuc_1100 donor gene fragments were the same as those described in 6.1, 6.2 and 6.3 of Example 6. Two combination strains expressing IL-10 and IL-22 simultaneously were constructed by transforming the IL-22 donor gene fragment into the strain expressing IL-10. Two combination strains expressing IL-10 and Amuc_1100 simultaneously were constructed by transforming the Amuc_1100 donor gene fragment into the strain expressing IL-10. Two combination strains expressing IL-22 and Amuc_1100 simultaneously were constructed by transforming the Amuc_1100 donor gene fragment into the strain expressing IL-22. Three combination strains expressing IL-10, IL-22 and Amuc_1100 simultaneously were constructed by transforming the Amuc_1100 donor gene fragment into the strains expressing IL-10 and IL-22 simultaneously. Each combination strain obtained in this example and its insertion element and knockout element are shown in Table 24 below, and the sequences of the relevant elements are shown in the sequences in Tables 2 to 9.
[0399] [Table 24]
[0400] The strains used in the experiment were cultured in LB (adjusted to pH 8.0 with phosphate and citrate buffer system) + 1% w / v glucose medium aerobically for 4 hours and anaerobically for 2 hours, and the expression levels of IL-10, IL-22 and Amuc_1100 in the culture supernatants are shown in Table 25.
[0401] [Table 25]
[0402] Example 9: Construction of a plasmid expressing IL-10 upon salicylic acid induction The salicylic acid inducible promoter Psal, ribozyme (sTRSV-HHRz), ribosome binding site (RBS), and repressor expression cassette 5'-PlacIQ-NahRAM-ter-3' of the salicylic acid inducible promoter were synthesized on a cloning plasmid (e.g., pUC57) by GeneScript. The promoterless IL-10 expression cassette 5'-USP45_IL-10_rrnB_T1_T7Te-3' sequence was amplified using the CBT4084 strain genome as a template. Psal_sTRSV-HHRz_RBS and PlacIQ_NahRAM_ter were amplified using a synthetic plasmid as a template. The LHA and RHA of the insertion site maeB were amplified using the genome of EcN as a template. The sgRNA of the maeB site was amplified using the plasmid pCBT003_maeB_sgRNA as a template. The plasmid backbone was amplified using pCBT010 as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they could be ligated using the kit ClonExpress Ultra One Step Cloning Kit (Vazyme) to form the plasmid pCBT010_maeB_Psal_IL-10, which contains the expression cassette 5'-Psal-sTRSV HHRz_RBS_USP45_IL-10_rrnB_T1_T7Te-3' linked to LHA at one end, the expression cassette 5'-PlacIQ-NahRAM-ter-3' linked to RHA at the other end (sequence shown in SEQ ID NO: 243), and the maeB site sgRNA. The plasmid pCBT010_maeB_Psal_IL-10 was transformed into competent cells containing pCBT001. The resulting single colonies were amplified with primers for verifying the insertion site, and clones with IL-10 inserted into the genome were screened based on the size of the amplified band. The yield of IL-10 was detected using an ELISA kit (Sino Biological, KIT10947A).
[0403] PlacIQ-NahRAM-ter sequence (SEQ ID NO: 243)
[0404] [Table 26]
[0405] The CBT4113 strain was aerobically cultured in LB medium for 3 hours, and then various concentrations of sodium salicylate were added and cultured for 1 to 4 hours. The expression levels of IL-10 in the culture supernatant are shown in Figure 5. The results showed that the expression level of IL-10 could be precisely controlled by adjusting the concentration of the inducer and the induction time.
[0406] Example 10: Expression of other cytokines In addition, the applicant also tried to select various other cytokines with similar immunomodulatory effects, such as IL-23 (IL-12p40_linker1_IL-23p19), IL-17A, IL-19, IL-35 (EBI3_linker2_IL-12p35), IL-37 and TGF-β, and construct genetically modified bacteria to study their in vivo effects. The specific process was as follows: IL-23 (IL-12p40_linker1_IL-23p19), IL-17A, IL-19, IL-35 (EBI3_linker2_IL-12p35), IL-37, TGF-β coding sequences were amplified using synthetic plasmids as templates. The sequence of the plasmid backbone containing the salicylic acid inducible promoter Psal, the ribozyme (sTRSV-HHRz), the ribosome binding site (RBS), the 5′-Psal_sTRSV-HHRz_RBS_USP45-3′ sequence containing the secretory signal peptide USP45, the transcription terminator rrnB_T1_T7Te and the salicylic acid regulatory element PlacIQ-NahRAM-ter 5′-rrnB_T1_T7Te_PlacIQ_NahRAM_ter-3′ was amplified using the plasmid pCBT010_maeB_Psal_IL-10 as a template. The PCR primers for amplifying these fragments have 15-20 bp of homology to each other, so they were ligated using the kit ClonExpress Ultra One Step Cloning Kit (Vazyme) to form the expression cassette 5'-Psal-sTRSV HHRz_RBS_USP45_cytokine_rrnB_T1_T7Te-3', and pCBT010_Psal_IL-23, pCBT010_Psal_IL-17A, pCBT010_Psal_IL-19, pCBT010_Psal_IL-35, pCBT010_Psal_IL-37, and pCBT010_Psal_TGF-β, which contain the expression cassettes. These plasmids were transformed into competent cells in the chassis strain CBT4114 (genotypes are shown in Table XX). The resulting single colonies were amplified with primers for verifying the plasmid, and the success of the transformation of the plasmid was verified by the size of the amplified band. The yields of cytokines were detected by ELISA kits.The kits used in this example are shown in Table 27.
[0407] [Table 27]
[0408] The strains containing these cytokine expression plasmids were aerobically cultured in LB medium for 4 hours, and then 100 μM sodium salicylate was added and culture was continued for 2 hours. The cytokine contents in the supernatant and cells after the culture were then shown in Table 28.
[0409] [Table 28]
[0410] As a result, we unexpectedly found that the expression and secretion levels of the above cytokines were too low to reach effective concentrations. It was speculated that the above factors were not suitable for expression and secretion in EcN because EcN may have low tolerance to these proteins or the above proteins may be unstable after expression.
[0411] Example 11: Study of efficacy in T cell transfer-induced mouse colitis (IBD) model The mouse colitis used in this study was caused by purified CD4 + CD45RB high The CD4 T cells were injected into severe combined immunodeficiency (SCID) mice (which lack T and B cells). Balb / C mice (20 g, 8–10 weeks old) were used to generate CD4 T cells. + CD45RB low and CD4 + CD45RB high 1. Preparing RAG1 Cells - / - Mice (20 g, 8–10 weeks old) were used to receive T cell transfer. - / - Mice were randomly divided into 11 groups of 10 mice each. Group 1 was the healthy group; + CD45RB low Groups 2 to 11 were classified as diseased groups, and CD4 +CD45RB high The day of T cell transplantation induction was set as day 0, and administration began on day 14. EcN, CBT4084, CBT4095, CBT4096, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial liquids cultured aerobically in LB for 4 hours were concentrated and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. Group 2 was the positive administration group, and TNF-α antibody was injected intraperitoneally once every 7 days from day 14 to day 37, and 100 μL of EcN bacterial suspension was administered intragastrically every day. 100 μL of EcN, CBT4084, CBT4095, CBT4096, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial suspensions were administered intragastrically once a day to groups 3 to 11, respectively. The dose was 2.5 × 10 per mouse. 9 On day 41, the mice were sacrificed and the intestinal lengths were measured, and pathological analysis was performed by HE staining.
[0412] The colon length at the end point of the T cell transfer-induced mouse colitis model in each experimental group is shown in Figure 6A. In the figure, CBT4096 expressed Amuc_1100 alone. CBT4084 expressed IL-10 alone. CBT4088 simultaneously expressed IL-10 and Amuc_1100. CBT4095 expressed IL-22 alone. CBT4098 simultaneously expressed IL-22 and Amuc_1100. CBT4110 simultaneously expressed IL-10 and IL-22. CBT4111 simultaneously expressed IL-10, IL-22, and Amuc_1100. As a result, the recombinant bacteria expressed alone or in combination were effective in maintaining the colon length of the enteritis model mice, and statistical analysis showed that all recombinant bacteria expressed in combination had significantly longer colon length than the control group (p<0.05), and their effect was comparable to that of the positive control TNF-α antibody. This result indicates that the recombinant bacteria expressed in combination have a better therapeutic effect than recombinant bacteria expressed alone in the T cell transplantation-induced mouse enteritis model.
[0413] HE stained colon samples from the EcN control group and CBT4110 mice that simultaneously expressed IL-10 and IL-22 are shown in Figure 6B. The CBT4110 mice had significantly better colon inflammation than the control group.
[0414] Example 12: Study on efficacy in DSS-induced mouse colitis (IBD) model In addition to the mouse intestinal model of Example 11, the applicant further verified the therapeutic effect of the genetically modified bacteria on mouse enteritis in a DSS-induced mouse enteritis model. Specifically, Balb / C mice (20 g, 50 C57 / B6 mice, 8 weeks old, 18-20 g, female.) were randomly divided into 10 model groups of 5 mice each, and starting with 2.5% DSS on day 0, they were switched to normal water on day 4 for 3 days, and a total of 4 rounds of DSS induction were performed. The first group was the model control group and was not administered any medication. The second group was the positive drug group, and positive drug CsA was administered intragastrically at a dose of 25 mpk every day from day 0 to day 27. EcN, CBT4096, CBT4088, CBT4098, and CBT4110 bacterial liquids aerobically cultured in LB for 4 hours were concentrated and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. 100 μL of bacterial suspension of EcN, CBT4096, CBT4088, CBT4098, and CBT4110 was administered intragastrically once a day to each of groups 3 to 10. The dose was 2.5 × 10 per mouse. 9 The CFU was determined. The mice were administered from day 0 to day 27, and the experiment was terminated on day 28. Then, the mice were sacrificed and the intestinal length was measured.
[0415] Figure 7 shows the changes in body weight, DAI score (Disease activity index, a commonly used index to evaluate colitis), and colon length at the endpoint in the DSS-induced mouse colitis model. Compared with the EcN control group, the recombinant CBT4096, CBT4088, CBT4098, and CBT4110 groups showed a significant increase in colon length (p<0.05) (Figure 7C). CBT4110 had a more obvious advantage in maintaining body weight (Figure 7A) and reducing DAI score (Figure 7B) (p<0.001).
[0416] Example 13: Study on efficacy in GvHD model BALB / c (H-2d) and C57BL / 6 (H-2b) mice (6-8 weeks old) were used as donors and recipients, respectively. The day of bone marrow transplantation (BMT) was defined as day 0, and the day of radiation was defined as day -1. Group 1 contained 7 allografted mice. Groups 2-10 contained 9 allografted mice. Group 11 contained 7 mice that were irradiated but not transplanted. EcN, CBT4084, CBT4095, CBT4096, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial liquids cultured aerobically in LB for 4 hours were concentrated and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. From day -1 to day 30, mice in groups 1, 2, 10, and 11 were inoculated with 2.5 × 10 9 100 μL of EcN cell suspension was intragastrically administered to each group at CFU, and at the same time, the mice in group 10 were injected with 20 mg / kg prednisone daily, and 100 μL of CBT4084, CBT4095, CBT4096, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial suspension was intragastrically administered to groups 3 to 9, respectively, and the survival rate of the mice was recorded daily.
[0417] The survival rates of the GvHD animal models are shown in Figure 8. As a result, on day 20, the survival rates of mice in the CBT4096 group expressing Amuc_1100 alone, the CBT4098 group expressing IL-22 and Amuc_1100 simultaneously, the CBT4110 group expressing IL-10 and IL-22 simultaneously, and the CBT4111 group expressing IL-10, IL-22, and Amuc_1100 simultaneously were equal to or higher than those of the positive drug group. On day 25, mice in the CBT4088 group expressing IL-10 and Amuc_1100 simultaneously, the CBT4098 group expressing IL-22 and Amuc_1100 simultaneously, the CBT4110 group expressing IL-10 and IL-22 simultaneously, and the CBT4111 group expressing IL-10, IL-22, and Amuc_1100 simultaneously had higher survival rates than mice in the CBT4084 group expressing IL-10 alone, the CBT1095 group expressing IL-22 alone, and the CBT4096 group expressing Amuc_1100 alone. These results showed that the recombinant bacteria expressing combinations were superior to the recombinant bacteria expressing alone to various degrees in the GvHD model. At the end of the experiment on day 30, the survival rate of the CBT4098 group expressing IL-22 and Amuc_1100 simultaneously was still close to that of the positive drug group. These results demonstrated that recombinant bacteria expressing IL-22 and Amuc_1100 had the most significant therapeutic effect against GvHD.
[0418] Example 14: Study of drug efficacy in SLE models First, we evaluated the therapeutic effects of recombinant bacteria expressing two proteins simultaneously and one protein alone in an SLE model. Specifically, MRL / MpJ-Faslpr mice were used as the SLE model, and MRL / MpJ mice were used as the negative control, with the administration time being 8 weeks. EcN, CBT4084, CBT4096, and CBT4088 bacterial liquids cultured aerobically in LB for 4 hours were concentrated and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. The experimental mice were divided into 6 groups. Group 1 was the negative control group, which included 5 MRL / MpJ mice. Group 2 was the positive administration group, which included 10 MRL / MpJ-Faslpr mice and was intragastrically administered 9 mg / kg prednisone and 100 μL of EcN bacterial suspension daily. Groups 3 to 6 were the treatment groups, each of which contained 10 MRL / MpJ-Faslpr mice, and 100 μL of EcN, CBT4084, CBT4096, or CBT4088 bacterial suspension was administered at 2.5 × 10 per mouse. 9CFU After the experiment, kidneys were harvested and sliced to evaluate renal tubule damage.
[0419] Renal tubule damage is shown in Figure 9A. Compared with the control EcN, the recombinant bacteria CBT4084 expressing IL-10 alone and the recombinant bacteria CBT4096 expressing Amuc_1100 alone could not significantly reduce renal tubule damage, but the recombinant bacteria CBT4088 expressing IL-10 and Amuc_1100 simultaneously could significantly reduce renal tubule damage. This indicates that the simultaneous expression of IL-10 and Amuc_1100 produced a synergistic effect in the SLE model.
[0420] Next, the therapeutic effects of recombinant bacteria expressing IL-10 and Amuc_1100 simultaneously (CBT4088), recombinant bacteria expressing IL-10 and IL-22 simultaneously (CBT4110), and recombinant bacteria expressing IL-10, IL-22, and Amuc_1100 simultaneously (CBT4111) were further compared. Specifically, the experimental mice were divided into five groups. Group 1 was the negative control group and included six MRL / MpJ mice. Groups 2 to 5 were the treatment groups, each including ten MRL / MpJ-Faslpr mice, and 100 μL of EcN, CBT4088, CBT4110, and CBT4111 bacterial suspensions were administered at 1.0 × 10 per mouse. 10 After the experiment, the serum anti-dsDNA antibody IgG and urinary albumin concentrations were measured, and kidneys were sampled, sliced, and stained with PAS to evaluate glomerular damage.
[0421] First, the results of detecting the change in the concentration of anti-double-stranded DNA antibody IgG, a serological marker of SLE, in mouse serum are shown in Figure 9B. Both CBT4088 and CBT4110 could significantly reduce the concentration of anti-double-stranded DNA antibody IgG in the serum of model mice (p<0.01), with CBT4088 showing the greatest reduction. The results of kidney PAS staining showed that the diseased mice in the EcN group had significant proliferation of glomerular capillary endothelial cells and mesangial cells, narrowing or obstruction of the glomerular cavity, and loss of glomerular function, while the pathological slices of CBT4088 and CBT4111 showed significant improvement (Figure 9D). However, only CBT4088 could significantly reduce the urinary albumin concentration (an indicator of kidney damage) (p<0.01) (Figure 9C). The above results demonstrated that recombinant CBT4088, which simultaneously expresses IL-10 and Amuc_1100, has optimal efficacy in treating SLE.
[0422] Example 15: Study of drug efficacy in CIA model Collagen-induced athritis (CIA) is an experimental spontaneous immune disease that can be induced by immunizing susceptible rodent strains (rats and mice) with type II collagen. The immunized animals developed a type of spontaneous immune-mediated polyarthritis. DBA / 1 mice were used as the CIA model. On day 0, all DBA / 1 mice were anesthetized with 2%-5% isoflurane and then subcutaneously injected with 50 μL of collagen emulsion at the base of the tail, 2-3 cm away from the body. Three weeks later, on day 21, the mice were challenged by similar injection of the same amount of collagen emulsion at the base of the tail. On the day of the second collagen emulsion challenge, the model animals were randomly divided into six groups of 5 or 10 animals according to their body weight, and administration began on the day of grouping. EcN, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial suspensions were cultured aerobically in LB for 4 hours, concentrated, and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. Groups 1 to 5 each contained 10 mice, and 100 μL of EcN, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial suspensions were added to each mouse at a concentration of 1.5 × 10 10 The mice were intragastrically administered with the dose of EcN and 0.2 mg / kg dexamethasone daily. The sixth group was the positive treatment group, which included five mice and was intragastrically administered with 100 μL of EcN and 0.2 mg / kg dexamethasone daily. The treatment period was 36 days. The animals in each group were observed twice weekly for the onset of arthritis in the limbs and scored, and the thickness of the front and rear paws was measured at the same time.
[0423] The thickness of the front and rear paws of the mice and the arthritis score of the limbs are shown in Figure 10. The recombinant bacteria CBT4088 expressing IL-10 and Amuc_1100 simultaneously, the recombinant bacteria CBT4098 expressing IL-22 and Amuc_1100 simultaneously, the recombinant bacteria CBT4110 expressing IL-10 and IL-22 simultaneously, and the recombinant bacteria CBT4111 expressing IL-10, IL-22, and Amuc_1100 simultaneously were able to reduce the severity of the disease to some extent. Among them, CBT4088 expressing IL-10 and Amuc_1100 simultaneously showed the most significant improvement in the thickness of the paws (Figure 10A) and the disease score (Figure 10B) (p<0.05).
[0424] Example 16: Study on efficacy in OVA-induced asthma model Asthma is a chronic inflammatory disease of the airways characterized by increased numbers of type II T helper lymphocytes (Th2), eosinophils, and the development of airway inflammation, accompanied by high levels of serum immunoglobulin E (IgE), and interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin 13 (IL-13) produced in the lungs by allergen-specific Th2 cells. Airway inflammation is associated with infiltration of eosinophils, neutrophils, and T and B lymphocytes in airway and lung tissue.
[0425] In this study, ovalbumin (OVA)-induced asthma model was used in BALB / c female mice. Mice were randomly divided into 7 groups according to body weight, and the administration period was 31 days. EcN, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial liquids cultured aerobically in LB for 4 h were concentrated and resuspended in 0.2 M sodium bicarbonate + 1% w / v glucose aqueous solution. Groups 1 to 5 contained 10 mice each, and 100 μL of EcN, CBT4088, CBT4098, CBT4110, and CBT4111 bacterial suspension was administered at 1.5 × 10 per mouse. 10The cells were intragastrically administered daily at the cell dose. Group 6 was the positive-challenge group, which included 6 mice and received 100 μL of EcN bacterial suspension intragastrically every day, but the positive drug dexamethasone 1 mg / kg was additionally administered on days 27-31. Group 7 was the non-induced sensitization control group, which included 5 mice and received 100 μL of EcN bacterial suspension intragastrically every day. Mice in groups 1-6 were intraperitoneally injected with 100 μL of sensitization solution (containing 20 μg ovalbumin and 2 mg alum) on days 1 and 14. Mice in group 7 as a control were injected with 100 μL of PBS solution. On days 28, 29, and 30, mice in groups 1-6 were challenged with 1% OVA solution dissolved in PBS (pH=7.2) for 30 minutes, and mice in group 7 were challenged with PBS (pH=7.2) solution as a control.
[0426] On day 32, all animals were euthanized. The lungs were lavaged with PBS (pH=7.2) solution via tracheal intubation. The total number of cells in the bronchoalveolar lavage fluid (BALF) was counted using a hemocytometer. Eosinophils, macrophages, neutrophils, and lymphocytes were counted from cytocentrifugation preparations after using cytospin and Wright-Giemsa staining.
[0427] The results of the cell count in the bronchoalveolar lavage fluid (BALF) are shown in Figures 11A-11E. Compared with the control group 1, which was administered only EcN, all treatment groups had a decrease in the total number of cells, eosinophils, and macrophages in the bronchoalveolar lavage fluid (BALF). Among them, CBT4098, which simultaneously expresses IL-22 and Amuc_1100, could significantly reduce the total number of cells (p<0.01), the number of eosinophils (p<0.05), and the number of macrophages (p<0.05). CBT4110, which simultaneously expresses IL-10 and IL-22, and CBT4111, which simultaneously expresses IL-10, IL-22, and Amuc_1100, could also significantly reduce the total number of cells and the number of macrophages.
[0428] While the present disclosure has been particularly shown and described with reference to certain embodiments, some of which are preferred, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the disclosure herein.
Claims
1. a) Amuc_1100 polypeptide, b) an IL-10 polypeptide, and c) A genetically modified microorganism comprising at least two exogenous genes each encoding a polypeptide selected from the group consisting of IL-22 polypeptides.
2. a) an exogenous gene encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, b) an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, respectively; or 2. The genetically modified microorganism of claim 1, comprising: c) exogenous genes encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively.
3. 2. The genetically modified microorganism of claim 1, comprising exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
4. A genetically modified microorganism comprising an exogenous gene encoding an Amuc — 1100 polypeptide, an IL-10 polypeptide, or an IL-22 polypeptide.
5. 5. The genetically modified microorganism of any one of claims 1 to 4, wherein the Amuc_1100 polypeptide is a wild-type Amuc_1100 polypeptide or a functional equivalent that is functionally equivalent to a wild-type Amuc_1100 polypeptide.
6. The genetically modified microorganism of any one of claims 1 to 5, wherein the IL-10 polypeptide is a wild-type IL-10 polypeptide or a functional equivalent that is functionally equivalent to a wild-type IL-10 polypeptide.
7. The genetically modified microorganism of any one of claims 1 to 6, wherein the IL-22 polypeptide is a wild-type IL-22 polypeptide or a functional equivalent that is functionally equivalent to a wild-type IL-22 polypeptide.
8. 6. The genetically modified microorganism of claim 5, wherein said functional equivalent comprises a variant, fragment, fusion, derivative or any combination thereof of a wild-type Amuc_1100 polypeptide and at least partially retains one or more biological functions of wild-type Amuc_1100, optionally selected from the group consisting of: a) modulating and / or promoting intestinal immune system function in a mammal, b) maintaining, restoring and / or increasing the physical integrity of the intestinal mucosal barrier in a mammal, and c) activating TLR2.
9. The fragment of the wild-type Amuc_1100 polypeptide comprises: (a) an amino acid sequence as set forth in SEQ ID NO:2, or an amino acid sequence having at least 80% sequence identity to the amino acid sequence as set forth in SEQ ID NO:2; or (b) the amino acid sequence set forth in SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:
3.
10. 10. The genetically modified microorganism of any one of claims 1 to 9, wherein the Amuc_1100 polypeptide comprises an amino acid sequence comprising the sequence set forth in SEQ ID NO:5 or having at least 80% sequence identity with the sequence set forth in SEQ ID NO:5 and still retains the activity of modulating intestinal immunity and / or activating toll-like receptor 2 (TLR2).
11. the Amuc_1100 polypeptide has a mutation at position 259, Y, which is numbered based on the sequence set forth in SEQ ID NO:5; 11. The genetically modified microorganism of any one of claims 1 to 10, wherein preferably said Amuc_1100 polypeptide has a Y259A or Y259S mutation at position 259, the numbering being based on the sequence shown in SEQ ID NO:
5.
12. 12. The genetically modified microorganism of any one of claims 1 to 11, wherein the IL-10 polypeptide comprises the sequence set forth in SEQ ID NO:11 or an amino acid sequence having at least 80% sequence identity with the sequence set forth in SEQ ID NO:11 and still retains immune cell modulating activity.
13. 13. The genetically modified microorganism of any one of claims 1 to 12, wherein the IL-22 polypeptide comprises the sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least 80% sequence identity with the sequence set forth in SEQ ID NO: 15 and still retains the activity of binding to the IL-22 receptor and regulating IL-22 receptor expressing cells.
14. said microorganism is capable of expressing and / or secreting a polypeptide encoded by said exogenous gene; or The genetically modified microorganism according to any one of claims 1 to 13, wherein the microorganism is capable of expressing and / or secreting a polypeptide encoded by the exogenous gene in the intestinal tract of a human or animal.
15. The genetically modified microorganism of any one of claims 1 to 14, wherein the exogenous gene is contained in an exogenous expression cassette.
16. 16. The genetically modified microorganism of claim 15, wherein the exogenous expression cassette is contained in a plasmid, the plasmid being introduced into the microorganism and suitable for expression in the microorganism.
17. The genetically modified microorganism of claim 15, wherein the exogenous expression cassette is integrated into the genome of the genetically modified microorganism.
18. or the microorganism comprises a first exogenous expression cassette containing a nucleotide sequence encoding an Amuc_1100 polypeptide and a second exogenous expression cassette containing a nucleotide sequence encoding an IL-10 polypeptide; the microorganism comprises a second exogenous expression cassette containing a nucleotide sequence encoding an IL-10 polypeptide, and a third exogenous expression cassette containing a nucleotide sequence encoding an IL-22 polypeptide; or the microorganism comprises a first exogenous expression cassette containing a nucleotide sequence encoding an Amuc_1100 polypeptide and a third exogenous expression cassette containing a nucleotide sequence encoding an IL-22 polypeptide; or the microorganism comprises a first exogenous expression cassette containing a nucleotide sequence encoding an Amuc_1100 polypeptide, a second exogenous expression cassette containing a nucleotide sequence encoding an IL-10 polypeptide, and a third exogenous expression cassette containing a nucleotide sequence encoding an IL-22 polypeptide; or or the microorganism comprises a first exogenous expression cassette containing a nucleotide sequence encoding an Amuc_1100 polypeptide; or the microorganism comprises a second exogenous expression cassette containing a nucleotide sequence encoding an IL-10 polypeptide; 16. The genetically modified microorganism of claim 15, wherein the microorganism comprises a third exogenous expression cassette containing a nucleotide sequence encoding an IL-22 polypeptide.
19. The genetically modified microorganism of any one of claims 15 to 18, wherein the exogenous expression cassette is present in the genome in one or more copies (e.g., 2, 3, 4, 5 or 6 copies, etc.).
20. The genetically modified microorganism according to any one of claims 1 to 19, wherein the Amuc_1100 polypeptide, IL-10 polypeptide and / or IL-22 polypeptide is a polypeptide from which its own signal peptide sequence has been removed.
21. the N-terminus of the Amuc_1100 polypeptide is linked to a first signal peptide, the N-terminus of the IL-10 polypeptide is linked to a second signal peptide, and / or the N-terminus of the IL-22 polypeptide is linked to a third signal peptide; The genetically modified microorganism of claim 20, wherein the first signal peptide, the second signal peptide and / or the third signal peptide are capable of secreting the Amuc_1100 polypeptide, the IL-10 polypeptide and / or the IL-22 polypeptide extracellularly.
22. The first signal peptide, the second signal peptide, and the third signal peptide may be the same or different, and each comprises an amino acid sequence selected from the group consisting of the sequences shown in SEQ ID NOs: 80 to 122, or a homologous sequence having at least 80% sequence identity with the amino acid sequence; Preferably, the first signal peptide, the second signal peptide, and / or the third signal peptide is a USP45 signal peptide having an amino acid sequence as set forth in SEQ ID NO:114, or a homologous sequence having at least 80% sequence identity to SEQ ID NO:
114. The genetically modified microorganism of claim 20.
23. the first signal peptide, the second signal peptide, and / or the third signal peptide are processed by a secretion system present in the microorganism; In particular, the secretion system is native or non-native to the microorganism, a genetically modified microorganism as described in claim 21.
24. the exogenous gene is operably linked to an expression control element; Preferably, the expression control element comprises a promoter, More preferably, the promoter is selected from the group consisting of BBa_J23101, BBa_J23108, BBa_J23110, PfnrS, Psal, Pvan, BBa_J23119, BBa_J23102 and BBa_J23114.
25. the expression control element comprises a ribosome binding site (RBS); Preferably, the nucleotide sequence of the ribosome binding site is set forth in SEQ ID NO:
63.
26. The expression control element comprises a mistron, 26. A genetically modified microorganism according to claim 24 or 25, wherein the mistron is preferably selected from T7g10, BCD2, GFP and luciferase.
27. the expression control element comprises a terminator, Preferably, the terminator is the rrnB_T1_T7Te terminator, more preferably the sequence of the rrnB_T1_T7Te terminator is set forth in SEQ ID NO:
242. The genetically modified microorganism according to any one of claims 24 to 26.
28. 28. The genetically modified microorganism of any one of claims 1 to 27, further comprising one or more other genetic modifications to the genome of the microorganism.
29. The genetically modified microorganism of claim 28, wherein the one or more other genetic modifications include genetically engineering and / or optimizing a secretion system such that at least one gene encoding an outer membrane protein is deleted, inactivated or suppressed.
30. 30. The genetically modified microorganism of claim 29, wherein the outer membrane protein is selected from the group consisting of lpp, mrcA, ompT, tolQ, tolR, tolA and pal.
31. 30. The genetically modified microorganism of claim 29, wherein the at least one outer membrane protein is selected from the group consisting of lpp, mrcA, ompT, and combinations thereof.
32. 30. The genetically modified microorganism of claim 29, wherein the at least one outer membrane protein is lpp and mrcA.
33. 33. The genetically modified microorganism of any one of claims 29 to 32, further comprising one or more overexpressed molecular chaperones.
34. 34. The genetically modified microorganism of claim 33, wherein the molecular chaperone is selected from the group consisting of dsbA, dsbC, dnaK, dnaJ, grpE, groES, groEL, tig, fkpA, surA, and a combination of any two or more (e.g., three, four, five, six, seven, eight, nine, or ten) molecular chaperones thereof.
35. 30. The genetically modified microorganism of claim 28, wherein the one or more other genetic modifications comprise inactivation or deletion of at least one auxotrophy-associated gene.
36. 36. The genetically modified microorganism of any one of claims 1 to 35, wherein the microorganism is an auxotroph for one or more substances selected from the group consisting of uracil, thymine, diaminopimelic acid, leucine, histidine, tryptophan, lysine, methionine, adenine and non-wild-type amino acids.
37. 37. The genetically modified microorganism of claim 36, wherein the non-wild type amino acid is selected from the group consisting of l-4,4'-biphenylalanine, p-acetyl-l-phenylalanine, p-iodo-l-phenylalanine, and p-azido-l-phenylalanine.
38. 38. The genetically modified microorganism of any one of claims 1 to 37, wherein the microorganism comprises a bacterium, an archaea, a fungus or an algae.
39. 39. The genetically modified microorganism of claim 38, wherein the fungus comprises a yeast or a filamentous fungus.
40. 40. The genetically modified microorganism of any one of claims 1 to 39, wherein the microorganism comprises a probiotic microbial organism or a non-pathogenic microbial organism.
41. 41. The genetically modified microorganism of claim 40, wherein the probiotic microbial organism is a probiotic bacterium or a probiotic yeast.
42. 42. The genetically modified microorganism of claim 41, wherein the probiotic bacteria is selected from the group consisting of Bacteroides, Bifidobacterium, Clostridium, Escherichia, Lactobacillus, and Lactococcus.
43. 43. The genetically modified microorganism of claim 42, wherein the probiotic bacterium belongs to the genus Escherichia.
44. 43. The genetically modified microorganism of claim 42, wherein the probiotic bacterium is Escherichia coli strain Nissle 1917 (EcN).
45. 42. The genetically modified microorganism of claim 41, wherein the probiotic bacteria are bacteria normally present in the human intestinal tract.
46. 42. The genetically modified microorganism of claim 41, wherein the probiotic yeast is selected from the group consisting of Saccharomyces cerevisiae, Candida utilis, Kluyveromyces lactis, and Saccharomyces carlsbergensis.
47. A combination of genetically modified microorganisms comprising at least two (such as two, three or four) different genetically modified microorganisms according to any one of claims 1 to 46.
48. A nucleotide sequence comprising at least one recombinant expression cassette, the nucleotide sequence containing i) at least one or at least two exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide and / or an IL-22 polypeptide, respectively, and ii) one or more regulatory elements operably linked to the at least one or at least two exogenous genes.
49. 49. The nucleotide sequence of claim 48, comprising an exogenous gene encoding a) an Amuc_1100 polypeptide and an IL-10 polypeptide, b) an IL-10 polypeptide and an IL-22 polypeptide, or c) an Amuc_1100 polypeptide and an IL-22 polypeptide, respectively.
50. 49. The nucleotide sequence of claim 48, comprising an exogenous gene encoding each of an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide.
51. 49. The nucleotide sequence of claim 48, wherein the nucleotide sequence comprises a first recombinant expression cassette comprising a nucleotide sequence encoding an Amuc_1100 polypeptide and one or more regulatory elements operably linked thereto, a second recombinant expression cassette comprising a nucleotide sequence encoding an IL-10 polypeptide and one or more regulatory elements operably linked thereto, and / or a third recombinant expression cassette comprising a nucleotide sequence encoding an IL-22 polypeptide and one or more regulatory elements operably linked thereto.
52. The nucleotide sequence encoding the Amuc_1100 polypeptide encodes an Amuc_1100 polypeptide whose signal peptide has been replaced by a first signal peptide, the IL-10-encoding nucleotide sequence encodes an IL-10 polypeptide whose own signal peptide has been replaced by a second signal peptide; and / or The nucleotide sequence of claim 51, wherein the nucleotide sequence encoding the IL-22 polypeptide encodes an IL-22 polypeptide having its own signal peptide replaced by a third signal peptide.
53. The first signal peptide, the second signal peptide, and the third signal peptide may be the same or different, Optionally, the first signal peptide, the second signal peptide, and / or the third signal peptide is a USP45 signal peptide having an amino acid sequence as set forth in SEQ ID NO:114 or a homologous sequence having at least 80% sequence identity to SEQ ID NO:
114.
54. 49. The nucleotide sequence of claim 48, wherein the one or more regulatory elements are selected from the group consisting of a promoter, a ribosome binding site (RBS), a mistron, a terminator, and any combination thereof.
55. the promoter is selected from the group consisting of BBa_J23101, BBa_J23108, BBa_J23110, PfnrS, Psal, Pvan, BBa_J23119, BBa_J23102, and BBa_J23114; The ribosome binding site is synthetic and its nucleotide sequence is shown in SEQ ID NO:63, said mistron is selected from the group consisting of T7g10, BCD2, GFP, and luciferase; and / or 55. The nucleotide sequence according to claim 54, wherein the terminator is the rrnB_T1_T7Te terminator, preferably the sequence of the terminator is set forth in SEQ ID NO:
242.
56. 49. The nucleotide sequence of claim 48, wherein the recombinant expression cassette is suitable for expression in a probiotic bacterium or a probiotic yeast.
57. The nucleotide sequence according to claim 48, comprising any of the nucleotide sequences set forth in SEQ ID NOs: 139 to 163 and 235, or a combination thereof.
58. (a) a genetically modified microorganism according to any one of claims 1 to 46 or a combination of genetically modified microorganisms according to claim 47 as active ingredients, and (b) A composition comprising a physiologically or pharmacologically acceptable vector.
59. 59. The composition of claim 58, which is a pharmaceutical composition.
60. 60. The composition of claim 59, wherein the pharmaceutical composition is an oral formulation.
61. 60. The composition of claim 59, wherein the pharmaceutical composition is a liquid formulation, a solid formulation, or a semi-solid formulation.
62. 60. The composition of claim 59, wherein the dosage form of the pharmaceutical composition is selected from the group consisting of powder, dispersion, tablet, dragee, capsule, granule, suspension, solution, syrup, drops and sublingual tablet.
63. 61. The composition of claim 60, wherein the liquid formulation is a solution product or a suspension product.
64. The pharmaceutical composition is 8 ~1×10 12 60. The composition of claim 59, comprising a combination of CFUs of the genetically modified microorganism of any one of claims 1 to 46 or the genetically modified microorganism of claim 47.
65. 59. The composition of claim 58, which is an edible composition.
66. 59. The composition of claim 58, which is a probiotic composition.
67. 59. The composition of claim 58 which is a food supplement.
68. Use of a genetically modified microorganism according to any one of claims 1 to 46, a combination of genetically modified microorganisms according to claim 47, or a composition according to claim 58 in the manufacture of a medicament for treating or preventing an inflammatory disease or an autoimmune disease.
69. 69. The use of claim 68, wherein the autoimmune disease is selected from the group consisting of inflammatory bowel disease, graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), arthritis, asthma, and combinations thereof.
70. 70. The use according to claim 69, wherein the autoimmune disease is inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and / or arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis and juvenile idiopathic arthritis, and / or asthma, including allergic asthma and neutrophilic asthma.
71. Use of a genetically modified microorganism according to any one of claims 1 to 46, or a combination of genetically modified microorganisms according to claim 47, or a composition according to any one of claims 58 to 69, in the manufacture of a medicament for improving the therapeutic effect of a therapeutic agent for an inflammatory or autoimmune disease.
72. A method for producing a genetically modified microorganism according to any one of claims 1 to 46, comprising the steps of: A method for producing a nucleotide sequence according to any one of claims 48 to 57, comprising the step of introducing said nucleotide sequence into a microorganism such that an exogenous gene in said nucleotide sequence is expressed in said microorganism.
73. 1. A method for treating or preventing an inflammatory or autoimmune disease in an individual in need thereof, comprising: A method comprising administering to said individual an effective amount of a genetically modified microorganism according to any one of claims 1 to 46, or a combination of genetically modified microorganisms according to claim 47, or a composition according to any one of claims 58 to 69.
74. 74. The method of claim 73, wherein the autoimmune disease is selected from the group consisting of inflammatory bowel disease, graft-versus-host disease (GvHD), systemic lupus erythematosus, arthritis, asthma, and combinations thereof.
75. 74. The method of claim 73, wherein the autoimmune disease is inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and / or arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis and juvenile idiopathic arthritis, and / or asthma, including allergic asthma and neutrophilic asthma.
76. 1. A method for improving a therapeutic effect of a drug in an individual undergoing treatment with the drug, including a therapeutic agent for an inflammatory disease or an autoimmune disease, comprising: A method comprising administering to said individual an effective amount of a genetically modified microorganism according to any one of claims 1 to 46, or a combination of genetically modified microorganisms according to claim 47, or a composition according to any one of claims 58 to 67.
77. 1. Use of a genetically modified microorganism in the preparation of a medicament for treating an inflammatory disease or an autoimmune disease, wherein the inflammatory disease or the autoimmune disease is selected from the group consisting of inflammatory bowel disease (IBD), graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), arthritis and asthma; The genetically modified microorganism comprises: a) Amuc_1100 polypeptide, b) an IL-10 polypeptide, and c) at least one, at least two or at least three exogenous genes each encoding a polypeptide selected from the group consisting of IL-22 polypeptides.
78. (1) The genetically modified microorganism comprises exogenous genes encoding an Amuc_1100 polypeptide and an IL-10 polypeptide, (2) The genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide and an IL-22 polypeptide, (3) The genetically modified microorganism comprises exogenous genes encoding an Amuc_1100 polypeptide and an IL-22 polypeptide, (4) The genetically modified microorganism comprises an exogenous gene encoding an IL-10 polypeptide; (5) The genetically modified microorganism comprises an exogenous gene encoding an Amuc_1100 polypeptide; (6) The genetically modified microorganism comprises an exogenous gene encoding an IL-22 polypeptide; or (7) The use according to claim 77, wherein the genetically modified microorganism comprises exogenous genes encoding an Amuc_1100 polypeptide, an IL-10 polypeptide, and an IL-22 polypeptide, respectively.
Citation Information
Cited By
Genetically engineered algae capable of resisting aquatic pathogenic bacteria as well as construction method and application of genetically engineered algae
CN121046212A
